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There are approximately 2.4 million acute ocular injuries annually in the U.S. Twenty 
percent of these injuries result in partial or complete blindness due to traumatic injury to retinal 
ganglion cells (RGC). Like all central nervous system (CNS) neurons, RGC fail to regenerate 
injured axons because of multiple factors that lead to secondary tissue damage. We currently lack 
a therapeutic platform that can alter the default non-regenerative healing response. Stated 
differently, we lack a method to preserve or restore CNS function.   
Extracellular matrix (ECM) bioscaffolds have been shown to promote site appropriate 
tissue remodeling in multiple anatomical sites through stem and progenitor cell recruitment, 
proliferation, and differentiation. Additionally, redirection of the default immune response is 
facilitated by providing factors derived from the ECM that promote the phenotypic transition of 
immune cells from a pro-inflammatory to a pro-remodeling state. Recently discovered matrix 
bound nanovesicles (MBV) were found in all tested laboratory produced and commercially 
available ECM. MBV are bioactive and recapitulate some effects of the parent ECM from which 
they are derived and represent a potentially significant vertical advance in treating traumatic optic 
nerve and retinal injuries.   
The objective of the present thesis was to determine the efficacy of ECM and MBV to 
repair optic nerve and retinal tissue. First, we determined the functional and spatiotemporal 
changes in the visual system after acute ocular injury. Next, we measured the effect of ECM on 
optic nerve remodeling and the inflammatory response. Finally, we characterized the effect of 
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 v 
MBV on the inflammatory response, RGC survival, and retinal function after acute ocular injury. 
ECM improved tissue remodeling in some animals. However, the results were variable, indicating 
ECM has the potential to improve CNS remodeling, but may not be the optimal treatment platform 
in the visual system. MBV increased RGC neurite outgrowth and suppressed pro-inflammatory 
microglia and astrocyte polarization in vitro, and increased RGC survival and retinal function after 
ocular injury. MBV offer an easily injectable, minimally invasive therapy that can improve RGC 
survival and potentially increase visual function after ocular injury.  
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1.0  INTRODUCTION AND SPECIFIC AIMS 
Regenerative medicine is a branch of translational medicine aimed at replacing or remodeling 
damaged tissue or organs with the goal to restore lost function. Tissue engineering is a sub-section 
of regenerative medicine that utilizes engineering and materials science principles to restore or 
improve tissue functionality. Through tissue engineering, materials can be developed that utilize 
naturally occurring bioactive molecules and cellular components, or synthetic polymers and 
components to support functional tissue recovery. Naturally derived scaffolds are typically 
complex materials comprised of growth factors, cytokines, proteins, small molecules, and other 
bioactive factors, while synthetic materials can be engineered to deliver specific combinations of 
desired factors. Naturally derived extracellular matrix (ECM) biologic scaffolds are widely used 
in regenerative medicine and are produced through decellularization of healthy tissue to remove 
cellular content, while maintaining tissue specific bioactive molecules. ECM maintains 
homeostasis in tissues and organs throughout the body, therefore a logical approach is to use these 
scaffolds to influence the microenvironment to support normal tissue recovery and functionality. 
Recently, bioactive matrix bound nanovesicles (MBV) were found to be present in all available 
ECM scaffolds and were shown to recapitulate some favorable responses associated with ECM 
scaffolds. MBV open a new area of ECM technology and allows ECM bioactive components to 
be delivered in minimally invasive manners, thereby promoting functional recovery in injured 
tissues.   
 2 
1.1 TRAUMATIC OPTIC NEUROPATHY 
Traumatic injury to the central nervous system (CNS) results in irreversible neurologic 
impairments, and in the visual system injury often results in permanent vision loss. In the U.S., 
there are approximately 2.4 million eye injuries every year and the majority occur in 18-45 year-
olds, while up to 35% occur in individuals under the age of 17 [1, 2].  Foreign objects in the eye 
have the highest injury rate, followed by contusions and open wounds, and the majority of ocular 
injuries are treated in emergency departments (50.7%), followed by private physicians’ offices 
(38.7%) [3]. Currently, an estimated 4.2 million people in the U.S. are visually impaired while 1.3 
million are legally blind [4, 5], and besides drastically decreasing the patients’ quality of life, vision 
impairment is estimated to incur a total annual economic burden of $38.2 billion in the U.S. [6]. 
Therefore, there exists a need for a treatment therapy that can prevent ocular injury and vision loss, 
thereby improving quality of life and decreasing economic burden of affected individuals.   
1.2 NEUROIMAGING OF THE VISUAL SYSTEM 
The current gold standard for detecting axon degeneration and the efficacy of experimental 
therapies after injury is with histology. However, histology offers no information regarding the 
rate of tissue remodeling or tissue functionality. By utilizing multi-parametric imaging modalities 
in concert with histology, it is possible to gain a more comprehensive understanding of functional 
and structural changes in the visual system and central nervous system. In addition to detecting 
axon degeneration, multi-parametric imaging allows us to analyze the effects of therapeutics on 
the injured visual system over time as it pertains to tissue functionality and white matter integrity. 
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Diffusion tensor imaging (DTI) measures water diffusion patterns in compartments and 
gives information regarding microstructural and fiber organization [7, 8], therefore longitudinal 
DTI can be used to characterize the structural integrity of the visual system over time. 
Magnetization transfer imaging (MTI) measures the magnetization transfer between water bound 
to macromolecules and the surrounding free water [9], and is therefore able to examine changes in 
macromolecular structures. Manganese-enhanced magnetic resonance imaging (MEMRI) has 
been used to study the functional and structural changes in the central nervous system [10-12], as 
well as in identifying structural changes in the visual system [13-17]. Mn2+ ions act as a calcium 
analogue that can enter calcium channels following neuronal activation [11, 18] and can be actively 
transported along axonal pathways via microtubules [11, 19, 20], thereby giving information 
regarding axonal transport and the integrity of axonal pathway structures. Investigation of the 
structural organization of the visual system in glaucoma patients has also shown that glaucoma 
affects both vision-related and non-vision related cortical regions in the brain, which may reflect 
the severity of the disease [21]. Analysis of the brain network pattern revealed that while efficiency 
of functional communication is preserved globally, the efficiency of functional communication is 
affected at a local level [22]. Therefore, resting state functional connectivity MRI (RSfcMRI) can 
be used to examine the functional connectivity between brain regions throughout the visual system. 
In the first aim, two models of unilateral IOP elevation were used as models of optic neuropathy, 
and the effects of IOP elevation on the visual system was determined via optokinetics, multi-
parametric MRI, and histology.  
 4 
1.3 PRIMARY AND SECONDARY INJURY AFTER CNS INJURY 
Primary injuries following ocular trauma commonly involve impact and compression that result 
in tissue necrosis [23], neuronal cell apoptosis [24], and axonal death [25]. Following initial injury 
to the CNS, including the visual system, axons fail to regenerate due to numerous injury-induced 
factors that suppress axon regeneration, including poor intrinsic axon growth ability [26], 
dysfunctional organelle dynamics [27], lost neurotrophic support [28], inhibitory molecules 
expressed by glia [29] or released during cellular injury [30], and a tissue-destructive inflammatory 
immune response [31] that leads to astrogliosis and permanent scarring. Astrogliosis is caused by 
an increase in reactive astrocytes that deposit scar tissue, termed the glial scar, consisting of 
proteoglycans [32, 33]. The glial scar forms a physical and chemical barrier that prevents axonal 
regeneration by releasing axon growth inhibiting molecules, including chondroitin sulfate 
proteoglycan (CSPG) [34], semaphorin-3 [35], ephrin-B2 [36], and Slit proteins [37]. A recent 
study showed that pro-inflammatory microglia polarize reactive astrocytes to the pro-
inflammatory phenotype after optic nerve injury [38], suggesting modulating microglia phenotype 
can influence scar tissue formation and functional recovery after ocular injury.  
After CNS injury, a pro-inflammatory, innate immune response contributes to permanently 
lost neuronal function by promoting changes in the micro-environment and extracellular matrix 
(ECM) that lead to CNS neuronal degeneration and permanent scarring. This pro-inflammatory 
immune response is largely due to activated resident microglia and infiltrating macrophages 
adopting a predominantly pro-inflammatory, M1-like, phenotype. M1-like microglia and 
macrophages release pro-inflammatory factors, including cytokines and microvesicles, that recruit 
additional cells, including microglia, astrocytes, and naïve blood macrophages, that enter the 
injured tissue and polarize toward M1-like phenotypes that can lead to secondary tissue damage 
 5 
and increased scarring. After the initial inflammatory response resolves, M1-like macrophages and 
microglia persist due to pro-inflammatory cytokine signaling cascades that act by both autocrine 
and paracrine signaling mechanisms to maintain pro-inflammatory signaling, ultimately leading to 
permanent scarring. Scar tissue also appears to promote persistent inflammatory signaling. Thus, 
a logical approach to treating CNS injuries is to develop immunomodulatory strategies that 
interrupt cyclical pro-inflammatory signaling cascades while promoting anti-inflammatory, M2-
like, signaling, ultimately altering the default healing response in the CNS from tissue destruction 
and scarring toward positive tissue and ECM remodeling. While many processes are involved in 
preventing axonal remodeling, this dissertation will ultimately focus on the role of microglia and 
astrocytes after ocular injury and how ECM derived products can be utilized to ameliorate the 
initial immune response to preserve neuronal survival after injury. 
1.3.1 Microglia response  
Microglia are part of the innate immune response and act as the resident macrophages of the CNS, 
comprising ~10% of the adult brain [39, 40]. In addition to monitoring the microenvironment for 
signs of cellular damage, microglia are important regulators of synaptic pruning [41], 
oligodendrocyte differentiation [42], and neural precursor migration [43] during development. 
Microglia originate from primitive erythromyeloid progenitors in the yolk sac [44, 45] and 
populate the neuroepithelium early in development. During development, microglia proliferate and 
colonize the CNS, from where they mature into ramified microglia [46]. After birth, microglia 
proliferation rate decreases, and homeostasis is maintained with controlled apoptosis [47].  
In an uninjured CNS, microglia remain in a resting, neuronal support state, assessing the 
surroundings for injury induced signals [48]. After injury, the expression of serum proteins, 
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cytokines, and abnormal neurotransmitters increases [49], thereby signaling microglia to adopt the 
classically activated, M1-like, pro-inflammatory phenotype. Microglia respond rapidly to injury 
induced factors, often within 30 minutes of injury [50, 51]. Once in the M1-like phenotype, 
microglia release inflammatory cytokines, including tumor necrosis factor 1-α (TNF-α), 
interleukin-6 (IL-6), interleukin-1β (IL-1β), interferon- γ (IFNγ), and chemokines [52] to recruit 
immune cells to the injury site and polarize the infiltrating cells to pro-inflammatory phenotypes. 
The M1-like microglia undergo a transition from a ramified resting-state cell to an amoeboid 
shaped phagocytic cell which engulfs debris, damaged cells, and microbes [53]. Recent studies 
showed microglia have a direct effect on astrocyte polarization by secreting TNF-α, IL-6, and 
complement protein 1q (C1-q) which polarizes astrocyte to the A1-like reactive astrocyte 
phenotype [38]. In conjunction with macrophages, microglia contribute to creating a pro-
inflammatory environment by secreting nitric oxide (NO), superoxide, hydrogen peroxide, and 
reactive oxygen species (ROS) [54]. 
Microglia can also polarize to an alternatively activated, M2-like, anti-inflammatory 
phenotype [55]. M2-like microglia are induced by numerous factors, including IL-4, IL-10, and 
IL-13. The effect of the microglia phenotype on tissue remodeling has not been studied as 
extensively as the macrophage phenotype. However, M2-like macrophage polarization promotes 
functional tissue remodeling in non-CNS tissues [56, 57]. Macrophages and microglia polarize to 
one of three M2-like phenotypes, i.e. M2a, M2b, an M2c, based on their function [55, 58-60].  The 
M2a phenotype is induced by IL-4 and IL-13 and provides parasite resistance and suppresses 
inflammation by upregulating Arg1 expression and inhibiting NF-κB isoforms [61, 62]. The M2b 
phenotype is induced by immune complexes and stimulation of toll-like receptors (TLR) and is 
involved in immunoregulation [63]. The M2c phenotype is induced by IL-10, TGF- β, and 
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glucocorticoids and is involved in immunoregulation, tissue remodeling, and ECM deposition after 
injury [64]. Microglia are a versatile cell type and the phenotype and function of microglia depend 
factors in the micro-environment. Microglia phenotype are an early cellular factor in the immune 
response that sets the pro-inflammatory cascades in motion, therefore modulating the microglia 
phenotype can influence downstream inflammatory responses and tissue remodeling after injury.  
1.3.2 Astrocyte response  
Astrocytes are the most abundant cell type in the CNS. Astrocytes originate in the neuroectoderm 
and are divided into two main classes: protoplasmic astrocytes in the grey matter and fibrous 
astrocytes that reside in the white matter. In the CNS, astrocytes participate in numerous functions 
essential to neuronal health [65, 66], metabolism [67, 68], survival, and signaling [69]. During 
development, astrocytes form connections with neurons and other non-neuronal cells [70, 71].  In 
response to CNS injury or degeneration, astrocytes show a marked change in gene expression, 
hypertrophy, and proliferation [72, 73], in a process called reactive astrogliosis. Reactive 
astrogliosis can lead to several beneficial functions, including sequestration of damaged tissue and 
the buffering of excess cations and neurotransmitters [74-76]. However, these changes in astrocyte 
activity and gene expression also have negative consequences including exacerbation of tissue 
damage and glial scarring which inhibits axon regeneration [32]. These negative effects may be 
due to the over-production of reactive oxygen species and inflammatory cytokines as well as the 
release of extrinsic growth inhibitory factors [72, 77], which ultimately induce neuronal cell death 
after injury. Modulation of the astrocyte phenotype is therefore an important consideration in 
promoting neuronal survival after injury. 
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1.4 CURRENT APPROACHES TO OPTIC NERVE REGENERATION  
Injuries to the mature CNS results in lifelong neurologic and functional loss. Ocular injuries can 
lead to irreversible vision loss and decrease the productivity, independence, and quality of life of 
affected individuals. Current treatment therapies include surgery to repair damaged tissues. 
However, no treatments currently exist that can increase neuronal survival and axonal growth after 
injury. Retinal ganglion cells (RGCs) have been shown to have the ability to extend axons in vitro 
and regenerate over short distances in vivo when cultured in optimal conditions. Embryonic RGCs 
have the intrinsic ability to regenerate. However, this ability is lost soon after birth [78], which is 
partially due to amacrine signaling inhibiting RGC growth [26]. Changes in gene expression are 
responsible for the lost intrinsic ability to promote rapid axonal growth [79, 80], and after birth 
RGCs only extend neurites by default when they receive peptide trophic factors that signal the 
cells to promote growth [81].  
Several experimental strategies have been tested to promote retinal ganglion cell (RGC) 
regeneration after injury and some strategies have been successful in promoting partial RGC 
regeneration in the optic nerve [82, 83]. Injection of Zymosan causes RGCs to adopt an active 
growth state [84], and injecting CPT-cAMP in addition to Zymosan with inhibition of phosphatase 
and tensin homolog (PTEN) further enhances the regenerative ability of the RGC axons [85]. The 
Klf family has been associated with regulating axonal regeneration [86], with Klf-4 and -9 
decreasing RGC axon growth and Klf-6 and -7 increasing RGC axon growth. Klf-4 deletion has 
been shown to promote axon regeneration after optic nerve injury [87], and studies have suggested 
Klf-4 deletion enhances CNTF-induced axon regeneration in both optic nerve crush and traumatic 
brain injury models [88]. Transcription factor STAT3 regulates functions that are important for 
axon regeneration, and mitochondrial STAT3 enhances bioenergetics that further potentiates 
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axonal regrowth [89]. The peripheral nervous system (PNS) has limited regenerative potential and 
STAT3 has been shown to be upregulated after injury. Upregulation of STAT3 in CNS has also 
been shown to promote neurite growth in vivo in mice [90]. Klf-4 interacts with STAT3 through 
cytokine induced phosphorylation and the binding suppresses STAT3 dependent gene expression 
[91], and deletion of Klf-4 in vivo therefore induces axon regeneration through the JAK-STAT3 
signaling. Additionally, Wnt3a induces Wnt signaling in RGC which leads significant axonal 
regrowth past the lesion site after optic nerve injury, and the Wnt3a-induced axonal regeneration 
and RGC survival are associated with elevated activation of STAT3. Zinc (Zn) dysregulation in 
retina interneurons are partially responsible for why RGC axons don’t regenerate after injury. Zn 
increases in the retinal amacrine cell processes within an hour after optic nerve injury and 
continues to rise over 24 hours, after which the Zn is transferred to the RCGs via vesicular release 
[92], and intravitreal injections of Zn chelators have been shown to increase RGC survival after 
injury. CNTF an RhoA have been shown to have additive effects that promote axon regeneration 
when used in conjunction with one another [93], and SOCS3 [94] and PTEN [95] deletion also 
increase axon regeneration potential and promote axon regrowth [96].   
The aforementioned experimental therapies can induce long distance axon regrowth in 
mouse models of optic nerve injury. However, these multi-factorial approaches often include gene 
therapies of which down-stream effects are unclear. Although the approaches are not optimal and 
face clinical translation hurdles, these studies indicate RGC axons have the ability grow and 
remodel when presented with the correct factors.  
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1.5 EXTRACELLULAR MATRIX SCAFFOLDS 
Redirecting the default immune response can be done by providing factors derived from the ECM 
that modulate the phenotypic transition of macrophages and T-helper cells from a pro-
inflammatory to a pro-remodeling state. Regenerative medicine strategies using inductive biologic 
scaffolds composed of ECM have been successful in numerous pre-clinical and clinical studies. 
More than 8 million patients have been successfully treated with ECM bioscaffolds in a variety of 
clinical applications involving musculoskeletal, gastrointestinal, and urogenital tissues, among 
others [97]. Initial studies using ECM technology in nervous system tissues are also now showing 
encouraging results [98]. Extracellular matrix consists of the secreted structural and functional 
molecules of the resident cells of each tissue that define both cellular and tissue identity [97, 99]. 
ECM bioscaffolds are derived by decellularizing healthy tissues, typically xenogeneic (porcine) in 
origin, to decrease scarring and promote site-appropriate tissue repair in tissues the body cannot 
repair by default. ECM provides mechanical and biochemical support, facilitates intercellular 
communication, and modulates cellular and metabolic functions in a tissue-appropriate manner 
[100]. When prepared properly, ECM is a tunable biocompatible platform that can be derived from 
numerous tissue sources and used in various forms, including powders [101], sheets [102], and 
injectable hydrogels [103], which can all be further tuned mechanically and biochemically based 
on the nature and severity of the injury [104]. 
Though the specific mechanisms by which ECM derived factors influence cell and tissue 
remodeling are only partially understood, ECM bioscaffolds are known to promote an anti-
inflammatory, reparative, M2-like macrophage phenotype, recruit endogenous stem and 
progenitor cells and promote their differentiation in a site-appropriate manner, and mitigate scar 
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tissue formation [105-108]. Specifically, ECM is hypothesized to increase anti-inflammatory 
signaling at the injury site by increasing the M2/M1 macrophage ratio [109]. A low ratio M2/M1 
is suggested to promote inflammation and scarring, whereas a high M2/M1 ratio appears to 
promote positive tissue remodeling [57, 105]. ECM appears to increase the M2/M1 macrophage 
ratio, in part, by releasing protein degradation products, termed matricryptic peptides [110], as 
infiltrating immune system cells degrade ECM bioscaffolds. In addition to modulating the innate 
immune response, matricryptic peptides are hypothesized to regulate several components of the 
healing response, either directly or indirectly, including angiogenesis [111], stem cell recruitment 
and differentiation [110], and neurogenesis [112], with ECM from younger, homologous tissues 
often being more effective [113-115], like fetal heart [116] and kidney [117]. Macrophages 
polarized toward an alternatively activated, M2-like, phenotype secrete cytokines and neurotrophic 
factors, and express cell-surface markers consistent with antigen-presenting activity, indicating 
ECM bioscaffolds have the potential to influence nerve, immune, and glial cell activities by 
modulating macrophage phenotypes. In agreement with this idea, pre-clinical studies suggest ECM 
bioscaffolds can promote positive tissue remodeling in rodent CNS injury models.  
1.5.1.1 Matrix bound nanovesicles 
MBV are nano-sized lipid bound bodies embedded securely within the extracellular matrix, are 
distinct and separate from exosomes, and represent a significant vertical advance in understanding 
tissue homeostasis and cellular function. Emerging evidence shows MBV release during ECM 
scaffold degradation is critical to promoting reparative, anti-inflammatory macrophage phenotypes 
[108]. MBV are nanometer-sized, membranous vesicles similar in size and structure to exosomes, 
but distinct with respect to cargo, surface markers, and compartmentalization. Whereas exosomes 
primarily exist in body fluids, MBV are localized to the collagen fibrils within all experimental 
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and commercial ECM bioscaffolds analyzed to date [118]. MBV are highly stable and protect 
biologically active signaling cargo, including miRNAs and proteins, from degradation [118, 119]. 
These MBV survive even harsh ECM decellularization processes and thus likely play a 
fundamental role in tissue and organ organization across species and a regulatory role in the tissue 
response to injury. Recognition of their presence and an understanding of their biologic activity 
provides for possible new therapeutic approaches that are otherwise untenable. Derived from 
healthy, pro-regenerative tissues, MBV have biologic potential that exceeds that of extracellular 
vesicles derived from cultured cell lines. MBV are plentiful, lyophilizable, highly stable, and easily 
incorporated into injury-specific platforms like dressings, injections, or gels. MBV stability and 
adaptability make them easily customizable for therapeutic platforms appropriate to the nature and 
to the severity of the injury. 
MBV can recapitulate effects of the ECM bioscaffolds from which they were derived and 
these effects appear to depend on MBV miRNA cargo [120]. MBV carry unique (i.e. tissue 
specific) and complex cargo, including miRNAs, lipids, proteins, cytokines, carbohydrates, and 
other small molecules, capable of activating a variety of extra- and intracellular signaling 
pathways. Initial studies indicate that the cellular response to MBV depends on both surface 
proteins and the intra-luminal miRNA cargo [121]. Interestingly, miRNA cargo in MBV, derived 
from different tissues, are enriched in highly conserved miRNAs involved in cell cycle regulation 
and differentiation [121, 122], suggesting MBV play a fundamental role in ECM mediated tissue 
and organ development, organization, and function, possibly by regulating cellular phenotypes in 
a site appropriate manner. Small RNQ sequencing RNA-seq identified known and novel candidate 
miRNA packaged within MBV [118], and showed a differential miRNA signature dependent on 
the anatomical origin of the source tissue. Moreover, a cohort of miRNAs known to regulate 
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neuronal signaling pathways involved in neuronal differentiation and neurite growth, including 
miRNAs -30b, -125b, and -133b [123-125], were identified to be highly enriched in MBV. These 
results indicate MBV contain bioactive components able to regulate cellular function and have the 
potential to regulate and promote CNS tissue remodeling after injury.   
1.6 SPECIFIC AIMS  
Specific Aim 1: After traumatic optic neuropathy, to determine if diffusion tensor imaging 
(DTIMRI), manganese-enhanced MRI (MEMRI), and optokinetics can predict changes in the rate 
of retinal ganglion cell axon degeneration that predict changes in visual behavior 
Hypothesis: After acute optic neuropathy, non-invasive, longitudinal MRI and behavioral studies 
can predict changes in RGC axon integrity along the visual pathway, axonal transport, and visual 
function 
 
Specific Aim 2: To determine if tissue-specific ECMs differentially modulate the default healing 
response in the CNS 
Hypothesis: Aim 2a tests the hypothesis CNS specific, brain derived ECM will increase RGC 
survival and neurite growth in vitro 
Hypothesis: Aim 2b tests the hypothesis that CNS specific brain ECM will increase RGC axon 
survival and growth and decrease astrocyte activation in vivo 
 
Specific Aim 3: To determine if matrix bound nanovesicles (MBV) recapitulate ECM mediated 
changes in the default healing response  
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Hypothesis: Aim 3 tests the hypothesis that MBV will increase RGC axon growth in vitro, and 
RGC survival and function in vivo as detected by immunohistochemistry and electroretinography 
(ERG) 
1.6.1 Impact of specific aims  
Ocular injuries resulting in blindness remain a persistent problem, yet little is known about axonal 
degradation progression and there is currently no off the shelf, easily administered product to 
provide neuroprotection and promote neuro-regeneration after injury. As a result, patients are 
relegated to a life of diminished productivity and a compromised quality of life. Imaging 
modalities allow us to probe the progression of white matter degeneration after injury, which is 
the first step to understanding the effects of injury on the visual system, as well as the effects of 
proposed therapeutics applied to injured ocular tissue. ECM-based medical technology continues 
to drive innovation from both a scientific and clinical perspective. Recently discovered MBV are 
an excellent example of such advancements and provide many opportunities for investigating 
signaling mechanisms by which tissue remodeling occurs during health and following injury in 
the adult mammalian CNS. The proposed minimally invasive MBV treatment has the very real 
possibility to preserve visual function in injured patients. The MBV treatment can be delivered 
intravitreally; therefore, requires no invasive surgical procedure and can be administered 
immediately after injury. In addition to treating ocular injuries, the MBV therapy may have benefit 
for other CNS injuries such as traumatic brain and spinal cord injuries, and this therapeutic 
approach applies to soldiers and civilians alike 
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2.0  CITICOLINE AMELIORATES THE NEUROBEHAVIORAL EFFECTS OF 
INTRAOCULAR PRESSURE ELEVATION ON THE VISUAL SYSTEM 
2.1 INTRODUCTION 
Glaucoma is a neurodegenerative disease of the visual system that involves progressive retinal 
ganglion cell death, optic nerve damage, and irreversible vision loss [126-129]. Glaucoma is the 
second leading cause of blindness worldwide; 60 million people are estimated to have glaucoma, 
with 8.4 million legally blind [130, 131]. One major risk factor for glaucoma is an increase in 
intraocular pressure (IOP). However, the direct causes of glaucoma are unknown, and how 
different degrees of IOP elevation affect glaucoma pathogenesis remains unclear. In addition, 
currently, the only clinically proven way to slow down the progression of glaucoma is decreasing 
IOP, yet neurodegeneration of the visual system may still occur after lowering IOP to population-
derived normal levels [132, 133]. Therefore, there exists a need for a better understanding of 
glaucoma mechanisms resulting from IOP elevation, as well as a treatment mechanism beyond 
lowering IOP that can further slow the progression of the disease or decrease the severity of 
damage to the visual system to preserve or restore visual function.  
To determine the pathophysiological mechanisms of glaucoma disease progression, several 
animal models have been developed targeting different aspects of IOP elevation-induced 
pathogenesis [134, 135]. However, because of limited methods available to probe eye-brain, and 
visual behavior relationships in vivo and simultaneously, these studies were mainly performed ex 
vivo, and the longitudinal effects of different degrees of IOP elevation on the structural and 
functional integrity of the visual system remain unclear. Recent studies also suggest that glaucoma 
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may not only involve the eye, but also the brain in a trans-synaptic manner [136, 137]. However, 
results remain controversial partly because of small samples [138], and there are barriers to 
determine if the brain can be the target for glaucoma therapeutics apart from the eye. Development 
of a well-controlled, in vivo model system for longitudinal neurobehavioral analyses may help 
clarify mechanisms affecting vision loss in glaucoma patients and provide a platform to evaluate 
the efficacy of proposed glaucoma treatments. Therefore, in this study, we combined the use of 
experimental glaucoma models, optokinetics, and advanced structural and functional magnetic 
resonance imaging (MRI) techniques to analyze the effects of acute and chronic IOP elevation on 
visuomotor behavior response, white matter integrity, axonal transport, and functional 
connectivity between visual brain nuclei over time. We hypothesize that different degrees of IOP 
elevation may induce different extents of structural and functional brain changes and behavioral 
outcomes. To explore treatment mechanisms that can reduce glaucomatous damage independent 
of IOP reduction, one may postulate candidate strategies that can act to preserve neural tissues, 
promote neurorepair, and reduce functional loss across other neurodegenerative diseases and 
injuries. Among these candidates, citicoline is an endogenous compound that has been suggested 
to slow down the detrimental effects of Alzheimer’s disease [139], traumatic brain injury [140], 
multiple sclerosis [141] and cerebral ischemia [142] when administered exogenously. Citicoline 
(cytidine 5’-diphosphocoline) is a non-toxic [143], endogenous compound that plays important 
roles in cell membrane lipid synthesis and repair and phospholipid degradation inhibition [144], 
Citicoline increases certain neurotransmitters such as dopamine (by enhancing tyrosine 
hydroxylase activity and inhibiting dopamine reuptake), noradrenaline, and serotonin; and serves 
as a choline donor in the biosynthesis of acetylcholine [145, 146]. The effects of citicoline on 
glaucomatous neurodegeneration remain unclear. After oral ingestion, citicoline is hydrolyzed in 
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the intestinal wall and liver to choline and cytidine, where both compounds are rapidly absorbed, 
enter systemic circulation, cross the blood-brain barrier, and enter the central nervous system 
[147]. Therefore, in this study, we hypothesize that oral citicoline treatment can ameliorate the 
effects of IOP elevation on glaucomatous damage and functional deterioration in the visual system.  
By using non-invasive multi-parametric MRI and behavioral studies, association can be 
made between the degree of IOP elevation and longitudinal structural and functional changes in 
the visual system after experimental glaucoma induction and oral citicoline treatment.  In this 
study, we used diffusion tensor imaging (DTI) to characterize microstructural fiber organization 
along the visual pathway by measuring water diffusion patterns in white matter compartments [7]. 
Specifically, DTI-derived parameters, including fractional anisotropy (FA; sensitive to overall 
microstructural integrity), axial diffusivity (λ//; sensitive to axonal integrity), and radial diffusivity 
(λ⊥; sensitive to myelin integrity [148, 149]) were used to assess the resultant structural integrity 
of the visual pathway after IOP elevation and oral treatment. We also used magnetization transfer 
ratio from magnetization transfer imaging (MTI) to examine changes in macromolecular 
structures, including myelin, by measuring the magnetization transfer between water bound to 
macromolecules and the surrounding free water [9] in the optic nerve. Manganese (Mn) ions can 
offer positive T1-weighted MRI contrast enhancement and act as a calcium analogue that enters 
calcium channels and be actively transported anterogradely along axonal pathways via 
microtubules [18, 19]. Therefore, Mn-enhanced MRI (MEMRI) was used to provide information 
regarding anterograde transport and the integrity of the axonal pathway after IOP elevation and 
oral treatment. Last but not least, resting-state functional connectivity MRI (RSfcMRI) was used 
to explore the functional connectivity (FC) between brain regions throughout the visual system 
[150]. These multi-parametric brain MRI findings were examined alongside optokinetic and 
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histological assessments, to determine how different magnitudes and durations of IOP elevation 
affected neurobehavioral outcomes with and without oral citicoline treatment. 
2.2 MATERIALS AND METHODS 
2.2.1 Experimental paradigm 
Eighty-two adult female Long Evans rats (Charles River Laboratories, Wilmington, MA) at about 
8 weeks old were used in this study. They were housed in a 12 hr light/dark cycle with rat chow 
and water available ad libitum. Animals from each of the acute IOP elevation, chronic IOP 
elevation and sham control groups received neurobehavioral assessments using optokinetics (days 
0, 7, 14, and 35), DTI (days 3, 7, 14, and 35), MTI (days 3, 7, 14, and 35), RSfcMRI (day 35), 
MEMRI (day 35), and histology (day 35) (Figure 1A). Additionally, a subset of the animals with 
chronic IOP elevation received oral doses of citicoline daily for 7 days prior to IOP elevation 
induction, and every 48 hours for 14 days after IOP elevation induction. The acute groups had their 
IOP measured during experimental induction, whereas the chronic groups had their IOP measured 
at days 3, 7, 14, and 35 to verify that the IOP remained elevated for the duration of the experimental 
period. All experiments were approved by the University of Pittsburgh Institutional Animal Care 
and Use Committee, and investigators followed guidelines from the Association for Research in 
Vision and Ophthalmology’s statement for Use of Animals in Ophthalmic and Vision Research 
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2.2.2 Anesthesia 
Animals were anesthetized via isoflurane inhalation (3% induction, 1.5% maintenance) for all 
chronic IOP elevation induction, MR imaging procedures, and Mn contrast agent injections. For 
acute IOP elevation induction, rats were anesthetized with an intraperitoneal injection of 75:10 
mg/kg ketamine/xylazine cocktail (Henry Schein, NY). All procedures were performed under 
sterile conditions, and rat body temperature was maintained and monitored using a circulating 
water blanket and a rectal thermometer. After experiments, animals were placed on a heating pad 
for recovery and monitored until fully conscious and ambulating. 
2.2.3 Acute IOP elevation induction 
Twenty-five animals received mild (n=13) or severe (n=12) acute IOP elevation in the right eye 
via physiological saline anterior chamber perfusion. The left eye remained untreated and served 
as an internal control. Proparacaine hydrochloride ophthalmic solution (Bausch & Lomb, Inc., 
Rochester, NY, USA) and tropicamide ophthalmic solution (Akorn, Lake Forest, IL) were 
topically applied to the right eye to induce analgesia and pupil dilation, respectively. A 30-gauge 
needle was connected to a sterile saline reservoir (0.9% sodium chloride; Baxter International 
Inc., Deerfield, IL, USA) via sterile tubing. The needle tip was inserted into the right eye’s 
anterior chamber under a surgical microscope, parallel to the iris, taking care not to touch the iris 
or lens. Once inserted, the needle was secured in place to avoid movement during the experiment. 
IOP was elevated to 40 mmHg and 130 mmHg for mild and severe acute IOP elevation, 
respectively, by elevating the saline reservoir to the appropriate height. The reservoir was secured 
in place for 60 min and IOP was measured with both a handheld tonometer (Icare TonoLab, 
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Finland) and a pressure transducer (BIOPAC Systems, Goleta, CA, USA) connected in line with 
sterile tubing. Afterwards, the reservoir was lowered, and the needle removed from the anterior 
chamber. Antibiotic ointment (Gentamicin, Akorn, Lake Forest, IL) was applied topically 
immediately after removal of the needle. Sham procedures (n=9) were performed by cannulating 
the right eye as described and keeping the saline reservoir at eye level for 60 min.  
2.2.4 Chronic IOP elevation induction 
Thirty-eight animals received an intracameral injection of an optically clear cross-linking 
hydrogel to the right eye to induce chronic IOP elevation. The left eye remained untreated and 
served as an internal control. Proparacaine and tropicamide were first topically applied to the 
right eye to induce analgesia and pupil dilation. The right eye was injected intracamerally with 
15 µl of a 1:1 mixture of 4% vinyl sulfonated hyaluronic acid and 4% thiolated hyaluronic acid 
[151]. The injections were performed under a surgical microscope with a microinjection system 
through a glass micropipette (World Precision Instruments, Sarasota, FL, USA). The solidified 
hydrogel obstructed aqueous outflow, thereby causing a sustained increase in IOP. Antibiotic 
ointment was applied topically immediately after injection. Sham procedures were performed on 
10 animals by injecting only the buffer solution into the right anterior chamber. IOP was 
measured with the handheld TonoLab tonometer at days 3, 7, 14, and 35 after hydrogel injection 
to verify that the IOP elevation was sustained. 
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2.2.5 Citicoline administration  
Among the 38 animals that received chronic IOP elevation induction, 19 of them also received 
daily citicoline treatment (500 mg/kg; Jarrow Formulas, Los Angeles, CA) via oral gavage for 7 
days prior to chronic IOP elevation induction, and every 48 hours for 14 days after chronic IOP 
elevation induction. Citicoline was freshly diluted in saline before each treatment.  
2.2.6 Optokinetics 
The OptoMotry virtual-reality optokinetic system (CerebralMechanics Inc., Lethbride, Alberta, 
Canada) [152, 153] was used to assess visuomotor behavior by quantifying the visual acuity of 
each eye. Prior to data collection, animals were acclimated to the system once per day for three 
days. Acclimation sessions lasted 20 min during which the animals were exposed to stimuli 
similar to those presented during data collection. During data collection, spatial frequency ranged 
from 0.042 to 0.750 cycles/degree using a simple staircase method while rotation speed (0.12 
degrees/s) and 100% contrast were maintained throughout the experiment.  
2.2.7 MRI Protocols 
All MR imaging was performed using a 9.4-Tesla/31-cm Varian/Agilent horizontal MRI scanner 
(Santa Clara, CA, USA) with a 38 mm diameter transmit-receive volume coil and a receive 
surface coil.  
DTI was acquired for all animals using a fast spin-echo sequence with 12 diffusion 
gradient directions at b = 1.0 ms/μm2 and 2 non-diffusion-weighted images at b = 0 ms/μm2 (b0). 
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Other imaging parameters included: repetition time/echo time (TR/TE)= 2300/27.8 ms, echo train 
length=8, diffusion gradient duration time (δ)/diffusion gradient separation time (Δ) = 5/17 ms, 
number of repetitions = 4, field of view = 2.6 x 2.6 cm2, acquisition matrix = 192 x 192 (zero-
filled to 256 × 256), number of slices = 20, and slice thickness = 1 mm. Slices were oriented 
orthogonal to the prechiasmatic optic nerves.  
MTI was acquired for all animals at the level of the prechiasmatic optic nerves at the same 
orientation and the same time points as DTI with 9.5 µT saturation pulses at 4000 Hz off-
resonance. Other parameters included: TR/TE = 1500/8.43 ms, echo train length = 8, number of 
repetitions = 2, field of view = 2.6 x 2.6 cm2, acquisition matrix = 192 x 192 (zero-filled to 256 
× 256), number of slices = 1, and slice thickness = 1 mm.  
MEMRI was done on a randomly selected subset of the mild acute IOP elevation (n = 9), 
severe acute IOP elevation (n = 9), acute sham control (n = 6), untreated chronic IOP elevation 
(n = 12), citicoline-treated chronic IOP elevation (n = 13), and chronic sham control (n = 6) 
groups. After all imaging and behavioral studies were completed, each animal received binocular 
intravitreal injections of 1.5 µL of 100 mM manganese chloride (MnCl2). T1-weighted images 
were acquired before and at 8 hr after MnCl2 injections with a fast spin-echo sequence. The same 
geometric parameters were used as for DTI, with TR/TE = 600/8 ms, echo train length = 8, 
number of slices = 8 and slice thickness = 1 mm.  A saline syringe phantom was placed next to 
the rat head for signal normalization to account for potential system instability between imaging 
sessions. 
For RSfcMRI, T2-weighted images were first acquired with the following parameters to 
serve as an anatomical reference: TR/TE = 4000/36 ms, echo train length = 8, field of view = 2.6 
x 2.6 cm2, acquisition matrix = 192 x 192 (zero-filled to 256 × 256), number of slices = 6, and slice 
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thickness = 1 mm. For RSfcMRI, a single-shot gradient-echo echo-planar imaging sequence with 
420 repetitions was used for session. Each session resulted in 14 min of scan time, and 4 sessions 
were acquired per animal, resulting in approximately 1 hr of total scan time per animal. Other 
parameters included: TR/TE = 2000/18 ms, field of view = 32 x 32 mm2, acquisition matrix = 64 
x 64, number of slices = 6, and slice thickness = 1 mm.    
2.2.8 Histology 
Animals not receiving Mn injection were sacrificed at the terminal point and used for histology. 
They were euthanized with an intraperitoneal injection of pentobarbital (50 mg/kg) and whole-
body perfusion was used to fix the tissue for histology. When the animals no longer responded to 
a toe pinch, they were perfused with phosphate buffered saline (PBS) at pH 7.4, followed by 4% 
paraformaldehyde in PBS. Optic nerves were harvested and fixed for an additional 48 hours in 4% 
paraformaldehyde in PBS at 4ºC. Samples were placed in 30% sucrose for cryoprotection, and 
then embedded in optical cutting temperature medium. The optic nerves were sectioned into 10µm 
thick sections, placed on histology slides, and kept at -20ºC until use.  
Sections were stained for phosphorylated neurofilament (pNF) (1:1000, Covance, NJ, 
USA) and myelin basic protein (MBP) (1:50, Santa Cruz Biotechnology, TX, USA). The sections 
were washed three times with PBS and blocked and permeabilized overnight with 0.2% Triton X-
100, 1% bovine serum albumin (BSA), and 5% donkey serum in PBS. pNF and MBP primary 
antibodies were diluted to working concentrations in 1% BSA and 5% donkey serum in PBS and 
incubated for 3 days at 4ºC. The sections were washed three times in PBS and incubated with 
secondary antibodies (1:500 donkey anti-goat Alexa488 for MBP, 1:500 donkey anti-mouse 
Alexa546 for pNF) in 1% BSA in PBS for 2 hr at room temperature. Sections were rinsed in PBS, 
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stained with 4′,6-Diamidino-2-phenylindole (DAPI), and imaged with a confocal microscope 
(Olympus Fluoview1000, Tokyo, Japan) at 60X magnification with the same exposure times used 
across sections for each antibody.  
2.2.9 Data analysis 
For DTI, SPM8 (Wellcome Department of Imaging Neuroscience, University College, London, 
UK) was used for co-registration between diffusion-weighted and non-diffusion-weighted 
images. 3 x 3 diffusion tensors were placed on non-diffusion-weighted and diffusion-weighted 
images on a pixel-by-pixel basis using DTIStudio v3.02 (Johns Hopkins University, Baltimore, 
MD). DTI parametric maps including fractional anisotropy (FA), axial diffusivity (λ//) and radial 
diffusivity (λ⊥) maps were computed using eigenvectors and eigenvalues in DTIStudio. Regions 
of interest (ROIs) were drawn manually using ImageJ v1.47 (Wayne Rasband, NIH, USA) at the 
prechiasmatic optic nerves at Bregma 1.5 mm, and the optic tracts at Bregma -3.5 mm based on 
the FA directionality map, FA value map, λ// and λ⊥ maps and the rat brain atlas [154]. The 
corresponding DTI parametric values were then extracted. As more than 90% of the optic nerve 
fibers in adult rodents decussate at the optic chiasm to the contralateral optic tract [155], The 
visual pathway projected from the injured right eye (right optic nerve and left optic tract) was 
assessed relative to that projected from the uninjured left eye (left optic nerve and right optic 
tract), followed by between-group comparisons over time.  
For MTI, the magnetization transfer ratio (MTR) for the prechiasmatic optic nerve was 
calculated as MTR = (M0-Msat)/M0, where Msat represents the magnetization signal with 
saturation pulse, and M0 represents the magnetization signal without saturation pulse. ROIs were 
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manually drawn on the prechiasmatic optic nerve based on MTR maps and the rat brain atlas and 
quantified using ImageJ.  
For MEMRI, T1-weighted signal intensities in the left and right optic nerves, lateral 
geniculate nuclei (LGN), and superior colliculi (SC) were measured using manual ROI drawing 
in ImageJ. Signal intensities were normalized to the nearby saline phantom to counter for system 
instability between imaging sessions. Differences in Mn enhancement between injured and 
uninjured visual pathways were quantified by calculating the percentage difference in normalized 
T1-weighted signal intensities in the right optic nerve, left LGN and left SC relative to the left 
optic nerve, right LGN and right SC, respectively. 
For IOP, optokinetics and MRI (except RSfcMRI) assessments, all results are presented as 
mean ± standard error of mean (SEM). ANOVA was used in conjunction with a Tukey's post-hoc 
test to determine significance between groups using GraphPad Prism v5.00 (GraphPad Software 
Inc., La Jolla, CA, USA). Results were considered significant when p < 0.05. 
For RSfcMRI, images were realigned to the first volume to account for small head motions 
using a 3 degree-of-freedom rigid body transformation (translations in the imaging plane and 
rotations about the slice direction). The images were then smoothed with a 2D Gaussian function 
with a standard deviation of 2 voxels, followed by a temporal ideal bandpass filter with cutoff 
frequencies of 0.01 and 0.1 Hz. Finally, the effects of motion were regressed out of the signal using 
the motion parameters estimated during realignment, as well as the first and second order temporal 
derivatives of the motion parameters. Before this regression step, the motion parameters were also 
temporally filtered as above to avoid the reintroduction of high-frequency noise into the 
preprocessed data. ROIs were drawn manually on the LGN, SC, and visual cortex (VC) in each 
hemisphere, beginning with the first run of data for each animal and then propagated to all 
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remaining runs by performing a 3-degree-of-freedom transformation between the first image of 
each pair of runs, thereafter applying this transformation to the drawn ROIs. Functional 
connectivity (FC) in each run was then summarized by computing the mean time course in each 
region, computing the Pearson correlation between each pair of time courses, and converting these 
correlation coefficients to z-score using the Fisher r-to-z transformation. In this way, each run of 
data was summarized by a graph where the ROIs define the nodes and the strength of the 
correlation between a given pair of ROIs defines the edges. For each edge in the graph, effects for 
group-wise differences were investigated using a linear mixed-effects model with random slopes 
and intercepts included for each animal. An F-test was done on each group and a false discovery 
rate corrected Q<0.05 considered significant. Where the F-tests were significant, post-hoc testing 
was performed with the same model but with data restricted to the two groups being compared. 
2.3 RESULTS 
2.3.1 IOP was elevated to different magnitudes and durations and was unaffected by 
citicoline treatment  
A schematic of the experimental plan is provided in Figure 1. In brief, eighty-two adult female 
Long Evans rats were randomly assigned to one of six IOP elevation groups. In the acute IOP 
elevation groups, animals received mild elevated IOP at 40 mmHg (n=13), or severe elevate IOP 
at 130 mmHg (n=12), or normal physiological IOP of approximately 15 mmHg as a sham control 
(n=9) via anterior chamber perfusion to the right eye for 1 hour. In the chronic IOP elevation 
groups, IOP was elevated to about 30 mmHg sustainably for 5 weeks via intracameral injection 
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of an optically clear, crosslinking hydrogel into the right eye. Nineteen animals with chronic IOP 
elevation did not receive any oral treatment (n=19), whereas another 19 animals with chronic IOP 
elevation received daily citicoline treatment via oral gavage for 7 days prior to IOP elevation 
induction, and every 48 hours for 14 days after IOP elevation induction (n=19). Another batch of 
animals received sham procedures by intracameral buffer solution injection without oral 
treatment (n=10). Optokinetics, DTI and MTI were performed longitudinally over the 
experimental period of 5 weeks after IOP elevation induction, whereas RSfcMRI, MEMRI and 
histology were performed at the end experimental time point.  
2.3.2 Acute and chronic IOP elevation decreased visual acuity, whereas oral citicoline 
treatment increased visual acuity in the experimental eyes  
For the acute IOP elevation groups, the target IOP level was confirmed with both a handheld 
tonometer (Icare Tonolab, Finland) and a pressure transducer (BIOPAC Systems, Goleta, CA, 
USA) connected in line with sterile tubing during anterior chamber perfusion (Figure 2A). The 
same hand-held tonometer was used to confirm successful induction of chronic IOP elevation. 
As shown in Figure 2B, intracameral hydrogel injection to the right eye significantly elevated 
IOP for the duration of the experimental period, with no significant IOP difference between 
citicoline-treated and untreated animals. In both citicoline-treated and untreated groups, the IOP 
of the right eye steadily increased from day 3 to day 14 and remained unchanged from day 14 to 
day 35. The left uninjured eye of the experimental groups, as well as both eyes of the sham group, 
remained unchanged in terms of IOP over the experimental period.  
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Using optokinetic behavioral assessments, the visual acuity of the left, uninjured eye in all acute 
and chronic groups was found to remain unchanged over time and was comparable with the right 
experimental eye before IOP elevation (Figure 2C-D). The visual acuity of the right experimental 
eye under both mild and severe acute IOP elevation significantly decreased from pre-injury (day 
0) to day 7 and continued to be significantly lower than the visual acuity of the left eye at days 
Figure 1. A. Experimental timeline for measuring eye, brain, and behavioral changes following acute and 
chronic intraocular pressure (IOP) elevation across 5 weeks. B. Treatment paradigm for oral citicoline 
administration. A subgroup of animals in the chronic IOP elevation group received oral citicoline treatment at 
a concentration of 500 mg citicoline/ kg of the animal. Animals received daily citicoline administration for 7 
days prior to IOP elevation induction, and every 48 hours for 14 days following chronic IOP elevation 
induction. 
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14 and 35 (Figure 2C). At days 7, 14, and 35, the right experimental eye had a significantly lower 
visual acuity under severe acute IOP elevation than mild acute IOP elevation (Figure 2C).  
 
 
A 
Figure 2. Intraocular pressure (IOP) profiles (a & b) and visual acuity (VA) (c & d) in acute and chronic 
animals. a. Anterior chamber perfusion elevated IOP transiently for one hour, after which IOP returned to 
baseline at ~15mmHg. b. Hydrogel injection to the right eye significantly elevated IOP in all animals for the 
duration of the experimental period.  c. By day 7, the VA of the right eyes of the mild and severe groups were 
significantly decreased compared to the left eyes, and this persisted at days 14 and 35. d. The VA of the right 
eyes of both citicoline-treated and untreated animals became worse starting at day 7. The worsening of VA 
in the right eyes appeared significantly slower for the citicoline-treated group compared to the untreated 
group.  
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The right eye in both chronic IOP elevation groups and the chronic sham control group 
showed a significant visual acuity decrease from day 0 to day 7 (Figure 2D). By day 14, the right 
eye of the sham group had apparently recovered, and there was no visual acuity difference 
between left and right eyes at days 14 and 35. In contrast, the right eye of both citicoline-treated 
and untreated groups showed a persistent visual acuity decrease at days 14 and 35 after chronic 
IOP elevation. However, under similar levels of chronic IOP elevation, the treated group had a 
significantly higher visual acuity in the right experimental eye than the untreated group at days 
14 and 35 (Figure 2D).  
2.3.3 IOP elevation decreased fractional anisotropy and increased radial diffusivity along 
the visual pathway in diffusion tensor MRI, while citicoline treatment ameliorated such 
effects   
Fractional anisotropy, radial diffusivity, and axial diffusivity were calculated as percentage 
change between injured (right) and uninjured (left) visual pathways. When examining the 
structural integrity of the visual pathway using longitudinal DTI (Figures 3-4), among the acute 
groups (Figure 3), the fractional anisotropy in the optic nerve was significantly lower at day 35 
after severe acute IOP elevation compared to sham procedures (Figure 3B). Fractional anisotropy 
in the optic tract also showed a similar but statistically insignificant trend (Figure 3E), whereas 
radial diffusivity in the optic nerve was significantly higher at day 35 after severe acute IOP 
elevation compared to the sham control (Figure 3D). Over the time course, significant progression  
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Figure 3. A. Representative fractional anisotropy (FA) color and value maps in the optic nerve and optic tract in 
mild, severe, and sham injury animals. B. There were significant differences in FA and RD in the optic nerves at 
day 35 between the severe group and sham injury 
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Figure 4. A. Representative fractional anisotropy (FA) color and value maps in the optic nerve and optic tract 
in untreated, citicoline treated, and sham injury (untreated) animals. B. There were significant differences in 
FA, AD, and RD between groups in the optic nerve and optic tract. 
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in fractional anisotropy decrease and radial diffusivity increase were observed within severe acute 
IOP elevation group when comparing days 3 and 7 to day 35. 
Among the chronic groups (Figure 4), the optic nerve showed a significantly lower 
fractional anisotropy at days 7 and 35 after untreated chronic IOP elevation when compared to 
the sham control (Figure 4B), while the fractional anisotropy in the optic tract was significantly 
lower at days 14 and 35 after untreated chronic IOP elevation compared to citicoline-treated 
chronic IOP elevation (Figure 4E). The axial diffusivity in the optic nerve of the untreated chronic 
IOP elevation group was significantly lower at days 7 and 35 compared to the sham group (Figure 
4C), while the optic tract of the untreated chronic IOP elevation group showed a significantly 
lower axial diffusivity at day 3 compared to the sham group (Figure 4F). The radial diffusivity in 
the optic nerve was significantly higher at days 7, 14, and 35 after untreated chronic IOP elevation 
compared to the sham control (Figure 4D), while the radial diffusivity in the optic tract was 
significantly higher at days 14 and 35 after untreated chronic IOP elevation compared to the sham 
control (Figure 4G). No significant difference in DTI parametric value was observed between 
citicoline-treated chronic IOP elevation and sham control groups along the visual pathway 
(Figure 4B-G). 
2.3.4 IOP elevation decreased magnetization transfer ratio in the optic nerve, which was 
ameliorated by citicoline treatment  
Magnetization ratio was calculated as percentage change between injured (right) and uninjured 
(left) visual pathways. Among the acute groups (Figures 5A), the prechiasmatic optic nerve 
showed an early decline in magnetization transfer ratio at day 3 after severe acute IOP elevation. 
Such decline was significantly larger than both the mild acute IOP elevation and sham control 
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groups. The magnetization transfer ratio in the severe acute IOP elevation group remained 
significantly lower than the sham control group till the end experimental time point at day 35. 
Among the chronic groups (Figures 5B), the magnetization transfer ratio in the optic nerve was 
significantly lower after chronic IOP elevation without citicoline treatment when compared to 
that with citicoline treatment at both days 14 and 35, while the magnetization transfer ratio 
between untreated chronic IOP elevation and sham control groups was significantly different at 
day 35. No significant difference in magnetization transfer ratio was observed between citicoline-
treated chronic IOP elevation and sham control groups in the optic nerve. 
 
 
 
Figure 5. Magnetization transfer ratio between left and right optic nerves following acute (A) and chronic (B) 
IOP elevation. a. There was a significant difference between mild and severe groups 3 days after IOP elevation, 
and between sham and severe groups. b. There was a significant difference between untreated and citicoline 
treated groups 14 and 35 days after IOP elevation, and between untreated and sham groups. 
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2.3.5 IOP elevation decreased while citicoline recovered anterograde manganese 
transport to the optic nerve, lateral geniculate nucleus, and superior colliculus  
Mn enhancement along the visual pathways projecting from the injured right eye [i.e. right optic 
nerve, left lateral geniculate nucleus (LGN), and left superior colliculus (SC)] and from the 
uninjured left eye (i.e. left optic nerve, right LGN, and right SC) was evaluated by quantifying 
their T1-weighted signal intensities before (pre-MEMRI) and at 8 hr (post-MEMRI) following 
intravitreal injection of MnCl2 into both eyes at the end experimental time point at day 35 (Figure 
6). No significant differences in T1-weighted signals was observed along the visual pathway 
between both hemispheres or between acute and chronic groups before intravitreal Mn injection 
(data not shown).  
When assessing the percent intensity difference between injured and uninjured visual 
pathways, among the acute groups (Figure 6B-D), the left LGN showed a significantly larger 
reduction in Mn enhancement after severe acute IOP elevation to the right eye compared with 
mild acute IOP elevation and sham control (Figure 6C). The left SC also showed significantly 
larger reduction in Mn enhancement after severe acute IOP elevation compared to the sham 
control (Figure 6D).  
Among the chronic groups (Figure 6E-G), the right optic nerve, left LGN and left SC 
showed a significantly larger reduction in Mn enhancement after untreated chronic IOP elevation 
compared to the sham control (Figure 6E-G), whereas the left LGN showed a significantly 
smaller reduction in Mn enhancement after citicoline-treated chronic IOP elevation compared to 
untreated chronic IOP elevation (Figure 6F). No significant difference in Mn enhancement was 
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observed between citicoline-treated chronic IOP elevation and sham control groups in the optic 
nerve or the SC (Figures 6E & 6G). 
 
 
 
 
Figure 6. Representative post-MEMRI images in the optic nerve (ON) (top row), lateral geniculate nucleus 
(LGN) (middle row), and superior colliculus (SC) (bottom row) b. Percent difference in manganese 
enhancement was calculated between right and left ON, LGN, and SC 
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2.3.6 IOP elevation decreased functional connectivity between lateral geniculate nucleus, 
superior colliculus, and visual cortex, which was improved by citicoline treatment  
When comparing the resting-state FC between LGN, SC, and the visual cortex (VC) of 
each hemisphere, significant FC differences were observed in the subcortical visual nuclei 
between all three acute groups, with greater differences across increasing magnitudes of IOP 
elevation (Figure 7). Among the chronic groups, animals with untreated chronic IOP elevation 
showed significantly decreased cortico-collicular, cortico-geniculate, and subcortical FC 
compared to the sham control within and between hemispheres (Figure 8). In contrast, animals 
that received chronic IOP elevation and oral citicoline treatment appeared to have preserved or 
improved FC. Compared to untreated chronic IOP elevation, the citicoline-treated group had 
increased FC between left VC and left SC.  
2.3.7 IOP elevation decreased phosphorylated neurofilament and myelin basic protein 
expression in the optic nerve, while citicoline reduced such effects 
Immunohistochemical staining for phosphorylated neurofilament (pNF) and myelin basic protein 
(MBP) showed comparable expression in the left optic nerve across all groups (Figure 9). pNF 
staining was decreased by 43.6 ± 3.6% and 65.7 ± 0.7 % in the right optic nerve of the mild and 
severe acute IOP elevation groups, respectively, compared to the left optic nerve. In the chronic 
IOP elevation group, the pNF staining in the right optic nerves was decreased by 64.4 ± 1.4% in 
the untreated group, and by 43.6 ± 3.5% in the citicoline-treated group. MBP staining was 
decreased in the right optic nerve of the mild and severe acute IOP elevation groups by 24.6 ± 
4.2% and 65.1 ± 1.0%, respectively, compared to the left optic nerve. In the chronic IOP elevation 
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groups, the MBP staining was decreased by 59.4 ± 2.9% and 38.3 ± 4.2% in the untreated and 
treated groups, respectively, compared to the left optic nerve.  
 
 
 
 
 
Figure 7. Resting state functional connectivity MRI at 35 days after unilateral acute IOP elevation induction 
at 15mmHg (sham), 40mmHg (mild), and 130mmHg (severe). Top row represents the correlation strengths 
between lateral geniculate nucleus (LGN), superior colliculus (SC) and visual cortex (VC) of the left (L) and 
right (R) hemispheres in each acute group. Bottom row represents the differences in functional connectivity 
(FC) between acute groups. Only statistically significant FC differences were colored in the bottom row. 
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Figure 8. Resting state functional connectivity MRI 35 days after chronic intraocular pressure elevation (IOP) 
induction with (treated) or without (untreated) oral citicoline treatment, or sham operation (sham) without 
oral citicoline treatment. Top row represents the correlation strengths between lateral geniculate nucleus 
(LGN), superior colliculus (SC) and visual cortex (VC) of the left (L) and right (R) hemispheres in each acute 
group. Bottom row represents the differences in functional connectivity (FC) between chronic groups. Only 
statistically significant FC differences were colored in the bottom row. 
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Figure 9. Phosphorylated neurofilament (pNF) and myelin basic protein (MBP) staining 35 days after 
acute and chronic IOP elevation. 
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2.4 DISCUSSION 
This study demonstrated the neurobehavioral effects of different magnitudes and durations of IOP 
elevation on the visual system using well-controlled experimental glaucoma models. In addition, 
under similar levels of IOP elevation, oral citicoline treatment significantly reduced visual brain 
integrity loss and visual acuity decline. Studies have shown that glaucoma affects structural and 
functional connectivity in the human brain [156]. Both the acute and chronic models caused 
structural and functional changes in the visual system and demonstrated the neuromodulation of 
the visual system in behavioral outcomes in experimental glaucoma. Further the neuroprotective 
effects of oral citicoline in a chronic IOP elevation model were demonstrated.  
Acute IOP elevation caused a decrease in visual acuity with severe acute IOP elevation 
causing a larger decrease in visual acuity than mild IOP elevation. The IOP elevation groups had 
a gradual decrease in visual acuity which coincided with the progressive increase in IOP. While 
the acute sham group, which only had a needle inserted in the anterior chamber and no pressure 
increase, demonstrated no changes in visual acuity, the chronic sham group displayed an initial 
decrease in visual acuity at day 7 that recovered by day 14. The effects of the buffer injection in 
the sham group were not assessed specifically. However, no prolonged effects on visual acuity or 
structural MRI were observed in the sham group following the buffer injection. 
In experimental glaucoma models, moderate and severe acute IOP elevation do not cause 
any persisting changes to retinal nerve fiber layer thickness [157] or the optic nerve head and 
peripapillary structures [158, 159] and studies have shown that optic nerve dysfunction and 
disorganization may precede observable changes in vision and neuronal loss in glaucoma [160, 
161]. The effect of chronic IOP elevation on these structures remains unknown. Under severe acute 
IOP elevation, significant changes were observed in optic nerve FA and λ⊥, with no significant 
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change in λ//. The increase in λ⊥ suggests that demyelination occurred and continued progressing 
for up to 5 weeks after injury, even when IOP elevation was no longer present, and a similar but 
statistically insignificant trend was found in the optic tract. The decreased pNF positive staining 
and disrupted MBP morphology staining in the right optic nerve after acute IOP elevation, 
indicates that higher IOP elevation causes a larger disruption in neurofilament integrity and myelin 
density. In the chronic groups, the untreated group had significantly decreased pNF and MBP 
density compared to the sham and citicoline treated groups. The chronic groups had significantly 
lower axial diffusivity at day 35 as well, suggesting the decreased neurofilament integrity, as 
shown by decreased positive pNF staining, may be contributing to decreased axial diffusivity. The 
MBP results suggest that oral citicoline treatment preserves myelination after injury and may 
ultimately cause the increase visual acuity observed in the citicoline treated animals. 
The large decrease in λ⊥ was seen soon after induction of chronic IOP elevation indicating 
that the suggested demyelination occurs rapidly after with chronic IOP elevation. As in the visual 
acuity experiments, we observed less of a decrease in white matter integrity in the citicoline treated 
animals, suggesting that citicoline treatment ameliorates the damage caused by IOP elevation. In 
both the acute and chronic groups, we observed larger degrees of change in the optic nerve than 
the optic tract, suggesting that IOP elevation caused more severe structural alterations in the 
anterior visual pathway than the posterior visual pathway over 35 days. MTI can indicate changes 
in macromolecular structures [9]. Therefore, the larger MTI ratio in the citicoline treated group 
suggest that citicoline treatment before and after IOP elevation prevents, or inhibits, changes in 
white matter on a molecular level. The decreased myelin positive staining observed in the severe 
acute and chronic untreated animals coincides with λ⊥ results from DTI, which showed increased 
λ⊥ in the optic nerve. Together, these results indicate that the acute severe and chronic untreated 
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optic nerves may have undergone demyelination and that citicoline treatment preserved 
myelination.  
MEMRI has previously been shown to be capable of indicating injury severity in an optic 
nerve crush model [162] and can be used to examine physiological anterograde Mn transport 
between the retina and the brain’s visual pathway [163-165]. In the acute groups, there were no 
observable differences in λ// or Mn transport in the optic nerve. These coinciding results suggest 
λ// is related to Mn transport, as has been suggested in previous studies [166]. Following chronic 
IOP elevation without citicoline treatment, the optic nerve, LGN, and SC all showed significantly 
more Mn transport deficits compared to the sham injury group which coincides with decreased λ// 
integrity observed in these brain regions. The citicoline treated group showed significantly less 
Mn transport deficits in the LGN compared to the untreated group. These results indicate IOP 
elevation disrupts white matter integrity which may cause decreased anterograde transport in the 
visual system. Additionally, citicoline treatment ameliorates white matter integrity disruption after 
IOP elevation which preserves anterograde Mn transport.  
Acute and chronic IOP elevation decrease both photopic and scotopic contrast sensitivity 
in rodents, and treatment with brinzolamide or brimonidine, both of which are IOP lowering 
therapeutics, is able to partially prevent contrast sensitivity loss [167]. In experimental glaucoma 
models in rats, choline metabolites were significantly reduced in the contralateral visual cortex 
after 6 weeks of IOP elevation, indicating that the metabolism of choline-containing compounds 
may be altered in glaucomatous visual pathway structures [168]. In young human subjects, proton 
magnetic resonance spectroscopy has shown an increase in choline in the brain after a single oral 
dose of citicoline [169], indicating that oral administration is a viable method for delivering 
citicoline to the CNS. Increases in retinal bioelectrical responses and improvement in the 
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bioelectrical activity in the visual cortex were observed 4 months after initiation of citicoline 
treatment and returned to baseline 2 month after cessation [170]. Rodent studies have found that 
increased levels of acetylcholine in the cortex drive a greater intensity in cortical responses and 
trigger the upregulation of cholinergic receptors [171]. Recently, clinical studies found that genes 
regulating acetylcholine metabolism may be altered in glaucoma patients and could increase the 
risk for developing primary angle-closure glaucoma [172]. In our study, we found that citicoline 
may be able to slow down a decline in visual acuity after IOP elevation. Citicoline in the chronic 
treated groups therefore slowed down functional loss independent of lowering the IOP.   
Studies in mouse models have shown that although neurons may appear healthy 
histologically, IOP elevation may permanently decrease synaptic connections and neural activity 
[173]. Previous studies utilizing acetylcholinesterase inhibitors, compounds that prevent 
acetylcholine hydrolysis and increase the concentration and duration of acetylcholine in the CNS, 
have shown an increase in FC, visual perception, and processing [174], and enhanced brightness 
discrimination capacity after optic nerve crush [175]. Additional studies have shown that injection 
of an acetylcholine receptor antagonist leads to a decrease in FC in the default mode-like network 
[176], and decreased FC in the hippocampus, cortex, and thalamus, which could be partially 
reversed by administration of an agonist [177]. These previous studies, along with our current 
results demonstrating that oral citicoline preserves FC across the SC, LGN, and VC, suggest that 
increased citicoline concentration in the CNS may improve FC in the visual system and visual 
function after injury and disease.  
This study has several limitations. Of note, Mn may be toxic to neural pathways [178], 
meaning that histology could only be performed using samples from animals that were not used 
for MEMRI experiments. Since retinal apoptosis and retinal ganglion cell death affect Mn uptake 
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in the retina, MEMRI findings may reflect the damage of the retina in addition to changes in Mn 
transport alone. In future studies, longitudinal scans over hours can be taken after intravitreal Mn 
injection to determine the rate of Mn transport along the visual pathway. No direct RGC 
evaluations were done in this study and the mechanisms of visual function prolongation weren’t 
elucidated in the present study. However, previous. in vivo studies have shown that daily citicoline 
treatment slows down RGC death after optic nerve crush [179] and induced apoptosis with kainic 
acid [180], and studies using topical treatment of citicoline have shown increased RGC activity 
[170, 181]. These studies suggest that citicoline treatment can slow RGC apoptosis after injury 
and increase RGC activity, which may lead to increased visual acuity preservation after injury and 
citicoline administration. 
These experiments have important implications for both our understanding of 
glaucomatous degeneration and the ways in which we may be able to prevent such 
neurodegenerative processes. While it can be difficult to study glaucoma under controlled 
conditions in humans, this study uses experimental glaucoma animal models to simulate a variety 
of disease conditions. In doing so, it was possible to elucidate the differential effects of duration 
and magnitude of IOP elevation on structure and function in the visual pathway. More exciting, 
however, is the prospect of using such experiments to explore potential preventative and treatment 
measures for glaucoma. Recent literature suggest that citicoline may improve visual function 
outcomes in glaucoma patients [182-184]. However, several parameters need to be further 
investigated to optimize citicoline treatment, including dosage, timing, and route of administration 
[182, 185, 186]. Administration of citicoline, a choline supplement, concurrent with chronic IOP 
elevation resulted in improved visual acuity, white matter integrity, anterograde Mn Transport, 
and functional brain connectivity. Since brain regions other than the eyes are affected, treatment 
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mechanisms should focus on treating neural structures throughout the visual and nervous system 
and indicate intraocular pressure-lowering strategies combined with neuroprotective therapies can 
protect visual neurons in the retina and brain which may help to preserve vision in patients with 
glaucoma. This study provides a framework and experimental paradigm for such exploration, and 
experiments such as these will provide the groundwork for the future of glaucoma treatment. 
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3.0  AFTER ACUTE OPTIC NERVE ISCHEMIA IN RAT, FETAL PORCINE BRAIN 
ECM POSITIVELY MODULATES THE DEFAULT HEALING RESPONSE  
3.1 INTRODUCTION  
In adult mammals, central nervous system (CNS) neuron axons generally fail to regenerate after 
injury often leading to axonal degeneration, neuronal death, and permanently lost neurologic 
function. This failure is due, in part; to a default healing response in the CNS to prioritize rapid 
injury containment over preserving or restoring neurologic function. After injury, glial support 
cells adopt a pro-inflammatory phenotype, migrate to the injury site [38], and remodel the cellular 
and ECM architecture to form scar tissue [187]. Scar tissue is a complex multicellular mechanical 
and biochemical barrier critical to maintaining the integrity of the CNS by repairing breakdown 
of the blood brain barrier, containing lesions, foreign bodies, and infectious agents, among many 
other physical and metabolic functions [188]. However, the glial scar inhibits axon regeneration 
by multiple mechanical and biochemical barriers. Combinatorial approaches addressing intrinsic 
axon growth ability with or without modulating the innate immune response have shown that 
CNS axons can regenerate significant distances to restore functional reinnervation [189-191]. 
However, the number of regenerating axons is typically low, and many axons are misguided [192, 
193]. A logical and perhaps complimentary approach to therapies that increase retinal ganglion 
cell (RGC) survival and axon growth may be to alter the default healing response by shifting the 
innate immune response within the affected CNS tissues from primarily pro-inflammatory toward 
a more anti-inflammatory, pro-repair response. 
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Extracellular matrix (ECM) technology can alter the default healing response by 
modulating the innate immune response [109, 194],  , stabilizing the wound microenvironment 
[195], and stimulating site-appropriate cellular recruitment and differentiation to restore tissue 
function [110, 196]. Over 100  FDA approved ECM-based devices are used clinically to promote 
positive tissue remodeling over scarring [97]. ECM scaffolds have been used in preclinical 
models in numerous tissues, including heart [197, 198], esophagus [199-201], bladder [202], and 
muscle [203] , and recently both in the PNS and in the CNS [97, 204, 205]. ECM harvested from 
homologous tissue provides a more favorable environment in skin [206], cartilage [207], heart 
[208], tendon [209], and liver [210], among others. Moreover, ECMs derived from younger, 
homologous tissues can be more effective [113-115], like fetal heart [116] and kidney [117]. 
Studies using ECM for CNS applications are increasingly showing promise in supporting 
neuronal migration [211], differentiation [212], and neurite growth [213]. However, whether 
ECM derived from fetal brain tissue can positively modulate the default healing response in the 
CNS remains unreported. 
The objectives of this study were to first successfully decellularize fetal porcine brain 
ECM. Traditional decellularization methods based using agitation are too harsh and disrupt the 
structure of fetal tissues. In delicate tissue like brain the majority of the ECM is lost, leading to 
low yields that are likely not representative of the native ECM. Therefore, vacuum assisted 
decellularization (VAD) [204] was used, which uses changes in pressure to pulse the 
decellularization agents in and out of delicate tissues, like fetal brain and retina, while maintaining 
the native ECM architecture to produce an acellular fB-ECM bioscaffold. The acellular scaffolds 
were used to develop an injectable fB-ECM hydrogel, and to test fB-ECM hydrogel 
biocompatibility and bioactivity in vitro in primary retinal ganglion cell cultures, and in vivo in 
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an established acute optic nerve ischemia model. Fetal porcine brains were successfully 
decellularized by VAD, preserving the delicate fetal brain ECM architecture, which is largely 
lost by traditional harsher agitation methods, and solubilized fB-ECM readily formed a hydrogel 
at 37°C. After acute optic nerve ischemia, fB-ECM pre-gel digests were easily injected into and 
filled the irregular retrobulbar space behind the eye, enveloping the injured optic nerve before 
gelling. These initial studies show fB-ECM hydrogels are biocompatible and bioactive both in 
vitro, increasing both RGC dendrite and axon growth, and in vivo, reducing GFAP expression by 
astrocytes at the injury site and, although speculative, possibly slowing the rate of RGC axon 
degeneration. 
3.2 MATERIALS AND METHODS  
3.2.1 Animals, reagents, and tissues 
Sprague-Dawley rats were provided by Charles River (Wilmington, MA). All chemicals and 
enzymes were provided by Sigma-Aldrich (St. Louis, MO) and cell culture reagents by Life 
Technologies (San Diego, CA) unless otherwise noted. Fetal pigs (5-7 inches) were provided by 
Nebraska Scientific (Omaha, NE). 
3.2.2 Fetal brain ECM (FB-ECM) 
Fetal pig brains were dissected and decellularized using vacuum assisted decellularization (VAD) 
as described [119]. The resulting acellular fB-ECM was treated with deoxyribonuclease (DNase, 
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300 Kunitz units per ml) for 1h, then with 0.1% peracetic acid (PAA, Rochester Midland Corp., 
Rochester, NY, USA) in 4.0% ethanol for 1h. FB-ECM was washed with 1X PBS and nanopure 
water (3× for 15 min each). FB-ECM was frozen, lyophilized, sterilized using EtO, and stored at 
room temperature (rt) until further use. Qualitatively, decellularization was confirmed by 
hematoxylin and eosin (H&E) staining of fB-ECM sections fixed in 10% buffered formalin. 
3.2.3 FB-ECM scanning electron microscopy (SEM) topography 
FB-ECM pre-gel solutions (6 mg/ml) were incubated at 37ºC for 30 min, fixed overnight in 2.5% 
glutaraldehyde, washed in PBS (3× for 15 min each), dehydrated in graded ethanol (30, 50, 70, 
and 90%) for 30 min each and in 100% ethanol overnight, and finally critically point dried (Leica 
EM CPD030 critical point drier, Leica Microsystems, Buffalo Grove, IL, USA). Critically point 
dried fB-ECM was sputter-coated with a gold/palladium alloy (4.5 nm) using a Sputter Coater 
108 Auto (Cressington Scientific Instruments, UK) and imaged on a JEOL JSM6330f scanning 
electron microscope (JEOL, Peabody, MA, USA). 
3.2.4 Residual FB-ECM DNA 
Residual DNA was quantified by digesting fB-ECM overnight with 0.1 mg/ml proteinase K at 
50°C in Tris-EDTA buffer (10mM Tris, 1mM EDTA). Protein was removed by phenol/chloroform 
extraction and centrifugation. The aqueous phase was mixed with 3M sodium acetate in 100% 
ethanol, centrifuged, the pellet rinsed with 1X PBS, recentrifuged, and dried. Double-stranded 
DNA (ds-DNA) was visualized by gel electrophoresis and quantified by PicoGreen per 
manufacturer’s instructions (Invitrogen, Carlsbad, CA). 
 51 
3.2.5 Collagen and sulfated glycosaminoglycan (sGAG) 
Collagen was quantified using a Sircol Collagen Assay kit (Biocolor Ltd., UK) and sGAG 
quantified using a Blyscan Glycosaminoglycan Assay kit (Biocolor Ltd., UK). Briefly, fB-ECM 
(50 mg/ml) was digested with proteinase K, and collagen and sGAG contents analyzed by 
absorption at 550 nm and 656 nm, respectively, using a SpectraMax M2 spectrophotometer 
(Molecular Devices, LLC., Sunnyvale, CA, USA). One-way ANOVA statistical analysis was done 
using SPSS Statistics 19 (IBM, Armonk, NY, USA). Three samples from three independent ECM 
preparations were analyzed, totaling 9 samples. 
3.2.6 FB-ECM hydrogel and material properties  
FB-ECM hydrogels were made as described [214]. Briefly, lyophilized fB-ECM (6 mg/ml) was 
solubilized with pepsin (1 mg/ml; 2500 IU/mg) in 0.01 N HCl for 24h at rt, and fB-ECM pre-gel 
digests stored at -20°C. For use, pre-gels were thawed on ice and neutralized in media for in vitro 
or PBS for in vivo experiments. Turbidimetric gelation kinetics were measured using a 
SpectraMax M2 spectrophotometer (Molecular Devices). Briefly, a 6 mg/ml fB-ECM pre-gel 
solution at 4ºC was placed into a precooled 96-well plate (100 ml/well), immediately transferred 
to a spectrophotometer preheated to 37ºC, and the absorbance at 405 nm was measured every 2 
min for 50 min. The assay was repeated in triplicate for three independent fB-ECM preparations. 
The following parameters were calculated: time to reach 50% and 95% maximum absorbance 
(t0.5 and t0.95), lag phase (tlag, extrapolated from the linear portion of the curve), and the 
turbidimetric speed of gelation (S, determined by calculating the growth portion slope of the 
curve normalized to absorbance) [103]. Rheology was measured on a rheometer (AR2000, TA 
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instruments, New Castle, DE). Briefly, neutralized fB-ECM pre-gel was immediately put on a 
40mm parallel geometry, the rheometer gap was set at 550 µm, and a dynamic time sweep was 
done with a 1 Pa stress, 0.5 % strain, and 1 rad/s after the temperature was increased to 37ºC. 
3.2.7 Retinal ganglion cell (RGC) cultures 
Primary RGCs were purified from male and female postnatal day 3 (P3) Sprague-Dawley rat 
pups (Charles River, Wilmington, MA) by immunopanning and cultured in NB-SATO media as 
described [215]. Purified RGCs were plated in NB-SATO (50 µl) at low density (5 × 103/cm2) in 
96-well plates coated with poly-D-lysine (70 kDa, 10 µg/ml; Sigma-Aldrich Corp., St. Louis, 
MO, USA) and laminin (2 µg/mL, Sigma-Aldrich Corp.) and cultured at 37ºC. To analyze fB-
ECM effects on RGC viability and neurite growth, 2X stocks of fB-ECM (500µg/ml), or pepsin 
(50µg/ml) were thawed on ice, neutralized to pH 7.4, and added to the cultures by pipetting 
immediately after plating, yielding a final concentration of 250 µg/ml. The RGCs were cultured 
at 37°C in 10% CO2 for 3 days in vitro (DIV). All RGC cultures were performed in triplicate for 
at least three experimental repeats. One-way ANOVA statistical analysis was done with SPSS 
Statistics 19 (IBM, Armonk, NY, USA).  
3.2.8 RGC viability  
After 3 DIV, viability was analyzed using a live/dead cell imaging kit per manufacturer’s 
instructions (R37601, Molecular Probes, Life Technologies). RGCs were imaged by epi-
fluorescence (Zeiss AxioObserver, Zeiss, Oberkochen, Germany) using rhodamine and 
fluorescein filter sets. At least 3 randomly selected fields of view were imaged per well, for a 
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total of 9 fields of view per condition per experiment and analyzed using ImageJ (National 
Institutes of Health, Bethesda, MD, USA). Thus, data represents at least 27 fields of view per 
condition, totaling more than 300 cells per condition from three independent experiments. One-
way ANOVA statistical analysis was done with SPSS Statistics 19 (IBM, Armonk, NY, USA).  
3.2.9 RGC neurite growth  
RGC neurite growth was analyzed as described [216]. After 3 DIV, fixed RGC cultures were 
incubated with anti-β III tubulin (1:300, TUJ-1, Millipore) primary antibody and amplified with 
a FITC-labeled rabbit anti-chicken IgY H+L (1:150, CAT31501, Thermo Scientific) for 1h at rt. 
RGCs were counterstained with DAPI (1:3000, 62247, Thermo-Fisher Scientific) and imaged 
using epi-fluorescence (Zeiss, Axio Observer, Germany). Neurite length was quantified using the 
ImageJ Plugin, NeuronJ (National Institutes of Health, Bethesda, MD, USA) as described [216]. 
Total and axon length were quantified as described [121]. One-way ANOVA statistical analysis 
was done using SPSS Statistics 19 (IBM, Armonk, NY, USA). At least 10 randomly selected 
RGCs were imaged per well in triplicate, totaling at least 30 RGCs for three experimental repeats, 
equaling 90 neurons per condition.  
3.2.10 Acute optic nerve ischemia  
Adult Sprague-Dawley rats were anesthetized with an intraperitoneal injection of a ketamine (45 
mg/kg) and xylazine (10 mg/kg) and anesthesia confirmed by toe-pinch reflex. The optic nerve 
was exposed by making an incision in the lateral conjunctiva. A nearly bloodless plane was made 
using blunt dissection posteriorly until the optic nerve was exposed. Ischemia was induced by 
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clamping a Yasargil aneurysm clip (Aesculap FT252T) [217] (B. Braun Medical Inc.)  
approximately 2 mm behind the globe for exactly 10 sec. The clip was removed, and the 
ophthalmic artery visualized to confirm integrity. The optic nerve sheath was then fenestrated by 
making a lateral 2 mm incision in the optic nerve sheath using a Grieshaber ultrasharp (Alcon 
Grieshaber, Schaffhausen, Switzerland). Immediately after fenestration, fB-ECM pre-gel (2 μl, 6 
mg/ml) was injected into the retrobulbar space around the optic nerve in n=5 animals. Following 
surgery with or without fB-ECM injection, the connective tissue and the conjunctiva were sutured 
and antibiotic ointment (Gentamicin, Bausch & Lomb, Tampa, FL) applied to the eye. Sample 
size was determined through power analysis with G*power software (G*power software 3.1.9.2, 
Germany). Based on previous experiments, effect size was calculated to be 0.6, and power 
analysis for ANOVA dictated n=5 animals per group for in vivo studies to achieve 80% for α = 
0.05.  
3.2.11 Immunohistochemistry  
Animals were euthanized 14 days after surgery. The optic nerves were dissected, fixed in 4% 
paraformaldehyde in PBS for 2 h, cryoprotected in 30% sucrose in PBS for 4 h, embedded in 
optimal cutting temperature (OCT) medium (Tissue-Tek; Miles Inc, Elkhart, IN), frozen in liquid 
nitrogen, and stored at -80ºC until sectioning. For sectioning, 15 µm thick longitudinal optic nerve 
sections were cut using a cryostat (Leica CM 1850; Leica Biosystems, Wetzlar, Germany), noting 
proximal and distal ends of the nerve. Sections were labeled with anti-growth associated protein 
43 (anti-GAP43, 1:300, Thermo Scientific, RRID:AB_598153), anti-glial fibrillary acidic protein 
antibody (anti-GFAP, 1:300, Abcam, RRID:AB_296804), or anti-β-III tubulin (TUJ-1, 1:300, 
Millipore, RRID:AB_1977541). All sections were stained with the nuclear stain DAPI, and imaged 
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with epi-fluorescence (Zeiss, Axio Observer). Fluorescence intensity was measured using ImageJ 
as described [218, 219]. Briefly, fifteen 100x100 pixels ROIs were drawn 1mm before and after 
the crush site (GFAP) or 2mm after the crush site (GAP-43), four 100 × 100 pixels ROIs were 
drawn on the image background, and the area, mean fluorescence, and integrated density of each 
ROI was quantified. The corrected total fluorescence (CTCF) for each antibody was calculated 
using the formula: CTCF = integrated density – (area x mean background fluorescence). For βIII-
tubulin sections, βIII-tubulin positive fluorescence per area was measured by placing ten 50 × 50 
pixels ROIs approximately 2mm posterior to the crush site. The ImageJ particle counter function 
was used to measure the area of each ROI and the percentage of each area covered by βIII-tubulin 
staining. The percentage βIII-tubulin per total area was calculated: % coverage = (area βIII-tubulin 
positive staining/area of ROI) X 100. Data represents triplicate sections from each of the five 
animals per group. One-way ANOVA statistical analysis was done with SPSS Statistics 19 (IBM, 
Armonk, NY, USA). 
3.3 RESULTS 
3.3.1 Fetal porcine brain ECM derived by VAD 
Fetal porcine brains (fBs) were successfully decellularized by VAD [121] to produce acellular fB-
ECM, which was cotton-like after lyophilization (Figure 10 A-B). Scanning electron microscopy 
at 200× revealed ribbon-like structures of varying sizes (Figure 10C). At 10,000×, the ribbon-like 
structures had a granular surface without obvious fibrils (Figure 10D) typical of non-CNS [220] 
and CNS tissue ECMs [221] generated by agitation. H&E staining revealed hematoxylin positive 
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nuclear DNA in native fB (Figure 10E). After VAD, fB-ECM generally lacked hematoxylin 
positive staining, indicating nuclear and double stranded DNA removal (Figure 10F), while eosin 
positive staining remained, consistent with remaining ECM associated collagen and acidophilic 
proteins. Gel electrophoresis showed dsDNA was largely undetected in fB-ECM (Figure 10G). 
Quantitatively, VAD reduced dsDNA by 94% from 2859±17 ng/mg in native fB to 173±5 ng/mg 
in fB-ECM (Figure 10H). 
 
 
 
Figure 10. Native and vacuum assisted decellularized (VAD) fetal brain tissue. A. Macroscopic 
appearance of A. dry fetal brain and B. fetal brain ECM (fB-ECM) derived by VAD. C-D. Scanning 
electron microscopy of fB-ECM at C. 200× and D. 10,000×. E-F. H&E staining of fetal brain E. before 
(Native) and F. after VAD (fB-ECM). G. Gel electrophoresis of Native fetal brain and fB-ECM. G. 
PicoGreen analysis showed double stranded DNA (dsDNA) was largely removed by VAD. 
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3.3.2 FB-ECM collagen, sulfated glycosaminoglycan, and hyaluronic acid  
Collagen, sulfated glycosaminoglycan (sGAG), and hyaluronic acid (HA) content were analyzed 
in native fB and in fB-ECM (Figure 11). VAD increased collagen from 0.03±0.0 mg/mg dry weight 
in native fB to 0.5±0.02 mg/mg dry weight in fB-ECM. In contrast, VAD reduced sGAG from 
67±2 µg/mg in native fB to 24±1 µg/mg in fB-ECM (Figure 11B). Similarly, HA decreased from 
44±1 µg/mg in native fB to 12±1 µg/mg in fB-ECM (Figure 11C).  
 
 
 
Figure 11. VAD differentially alters collagen, sulfated glycosaminoglycan (sGAG), and hyaluronic acid 
(HA) content. Compared to Native fetal brain, A. Collagen is increased and both B. sGAG, and C. HA are 
decreased in fB-ECM. 
 58 
3.3.3 FB-ECM hydrogel morphology, gelation, and rheology 
Consistent with other ECM hydrogels including adult brain [221], solubilized fB-ECM formed 
opaque hydrogels at 37°C that retained the cylindrical form of the mold (Figure 12A). 
Microscopically, SEM showed fB-ECM hydrogels have a fibrous morphology (Figure 12B) with 
dense, randomly oriented collagen fibrils (Figure 12C). Quantitative analysis of fB-ECM 
hydrogel gelation revealed a turbidimetric gelation curve with a sigmoidal shape and a gelation 
speed of 0.15± 0.05 min-1. The gelation lag phase was 5.6±4.9 min, 50% gelation was reached 
at 12.4±2.7 min, and 95% gelation at 30.7±7.1 min (Figure 12D). The rheology of fB-ECM 
hydrogels was measured using a parallel plate rheometer (Figure 12E).  
 
Figure 12. Macro- and microscopic 6mg/ml fB-ECM hydrogel properties. A. Macroscopic and scanning 
electron microscopy (SEM) images of fB-ECM hydrogel at B. 1000× and C. 10,000×. D-E. Representative 
fB-ECM hydrogel (6 mg/ml) D. gelation kinetics and E. rheology curves. 
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The viscosity of the pre-gel fB-ECM solution was 0.12±0.04 Pa. Rheological analysis showed 
the storage modulus (G’) and loss modulus (G’’) increased sigmoidally as a function of time from 
10ºC to 37ºC. Once 37ºC was reached the pre-gel rapidly formed a gel. After 0.4±0.1 min, G’ 
became greater than G’’, indicating the gel became a solidified structure. G’ and G’’ maxima 
were reached at 14.7 ±0.5 min, with G’ = 6.6±0.5 Pa and G’’ = 1.1±0.1 Pa. 
3.3.4 FB-ECM hydrogels and RGC viability and growth 
To determine if fB-ECM hydrogels can modulate RGC survival and growth, RGC viability and 
total neurite and axon growth were analyzed (Figure 13). Previous dose response studies showed 
CNS neuron viability and neurite growth were maximally stimulated by both non-CNS and CNS 
derived ECMs at 250 μg/ml [121]. Primary RGCs were cultured in media, pepsin control, or 
media spiked with fB-ECM at 250 μg/ml and visualized with either calcein green and propidium 
iodide (Figure 13A) or anti-βIII tubulin and the nuclear marker DAPI (Figure 13B-D). Dose 
response studies were done with fB-ECM at 125, 250, and 500 μg/ml. Live/dead analysis showed 
RGC viability was unaltered by either pepsin or fB-ECM at 250 μg/ml. RGC viability in media 
at 3 DIV was 55.2 ± 7.8%. Normalized to media, viability was 93.48 ± 14 % in pepsin control 
and 99.1 ± 14.5 % in fB-ECM media (Figure 13E). In contrast to viability, fB-ECM increased 
total neurite growth by approximately 45% to 293.1 ± 18.9 µm compared to 202.3 ± 19.2 µm in 
media and 191.9 ± 19.9 µm in pepsin (Figure 13F). Similar to total neurite growth, fB-ECM 
increased the longest neurite, the presumptive axon, by approximately 35% to 154.4 ± 10.6 µm, 
compared to 121.5 ± 10.8 µm in media and 113.1 ± 11.2 µm in pepsin (Figure 13G). When 
cultured with 125, 250, or 500 μg/ml fB-ECM, RGC did not show a dose response for viability 
at 113.2 ± 13.8%, 99.1 ± 14.5%, and 116.5 ± 13.6%, respectively. Similar to viability, total neurite  
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Figure 13. FB-ECM differentially regulates primary RGC viability and neurite growth. E-G. Dose response 
using 125, 250, and 500 µg/ml fB-ECM for E. Viability, F. Total neurite growth, and G. Axon growth. H. 
Viability was unchanged by fB-ECM. I. Total neurite growth increased in fB-ECM and most of this increased 
growth was due to J. increased axon growth. 
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growth for 125, 250, or 500 μg/ml fB-ECM did not show a dose response with neurite growth at 
3 DIV at 297.2 ± 18.9 µm, 293.1 ± 14.3 µm, and 301.7 ± 18.3µm, respectively. Lastly, longest 
neurite growth also did not show a significant dose response, with longest neurites for 125, 250, 
or 500 μg/ml fB-ECM being 164.7 ± 10.6 µm, 154.4 ± 8.03 µm, and 187.3 ± 10.3 µm, 
respectively.  
3.3.5 FB-ECM hydrogels decrease glial fibrillary protein expression  
To determine if fB-ECM hydrogels can alter the default glial response to CNS trauma, fB-ECM 
hydrogel was injected retrobulbarly after acute optic nerve (ON) ischemia (Figure 14). 
Immediately after ischemic injury, the optic nerve sheath was fenestrated, and the hydrogel 
injected into the cavity where it formed a hydrogel. Glial fibrillary acidic protein (GFAP) 
immunoreactivity was analyzed two weeks post injury (Figure 15). Compared to GFAP expression 
in uninjured ONs (Figure 15A), GFAP was elevated at the injury site in untreated injured ONs 
(Figure 15B). In contrast, GFAP was noticeably lower at injury sites in fB-ECM treated ONs 
(Figure 15C). Higher magnification images showed the typical linear organization of GFAP 
expression and DAPI positive nuclei in uninjured nerves.  In untreated, injured nerves both GFAP 
and DAPI positive nuclei were elevated, consistent with typical inflammation and astrogliosis 
[222]. In contrast, GFAP and DAPI varied qualitatively from animal to animal in fB-ECM treated 
ONs. In some ONs, GFAP and DAPI were noticeably elevated compared to the surrounding ON 
(Figure 15F) though to a much lesser extent than untreated, injured ONs. In other fB-ECM treated 
ONs, GFAP expression and the number of DAPI positive nuclei were similar to uninjured nerves. 
Though, the organization of both markers was exhibited a less orderly organization (Figure 15G). 
However, despite the apparent variability and altered organization, GFAP expression in fB-ECM 
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ONs was quantitatively similar to untreated nerve compared to untreated nerves which were 
significantly higher (Figure 15H).     
 
 
 
 
 
 
To determine if fB-ECM stimulated RGC axon growth in vivo growth associated protein-43 (GAP-
43) immunoreactivity was analyzed (Figure 16). Compared to uninjured ONs and untreated injured 
ONs (Figure 7A-B), GAP-43 was elevated in some but not all ONs treated with fB-ECM (Figure 
16C-D). Similar to GFAP expression, GAP-43 expression varied qualitatively in intensity between 
animals (compare Figure 16 C-D). However, despite the apparent qualitative variability, the 
quantified intensity of GAP-43 immunoreactivity was approximately two-fold greater than 
uninjured and untreated ONs (Figure 16E). However, even in those animals with increased GAP-
43 expression, the expression pattern was atypical and inconsistent with the patterning of RGC 
Figure 14. FB-ECM hydrogel injection after acute optic nerve ischemia. A. Schematic image of optic nerve 
injury, showing fenestration in the optic nerve sheath and fB-ECM hydrogel placement. B. Image showing 
minimally invasive optic nerve crush procedure and fB-ECM hydrogel filling the retrobulbar space.  
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axons in the ON. In GAP-43 positive animals, GAP-43 was localized to clusters that often 
appeared to have fine processes emanating from them and were spaced uniformly along the length 
of the ON. Moreover, these clusters failed to co-localize with GFAP, CD11b, SOX2, and 
doublecortin, suggesting the GAP-43 positive clusters were acellular remnants of degenerated 
RGC axons that in some cases may have activated a pro-growth program that initially increased 
GAP-43 expression but ultimately degenerated. 
To visualize RGC axon organization, ON sections were stained with βIII-tubulin (Figure 
17). Though the anterograde tracer cholera toxin subunit B is the gold standard for visualizing 
regenerated RGC axons in the optic nerve, βIII-tubulin localization is a reliable marker for 
evaluating RGC axon organization in ON sections. In the ON, RGC axons are bundled in highly 
ordered fascicles that are visibly and quantifiably disrupted by significant RGC axon degeneration. 
Compared to uninjured ONs (Figure 17A), βIII-tubulin immunoreactivity in untreated injured ONs 
was fragmented and disordered (Figure 17B). In contrast and similar to both GFAP and GAP-43 
expression, βIII-tubulin was variable from animal to animal. βIII-tubulin immunoreactivity 
appeared fragmented in all fB-ECM treated animals. However, βIII-tubulin positive fascicles were 
identifiable to varying degrees in all fB-ECM treated ONs (Figure 17 C-D), suggesting RGC axons 
degenerated at a slower rate in fB-ECM treated ONs. 
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 Figure 15 After acute optic nerve ischemia in rat, fB-ECM hydrogels decrease GFAP expression at the injury 
site.  
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Figure 16. After acute optic nerve (ON) ischemia, fB-ECM increases GAP-43 immunoreactivity. 
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Figure 17. FB-ECM increases βIII-tubulin expression after optic nerve ischemia. B. Optic nerve 
ischemia alters the βIII-tubulin expression pattern, while C. fB-ECM treatment maintains an 
expression pattern resembling uninjured control. 
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3.4 DISCUSSION 
This study reports on the decellularization of fetal brain tissue by VAD, initial material properties, 
and initial effects in vitro on purified RGCs and in vivo on the expression of markers of optic nerve 
remodeling after injury. The resulting fB-ECM had low dsDNA and high sGAG content, and 
successfully formed a hydrogel. The delicate nature of the fetal brain tissue makes standard 
agitation decellularization unfavorable due to its disruptive effects on the ECM microstructure, 
while the differential pressure used in VAD helps solutions penetrate deep into tissues to remove 
cellular content, thereby effectively decellularizing tissue while preserving ECM organization 
[204, 223, 224]. 
Collagen is one of the main components in ECM and plays a vital role in the ability of 
ECM to form a hydrogel. Relative collagen content is calculated based on total weight, and 
decellularization therefore increases the relative collagen content due to the removal of cellular 
components and conservation of collagen. Although FB-ECM had a relatively lower collagen 
content compared to AB-ECM [221], FB-ECM successfully formed a hydrogel. sGAGs help 
with maintaining tissue hydration, binding growth factors, and regulating cellular behavior in 
vivo. Native fetal brain has a higher sGAG content than AB-ECM [221], and approximately one 
third of the sGAG content remains in the FB-ECM after decellularization, resulting in the FB-
ECM having a significantly higher sGAG content than AB-ECM. The increased sGAG content 
suggests that that FB-ECM retains a higher ratio of functional components that can alter cellular 
function, survival, and growth [225].  
VAD allows decellularization of delicate fetal brain tissue, and the resulting FB-ECM 
forms hydrogels with desirable characteristics. ECM is being investigated as a treatment for stroke, 
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and the gelation ability of ECM hydrogels in vivo is a critical factor that affects the host-biomaterial 
interface, distribution of the ECM within the cavity, and cell infiltrate composition at the injury 
site [98, 211, 226]. Injectable ECM hydrogels have also been investigated for spinal cord injuries, 
where ECM provides a platform for cell infiltration while providing neurotrophic factors to the 
surrounding tissue [227, 228]. AB-ECM treatment after traumatic brain injury showed decreased 
lesion volume, decreased white matter disruption, and increased behavioral outcomes [112]. 
Results show FB-ECM successfully forms a hydrogel, indicating FB-ECM hydrogels have a 
favorable composition to promote CNS remodeling in vivo. 
To examine the effects of FB-ECM on primary neurons, RGC neuron survival and growth 
was tested in vitro. After 3 days in culture, there was no difference in viability between RGCs 
treated with FB-ECM and the media control indicating an undetectable effect on RGC viability. 
FB-ECM increased total neurite growth and longest axon growth, indicating factors FB-ECM 
regulates neuronal architecture in cultured RGCs. Embryonic RGCs have the intrinsic ability to 
regenerate, however this ability is lost soon after birth [78], partially due to amacrine signaling 
inhibiting RGC growth [26] and changes in gene expression [79, 80], and after birth RGCs only 
extend neurites by default when receiving peptide trophic factor signaling neurite growth [81]. In 
addition to loss of intrinsic growth ability, the embryonic ECM environment supports robust axon 
growth and development. During CNS development, ECM components regulate progenitor cell 
migration and differentiation [229, 230]. ECM composition changes during development and 
adulthood, with fetal ECM encouraging robust de novo cell and tissue growth and development 
due to the ECM constituent composition. Studies have shown that ECM derived from younger 
sources are more beneficial for cellular growth and proliferation, and thus may be more effective 
at promoting constructive remodeling after injury [113]. In a study comparing fetal, neonatal, and 
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adult cardiac ECM, fetal derived cardiac ECM showed the lowest cellular adhesion, but was able 
to induce significantly more cardiomyocyte differentiation compared to neonatal and adult derived 
ECM [116]. Matrix metalloproteases (MMPs) are highly expressed in the developing brain and 
during neural development. However, MMP expression levels rapidly declined during the first 
weeks after birth [231]. MMPs are suggested as regulators of synaptic activity [232], neurogenesis 
[233], cell migration, and axon guidance [234, 235]. Although not tested in this study, a higher 
concentration of MMPs in FB-ECM compared to AB-ECM could explain the differential 
regulation in axon growth observed in vitro.  
After optic nerve crush, FB-ECM treatment can alter the default healing response. 
Previous studies have shown a significant increase in GFAP positive astrocyte activation after 
axonal injury [236, 237] which leads to increased glial scarring and axon growth inhibition. This 
study shows GFAP expression was decreased at the injury site following FB-ECM treatment, 
indicating FB-ECM may decrease scarring at the injury site. After CNS injury, reactive 
astrocytes contribute to glial scar formation. The response of reactive astrocytes depends on the 
location of the astrocytes relative to the injury. Soon after injury, the astrocytes closest to the 
injury site become hypertrophic and elongated, and start forming dense scar tissue [238]. The 
cellular composition of the scar varies, with the center populated with macrophages and 
microglia, while the periphery is densely populated with reactive astrocytes [239] that double in 
number compared to healthy tissue [240]. While the glial scar with high CSPG concentrations in 
the periphery prevents axonal outgrowth and regeneration, the scar is necessary to prevent injury 
from spreading to surrounding tissue. Additionally, ablating astrocytes have been shown to 
prevent glial scarring. However, astrocyte ablation increased chronic leukocyte infiltration, 
neuron degeneration, and inflammation, and prevented BBB repair [74, 241, 242]. These studies 
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indicate that astrocytes have a complex role in promoting adequate wound healing and they are 
partially responsible for neuronal regeneration failure.   
Recently, matrix-bound vesicles (MBV) were found in all commercially and laboratory 
produced ECM [118]. MBV contain RNA cargoes, are bioactive, and have been shown to 
recapitulate cell responses induced by parent ECM [118, 119], including macrophage 
polarization [243]. Recent studies have shown pro-inflammatory microglia release cytokines, 
including IL-1α, TNF-α, and C1q, that act on astrocytes to polarize them to an A1 activation 
state, which in turn promotes RGC apoptosis [38]. Since MBV influence macrophage phenotype, 
it is hypothesized that MBV can also affect microglia phenotype and consequently astrocyte 
phenotype after injury. Although outside the scope of this study, MBV isolated from FB-ECM 
or cells treated with FB-ECM may offer an alternative to FB-ECM hydrogels [244] for CNS 
injury treatment. MBV can be delivered directly to the injured RGCs in the retina through 
minimally invasive intravitreal injections and future studies will investigate the application of 
MBV to injured RGCs after optic nerve crush.    
FB-ECM application after optic nerve crush increases GAP-43 expression along the length 
of the optic nerve. The GAP-43 expression pattern observed in FB-ECM treated animals was not 
typical for that of a regenerating optic nerve axon as reported in previous studies [245, 246]. 
Several possible answers can be speculated to this observed pattern, and it is hypothesized the 
pattern may be due to an initial increase in axon regeneration, coupled with GAP-43 expression, 
followed by cessation of the regenerative response. At the point of tissue harvesting at day 14, 
there are no traces of FB-ECM remaining at the injury site or ocular cavity where the hydrogel is 
applied. It is possible that an initial axon growth response follows FB-ECM application while 
bioactive factors are actively secreted into the microenvironment. However, as the hydrogel 
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degrades and no longer secretes bioactive factors into the environment, there was no persistent 
regenerative response observed. 
In this study, only one time point was included at day 14, therefore future studies will 
include earlier time points to determine whether there is an initial burst in axon growth as shown 
by GAP-43 staining. Additionally, co-labeling with cholera toxin subunit-B (CtxB) and GAP-43 
will be done in future studies to determine whether the observed GAP-43 labeling is specific to 
neurons.  
The GAP-43 labeling results were variable for FB-ECM treated animals, indicating FB-
ECM treatment has the potential to alter the default healing response and promote axon 
regeneration after injury. However, ECM alone may not be an optimal solution. In order to 
deliver ECM to the injured optic nerve, the optic nerve sheath was fenestrated. Preliminary 
studies showed direct contact is needed between the ECM and optic nerve axon to elicit favorable 
cellular responses. However, the fenestration causes an additional injury, and the loss of cerebral 
spinal fluid from the incision can cause a decrease in pressure along the optic nerve and retina. 
Intravitreal delivery of MBV directly to the retina will offer an alternative approach to deliver 
bioactive factors within ECM to the injured ocular tissues.  
In this study, used VAD was used to effectively decellularize fetal brain tissue, resulting 
in a biocompatible, injectable hydrogel. The FB-ECM increased RGC axon growth in vitro and 
altered the default healing response in vivo following optic nerve crush. These results permit new 
investigations into the mechanisms regulating healing in the CNS.    
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4.0  MATRIX BOUND NANOVESICLES PROMOTE RGC SURVIVAL AFTER 
ACUTE OPTIC NERVE INJURY 
4.1 INTRODUCTION 
CNS neurons fail to regenerate after injury, leading to permanently lost neurologic function. The 
visual system, including retinal ganglion cells (RGCs), forms part of the central nervous system 
(CNS), and injury and disease usually results in neuronal death and permanently lost visual 
function. The inability to regenerate is due to numerous intrinsic and extrinsic injury-induced 
factors that suppress axon regeneration. Constructive and functional tissue remodeling can be 
facilitated in the CNS by modulating the default innate immune response, especially in the acute 
post-injury period [211].  
The pro-inflammatory innate immune response is an early factor that appears to modulate 
not only tissue remodeling but also neuronal connectivity and CNS neuron survival. Macrophage 
and microglia play a critical role in response to injury. After trauma, damaged cells release 
chemokines and other molecules [247, 248] that elicit inflammatory responses from neutrophils 
[249, 250], macrophages [251-254], and microglia [255] in the CNS. Depending on factors 
released in the local microenvironmental milieu, resident microglia and macrophages derived from 
circulating mononuclear cells can polarize toward either an M1-like, pro-inflammatory phenotype 
or an M2-like, anti-inflammatory, pro-repair phenotype [256]. After optic nerve injury, retinal 
microglia polarize toward an M1-like phenotype and secrete, among other factors, tumor necrosis 
factor-α (TNF-α), interleukin-1 α (IL-1 α), and complement protein C1q, which cause retinal 
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astrocyte polarization toward an A1-like, pro-inflammatory state which causes RGC cell death. 
Blocking TNF- α, IL-1 α, and C1q prevents microglial activation and increases RGC survival [38].  
The innate immune response can be positively modulated by extracellular matrix (ECM) 
derived factors that modulate the phenotypic transition of macrophages and T-helper cells from a 
pro-inflammatory to a pro-remodeling, anti-inflammatory state. ECM bioscaffolds and their 
resident MBV have been shown to differentiate macrophages toward an M2-like, pro-remodeling 
phenotype [120], and MBV isolated from tissues such as porcine urinary bladder (UBM-ECM) 
can increase primary CNS neuron growth in vitro similar to UBM-ECM hydrogels [119]. 
Regenerative medicine strategies using inductive biologic scaffolds composed of ECM have been 
successful in numerous pre-clinical and clinical studies, and until recently the mechanism and 
factors contributing to the functional remodeling have been largely unknown. MBV are nano-sized 
lipid bound bodies found within in the ECM and recapitulate effects of the parent ECM from which 
they are derived [118, 120]. MBV are similar in size and structure to exosomes, but distinct with 
respect to cargo, surface markers, and compartmentalization. Whereas exosomes primarily exist 
in bodily fluids, MBV are localized to the collagen fibrils within all experimental and commercial 
ECM bioscaffolds analyzed to date [118]. Recent studies show MBV release during ECM scaffold 
degradation, suggesting MBV may be critical to promoting reparative, anti-inflammatory 
macrophage phenotypes [108]. Since MBV promote an anti-inflammatory phenotype in 
macrophages, the hypothesis for this study is that MBV will also promote an anti-inflammatory 
phenotype in microglia, thereby preventing A1-like astrocyte polarization and RGC cell death. 
This study shows MBV are bioactive in vitro and in vivo. The effects of MBV derived from 
UBM-ECM were determined on primary RGC, microglia, and astrocytes in vitro, and RGC 
viability after acute ocular ischemia in vivo. MBV were non-cytotoxic to RGCs and increased RGC 
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neurite outgrowth after 3 days in vitro and suppressed the release of pro-inflammatory markers 
from primary microglia and astrocytes in vitro. MBV were injected intravitreally after acute ocular 
ischemia and, compared to controls, MBV increased RGC survival and photopic negative response 
(PhNR) amplitude as shown by electroretinography. These data support the hypothesis that MBV 
can modulate the default healing response in the CNS after injury and provide a minimally invasive 
approach to treating ocular and CNS trauma. 
4.2 MATERIALS AND METHODS 
4.2.1 Animals 
Sprague-Dawley rats were provided by Charles River Laboratories (Wilmington, MA). Animal 
care and protocols complied with the University of Pittsburgh Institutional Animal Care and Use 
Committee and followed guidelines from the Guide for the Care and Use of Laboratory Animals 
published by the National Institutes of Health. 
4.2.2 Urinary bladder extracellular matrix decellularization and hydrogel formation  
Porcine urinary bladders from adult market weight pigs were provided by a local abattoir (Thoma’s 
Meat Market, Saxonburg, PA, USA). Urinary bladders were decellularized as described [103, 121, 
257]. Decellularization was confirmed using established methods to quantify DNA, including 
H&E staining and visualization through gel electrophoresis [121]. Decellularized urinary bladder 
extracellular matrix (UBM-ECM) was frozen, lyophilized, and stored at -20ºC until use. UBM-
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ECM hydrogels at 10 mg/ml were made as previously described [121, 221]. Briefly, lyophilized 
UBM-ECM was milled to a powder, digested at 10 mg/ml with 1 mg/ml pepsin for 48 hrs, and the 
pH adjusted to 7.4. 
4.2.3 Matrix bound nanovesicle (MBV) isolation 
Lyophilized UBM-ECM was digested with Liberase TL (5401020001, Sigma-Aldrich) in Tris 
buffer (50mM Tris pH7.5, 5mM CaCl2, 150mM NaCl) for 24 hrs at room temperature (RT) on an 
orbital rocker. Digested UBM-ECM was centrifuged at (10,000g, 30 mins). The MBV were 
pelleted by ultracentrifugation (100,000g, Beckman Coulter Optima L-90K Ultracentrifuge) at 4ºC 
for 2 hrs and further purified by size exclusion chromatography, using a Sepharose CL-2B resin. 
Purified MBV were stored at -80ºC until use. All MBV isolations were analyzed morphologically 
by transmission electron microscopy (TEM) as described [118]. MBV on TEM grids were 
observed at 80kV with a JEOL 1210 transmission electron microscope equipped with a high-
resolution AMT digital camera.  
4.2.4 Retinal ganglion cell isolation  
RGCs were isolated from postnatal day three Sprague-Dawley rat pups as described [215]. Purified 
RGCs were seeded in neurobasal-SATO (nb-SATO) media at 3,000 RGCs per well in 96-well 
culture plates (087723B, Falcon) coated with poly-D-lysine for 1 hr at RT (70 kDa, 10 μg/ml, 
Sigma-Aldrich Corp., St. Louis, MO, USA) and laminin overnight (37ºC, 2 μg/ml, Sigma-Aldrich 
Corp.). MBV were resuspended in sterile PBS and added to RGC cultures in triplicate wells at 
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concentrations ranging from 5-80 µg/ml. UBM-ECM hydrogel (250 µg/ml) and nb-SATO media 
were used as controls. RGCs were cultured at 37°C, 10% CO2 for 3 days.  
4.2.5 RGC viability 
 RGC viability was analyzed using a calcein and propidium iodide live/dead kit per the 
manufacturer’s instructions (Life Technologies, R37601). Briefly, the calcein and propidium 
iodide were mixed and incubated with the RGCs for 15 mins at RT. Five random non-overlapping 
fields were imaged per well at 20X using epi-fluorescence fluorescein and rhodamine filter sets 
(Zeiss, Axio Observer). Live and dead RGCs were quantified using ImageJ (National Institutes of 
Health, Bethesda, MD, USA). Data represent triplicates from three independent experimental 
repeats totaling at least 45 fields of view. 
4.2.6 RGC neurite growth quantification  
Neurite growth was analyzed as described [216, 258]. Briefly, RGCs were fixed with 4% 
paraformaldehyde (Alfa Aesar, 30525-89-4) in PBS for 15 min and then washed with PBS (3X). 
RGCs were permeabilized with 0.2% Triton X-100 in PBS for 15 mins, blocked with 1% BSA 
(Fisher Scientific) in PBS for 15 mins, and incubated overnight at 4ºC with anti-β III tubulin 
(1:300, TUJ-1, Millipore) in PBS. After incubation, RGCs were washed with PBS (3X), incubated 
in FITC-rabbit anti-chicken IgY H+L (1:150, Thermo Scientific) for 3 hrs at RT, washed with PBS 
(3X), and stained with DAPI (1:3000, Invitrogen) for 15 mins at RT. RGCs were washed with PBS 
(3X) and imaged at 20X (Zeiss, Axio Observer). For each well, total neurite growth was measured 
for the first ten RGCs randomly encountered that were not contacting another RGC using the 
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ImageJ plugin NeuronJ. Data represent total RGC neurite growth from triplicate wells in three 
experimental repeats, totaling at least 90 neurons per group.  
4.2.7 Microglia cultures  
Primary rat microglia (Lonza, R-G-535) were plated at 50,000 cells per well in 96-well plates per 
the supplier’s recommendation. For all experiments, microglia were initially incubated for 24 hrs 
at 37ºC, 5% CO2 to facilitate adherence. After 24 hrs, the supernatants were removed and replaced 
with fresh microglia media.  
For unprimed microglia cultures, the following reagents were added to triplicate wells: 
microglia media only, lipopolysaccharide (LPS, 100 ng/ml) and interferon gamma (IFNγ, 20 
ng/ml), interleukin-4 (IL-4, 20 ng/ml), UBM-ECM hydrogel (250 µg/ml), or MBV (5 µg/ml). After 
24 hours, media was collected for ELISA analysis or to treat astrocytes.  
For primed microglial cultures, microglia were treated with LPS (100 ng/ml) and IFNγ (20 
ng/ml) for 6 hrs, supernatants removed, microglia rinsed with microglia media, and treated with 
the following in triplicate wells for an additional 24 hrs: microglia media, UBM-ECM (250 µg/ml), 
or MBV (5 µg/ml). After the additional 24 hrs incubation, supernatants were collected for ELISA 
assays or to treat astrocytes.  
4.2.8 Astrocyte cultures  
Primary rat astrocytes (ScienCell Research Laboratories, R1800) were plated at 5,000 cells per 
well in a 96-well plate per the supplier’s instructions. Astrocytes were allowed to adhere for 24 
hrs at 37ºC, 5% CO2.  
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To determine the effect that microglia polarization has on astrocytes, microglia conditioned 
media, as described above, was added to triplicate astrocyte wells and incubated for 24 hrs. After 
initial 24 hr incubation with microglia conditioned media, astrocytes were rinsed with astrocyte 
media, incubated with fresh astrocyte media for an additional 24 hrs, and supernatants collected 
for ELISA assays.  
To determine the effect of astrocyte supernatants on RGC viability, a transwell plate was 
used. Astrocytes were plated on the transwell insert at 5,000 cells per insert per the supplier’s 
instructions, and the bottom chamber filled with astrocyte media. Astrocytes were allowed to 
adhere for 24 hrs at 37ºC, 5% CO2. After initial 24 hr incubation, microglia conditioned media was 
added in triplicate to astrocytes in the insert and incubated for 24 hrs. After 24 hrs, the astrocytes 
were rinsed, and media replaced with fresh nb-SATO media for an additional 24 hrs. After 
incubation, the nb-SATO media in the bottom wells were collected for RGC cultures.  
4.2.9 ELISA analysis  
Microglia and astrocyte supernatants were analyzed IL-1β (R&D Systems, DY501), IL-6 (R&D 
Systems, DY506), and TNF-α (BioLegend, Cat. # 438204) expression according to manufacturer’s 
instructions. Duplicate samples were analyzed from three independent experimental repeats.  
4.2.10 Retinal ganglion cell responses to astrocyte conditioned media 
RGCs were isolated and plated as described above and allowed to adhere for 24 hrs at 37ºC, 10% 
CO2. To determine the effects of astrocyte conditioned media on RGC survival, supernatants from 
astrocytes were collected as described and added to RGC wells in triplicate and incubated for 72 
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hrs at 37ºC, 10% CO2. RGC viability from three independent experiments was analyzed as 
described above.   
4.2.11 In vivo MBV dose response 
RGC survival was tested with three doses of MBV in vivo: 5, 10, and 20 µg/ml (n=5 animals per 
group). Animals were anesthetized via isoflurane inhalation (3% induction, 1.5% maintenance). 
One drop proparacaine hydrochloride ophthalmic solution (Bausch & Lomb, Inc., Rochester, NY) 
and one drop tropicamide ophthalmic solution (Akorn, Lake Forest, IL) were topically applied to 
both eyes of twenty animals to induce analgesia and pupil dilation, respectively. An 18g needle 
was used to make a small hole in the sclera immediately posterior to the limbus. Under a surgical 
microscope, a Hamilton micro-syringe was inserted into the vitreous through the scleral opening. 
The needle tip was placed as close as possible to the optic nerve head, and care was taken not to 
touch the retina or lens. MBV were diluted in sterile PBS to the appropriate concentrations. All 
injection volumes were 1 µl, and sterile PBS was used as vehicle control (n=5 per group). 1 µl of 
MBV or PBS were injected into the vitreous and the needle was held in place for 30 secs to allow 
the MBV or PBS to diffuse into the vitreous. The needle was removed and one drop gentamicin 
antibiotic ointment (Akorn, Lake Forest, IL) was applied topically immediately after removal of 
the needle. The animals received two additional injections at days 2 and 7 using the same 
techniques described. Animals were sacrificed 14 days after MBV injection and retinas removed 
for RGC quantification.  
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4.2.12 Intraocular pressure elevation with MBV treatment  
Acute intraocular pressure (IOP) elevation was induced as previously described in chapter 2. 
Fifty-seven animals received IOP elevation in the right eye only via saline anterior chamber 
perfusion and the left eyes served as uninjured control. Animals were anesthetized with an 
intraperitoneal injection of a 75:10 mg/kg ketamine/xylazine cocktail, and anesthesia was 
confirmed with a toe pinch reflex. One drop each of proparacaine and tropicamide were applied 
to the right eyes to induce analgesia and pupil dilation, respectively. A 30g needle was connected 
to a sterile saline reservoir (0.9% sodium chloride; Baxter International Inc., Deerfield, IL) and 
the needle tip inserted into the anterior chamber. The needle was inserted parallel to the iris using 
a surgical microscope and secured in place. The saline reservoir was elevated to increase the IOP 
from 15 mmHg to 130 mmHg and secured in place for 60 mins. The IOP was measured using a 
pressure transducer (BIOPAC Systems, Goleta, CA, USA) and a handheld tonometer. After 60 
mins, the saline reservoir was lowered, and the needle removed from the anterior chamber. One 
drop gentamicin was applied to the eye immediately after removing the needle. Nineteen animals 
(n=10 for histology, n=5 for ERG, n=4 for MEMRI) received 1 µl of 5 µg/ml MBV treatment 
immediately after IOP elevation, and at days 2 and 7 after IOP elevation, using the injection 
technique described in the previous section. Nineteen animals (n=10 for histology, n=5 for ERG, 
n=4 for MEMRI) were used for vehicle controls and received 1 µl of sterile PBS injected 
intravitreally immediately after IOP elevation and at days 2 and 7 after IOP elevation. Nineteen 
animals (n=10 for histology, n=5 for ERG, n=4 for MEMRI) received IOP elevation without any 
injections.  
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4.2.13 Cholera toxin subunit B injection 
Five animals per group received cholera toxin subunit B (CtxB) injections on day 11, three days 
prior to sacrifice on day 14. Cholera toxin subunit B (recombinant), Alexa Fluor 594 Conjugate 
(LifeTech, Cat # C3477) was resuspended in sterile PBS to yield a 1% solution. Animals were 
anesthetized via isoflurane inhalation (3% induction, 1.5% maintenance). Intravitreal injection 
technique was used as described in the previous section, and 2 µl of the 1% CtxB solution was 
injected into the vitreous. The Hamilton syringe needle was held in place for 30 secs before 
removal, and one drop gentamicin applied topically after removing the needle from the eye.  
4.2.14 Immunohistochemistry  
Ten animals per group were used for immunohistochemistry. Animals were sacrificed, and the 
retinas and optic nerves removed and fixed in 4% paraformaldehyde in PBS for 30 mins. Retinas 
and optic nerves were rinsed three times in PBS for 5 mins each.  
Retinas were quartered and permeabilized/blocked in IHC blocking buffer (3% Triton X-
100, 0.5% Tween-20, 1% BSA, and 0.1% sodium azide in PBS) for 2 hrs at RT on a shaker at 60 
RPM. Retinas from animals that received CtxB injections were labeled with 1:250 anti-CtxB 
(Mouse anti-CtxB, Abcam, AB62429) in IHC blocking buffer, and remaining retinas were co-
labeled with 1:250 anti-RNA-binding protein with multiple splicing (Rabbit anti-RBPMS, 
Phosphosolutions, 1830-RBPMS) and 1:250 anti-Brn3A (Mouse anti-Brn3A, Santa Cruz, SC-
8429) in IHC blocking buffer for 48 hrs at 4ºC on a shaker at 60 RPM. Retinas were rinsed three 
times with 0.3% Tween-20 in PBS and incubated in 1:500 Alexa Fluor 488 donkey anti-rabbit 
(Abcam, AB150073) and Alexa Fluor 555 goat anti-mouse (Abcam, AB150114) in IHC blocking 
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buffer for 24 hrs at 4ºC on a shaker at 60 RPM. Retinas were rinsed three times with 0.3% Tween-
20 in PBS, mounted on glass microscope slides, coverslipped with Vectashield (Vector 
Laboratories, H-1200), and imaged with epi-fluorescence (Zeiss, Axio Observer). Previous studies 
showed IOP elevation causes higher RGC cell death at the periphery of the retina [259], therefore 
RGC survival was analyzed at two locations. Similar to previous quantification methods[260], 
retinas were quartered prior to staining and three images were taken at the periphery and the center 
retina (around the optic nerve head) on each quarter section, thereby totaling 12 images at the 
periphery and 12 images at the center per retina..  
Optic nerves were embedded in paraffin and sectioned on a cryostat in 15 µm sections. 
Sections were blocked/permeabilized in IHC blocking buffer for 2 hrs at RT and rinsed twice with 
0.3% Tween-20 in PBS. Sections were labeled with 1:500 anti-GAP43 (Rabbit anti-GAP-43, 
Abcam, AB16053), 1:500 anti-GFAP (Rabbit anti-GFAP, 1:500, Abcam, AB7260), or 1:250 anti-
CtxB (Mouse anti-CtxB, Abcam, AB62429) for 24 hrs at 4ºC. The sections were rinsed three times 
with 0.3% Tween-20 in PBS and incubated in 1:500 Alexa Fluor 488 donkey anti-rabbit (Abcam, 
AB150073) or Alexa Fluor 555 goat anti-mouse (Abcam, AB150114) in IHC blocking buffer for 
24 hrs at 4ºC. Sections were rinsed twice with 0.3% Tween-20 in PBS and incubated with 4 µg/ml 
Hoechst stain (Sigma-Aldrich, H6024) in IHC blocking buffer for 15 mins at RT. The sections 
were rinsed three times with 0.3% Tween-20 in PBS, mounted on a cover slip with Vectashield, 
and imaged with epi-fluorescence (Zeiss, Axio Observer). The signal intensities were measured 
with ImageJ as previously described [218, 258]. Fifteen regions of interest (ROIs) were drawn 
evenly distributed along the optic nerve and four ROIs were drawn on the image background. The 
area, mean fluorescence and integrated density was measured for each image and the signal 
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intensity calculated based on the following equation: CTCF = integrated density – (area x mean 
background fluorescence). 
4.2.15 Electroretinography 
ERG functional analysis was done according to an established protocol [261]. In brief, animals 
were anesthetized with an intraperitoneal injection of a 75:10 mg/kg ketamine/xylazine cocktail, 
and anesthesia was confirmed with a toe pinch reflex. One drop each of proparacaine and 
tropicamide were applied to each eye to induce analgesia and pupil dilation, respectively, and eyes 
were kept lubricated with Goniovisc 2.5% (Sigma Pharmaceuticals, Item #9050) during 
recordings. Two gold loop electrodes were placed on the cornea, the reference electrode was 
inserted into the inside of the cheek, and the ground lead electrode was inserted into the quadricep. 
Bilateral ERG recordings were done simultaneously from both eyes during the trials using a color-
light dome. In general, one step of a fixed intensity light was illuminated for 1 ms and the ERG 
response recorded as a sweep over multiple steps of increasing illumination. Fifty ERG responses 
were recorded per trial, and a total of three trials were done per light intensity step. The data were 
analyzed by measuring the Photopic Negative Response (PhNR) and the implicit time of the 
different waves recorded.  
4.2.16 Manganese enhanced MRI 
Manganese enhanced MRI (MEMRI) was used to analyze active axonal transport along the visual 
pathway. Mn2+ ions act as calcium analogue and enter calcium channels during neuronal activity 
from where they are transported along axonal pathways via microtubules. MEMRI was done on 
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for n=4 animals per group. Each animal received 1.5 µl bilateral injections of 100 mM MnCl2. T1-
weighted MEMRI was done before MnCl2 injections, and again at 8 hours after injections with a 
fast spin echo imaging sequence. Slices were oriented orthogonal to the pre-chiasmatic optic nerve. 
Other imaging parameters include: TR/TE = 600/8 ms, echo train length = 8, number of slices = 
8, and slice thickness = 1 mm. A saline phantom was placed next to the rodent head for signal 
normalization. Signal intensities were measured in the left and right optic nerves, lateral geniculate 
nucleus (LGN), and superior colliculus (SC) using ImageJ. Mn signal enhancement was calculated 
as percentage difference in normalized T1-weighted signal intensity between injured and uninjured 
optic nerves, LGN, and SC and compared between groups.  
4.2.17 Statistical analysis  
All analysis and measurements were done by blinded individuals. One-way analysis of variance 
(ANOVA) and post-hoc Tukey’s test was used to determine significant differences between groups 
with p<0.05. Graphs represent the mean with error bars indicating standard error of the mean 
(SEM) unless otherwise noted.  
4.3 RESULTS 
4.3.1 MBV are non-cytotoxic to RGC and increase RGC neurite growth in vitro 
Consistent with previous studies investigating the effects of MBV on primary neuronal cultures 
[119], in vitro studies suggest MBV derived from UBM-ECM are non-cytotoxic and increase RGC 
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neurite growth compared to media and UBM-ECM hydrogels (Fig. 18). After 3 days in vitro, there 
was no difference in RGC survival between groups treated with any of the five MBV 
concentrations, UBM-ECM, or media, indicating UBM-ECM and MBV are non-cytotoxic at the 
concentrations tested (Fig. 18B). In contrast to RGC viability studies, MBV increased RGC neurite 
length after 3 days in vitro (Fig. 18C). 5, 10, or 20 µg/ml MBV significantly increased RGC neurite 
growth to 621.5 ± 35.2 µm, 652.4 ± 23.2 µm, and 596.0 ± 32.3 µm, respectively, compared to 
media (275.2 ± 11.6 µm) and UBM-ECM (348.3 ± 12.1 µm) controls. 50 and 80 µg/ml MBV did 
not increase RGC neurite growth at 191.6 ± 9.9 µm and 76.4 ± 4.3 µm, respectively.  
4.3.2 MBV suppress pro-inflammatory cytokine secretion from microglia and astrocytes 
In vitro studies show MBV suppress pro-inflammatory cytokine secretion from microglia and 
astrocyte (Fig. 19). Primary microglia were primed with LPS/IFNγ to induce a pro-inflammatory 
M1-like phenotype, and subsequently treated with media (control), UBM-ECM, or MBV isolated 
from UBM-ECM to determine whether UBM-ECM and MBV can suppress pro-inflammatory 
cytokine secretion (Fig. 19 A, B, C, G). Microglia treated with LPS/ IFNγ for 24 hrs (unprimed) 
had increased release of IL-1β, IL-6, and TNF-α in the secretome. Analysis of the secretome of 
microglia primed with LPS/IFNγ for 6 hrs and then treated with media resulted in a comparable 
increased release IL-1β, IL-6, and TNF-α, indicating the microglia continued to release pro-
inflammatory cytokines after the supernatant was removed and replaced with media. Finally, 
microglia primed with LPS/IFNγ for 6 hrs and treated with UBM-ECM or MBV showed IL-1β, 
IL-6, and TNF-α expression levels similar to microglia only treated with media for 24 hrs, 
indicating the UBM-ECM and MBV treatment for 24 hrs after LPS/IFNγ priming suppresses the 
release of pro-inflammatory cytokines 
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Figure 18. MBV increases RGC neurite growth. A-C representative images of RGC A. survival and growth 
in B. media and C. MBV. D. RGC viability was unchanged by UBM-ECM and MBV Data is normalized to 
media control. E. Total neurite growth was increased by 5, 10, and 20 µg/ml MBV. 
 87 
Analysis of the astrocyte secretome showed comparable results and trends as the microglia 
results (Fig. 19 D, E, F, H). Astrocytes treated with supernatants from unprimed microglia treated 
with LPS/IFNγ showed increased expression of IL-1β, IL-6, and TNF-α, indicating the secretome 
from pro-inflammatory microglia upregulate the release of pro-inflammatory markers from 
astrocytes. The secretome from LPS/IFNγ primed microglia treated with media induced a similar 
upregulated expression of IL-1β, IL-6, and TNF-α from astrocytes, while the secretome from 
microglia primed with LPS/IFNγ and treated with UBM-ECM or MBV did not increase the 
expression of pro-inflammatory markers by astrocytes. These results indicate UBM-ECM and 
MBV treatment following microglia priming can down regulate microglia pro-inflammatory 
cytokine secretion and prevent secretion of pro-inflammatory cytokines by astrocytes.  
4.3.3 MBV suppress pro-inflammatory cytokine secretion which increases RGC survival 
in vitro 
RGC were treated with astrocyte supernatants, and results showed treating microglia with 
LPS/IFNγ, or priming with LPS/IFNγ, and subsequent treatment with media resulted in 100% 
RGC cell death, while UBM-ECM or MBV treatment after microglia priming increased RGC 
viability and prevented RGC cell death (Fig. 20). These results correspond with previous studies 
showing microglia M1-like polarization affects RGC viability via astrocyte A1-like polarization 
[38], and support the hypothesis that promoting an anti-inflammatory microglia phenotype over a 
pro-inflammatory phenotype will increase RGC survival after injury. 
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Figure 19. MBV decrease pro-inflammatory cytokine secretion from both microglia and astrocytes. A-C. In 
unprimed microglia, LPS/IFNγ increased pro-inflammatory cytokine secretion. In primed microglia, IL-1β, IL-
6, and TNF-α secretion remained elevated when treated with media, but the secretion of all three cytokines was 
reduced by both UBM-ECM and MBV. D-F. Similar to microglia, LPS/IFNγ increased pro-inflammatory 
cytokine secetion from astrocytes and these increases were decreased by both UBM-ECM and MBV. 
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4.3.4 MBV are non-cytotoxic at low concentrations in vivo 
Initial in vivo studies were conducted to determine which concentrations of MBV are non-
cytotoxic after intravitreal injection. RGC viability was quantified around the optic nerve head  
(Central) and around the periphery of the retina (Periphery) and results shown as percentage viable 
RGC as compared to uninjected control (Fig. 21). RGC viability around the periphery was 
unchanged after MBV and PBS injections compared to uninjected control. RGC viability in the 
central region was decreased to 82.8 ± 1.9% and 80.7 ± 4.4% of the uninjected control eyes 
Figure 20. MBV increase RGC survival in conditioned media from pro-inflammatory astrocytes. RGCs were 
treated with media from astrocytes cultured with microglia primed and unprimed media. RGCs treated with 
primed-MBV or primed-UBM-ECM media showed increased survival compared to primed-media group. 
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following the injection of 10 µg/ml and 20 µg/ml, respectively, while injection of 5 µg/ml MBV 
(104.4 ± 4.1%) and PBS (97.4 ± 3.0%) had no effect on RGC viability. The 5 µg/ml MBV 
concentration was therefore chosen for IOP elevation in vivo experiments.  
 
 
 
 
 
 
 
Figure 21. MBV toxicity in vivo. Three concentrations of MBV, 5, 10, and 20 ug/ml, were injected intravitreally 
at 0, 2, and 7 days into healthy, uninjured eyes. Compared to uninjected control, RGC viability was unaffected 
by either PBS or MBV at 5 ug/ml. 
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4.3.5 MBV increase RGC survival after IOP elevation  
Following IOP elevation, 5 µg/ml MBV were injected intravitreally immediately after IOP 
elevation, and at days 2 and 7 and resulted in a significant increase in RGC viability (Fig. 22). 
RGC viability was analyzed 14 days after IOP elevation, and IOP elevation only and IOP elevation 
with PBS injection resulted in significantly decreased RGC viability in the central retina with 47.4 
± 2.3% and 41.8 ± 2.3% RGC survival compared to uninjured control. MBV treatment caused 
significant increase in RGC survival in the central retina compared to the two untreated groups, 
with 79.5 ± 3.8% survival. Similarly, in the peripheral retina, IOP elevation only and IOP elevation 
with PBS caused a significant decrease in RGC viability at 36.3 ± 3.6% and 26.4 ± 2.8% RGC 
survival, respectively, compared to uninjured controls. MBV treatment significantly increased 
RGC survival to 75.9 ± 4.2% compared to uninjured controls. 
4.3.6 MBV increase RGC axon survival after IOP elevation  
CtxB labeling in the retina showed intact axon labeling in the central and peripheral retina in the 
healthy control group and decreased axonal labeling in the IOP elevation and IOP elevation with 
PBS injection groups (Fig. 23A). Animals treated with MBV showed intact axon labeling similar 
to healthy control groups, indicating the MBV treatment preserves RGC axons in addition to RGC 
cell bodies in the retina. In the optic nerves (Fig. 23B), the IOP elevation and IOP elevation with 
PBS injection groups showed significantly decreased CtxB labeling at 32.5 ± 6.3% and 26.8 ± 
4.4% of uninjured control, respectively (Fig. 23C). CtxB labeling in the MBV treated optic nerves 
was significantly decreased compared to uninjured controls at 78.6 ± 6.1% of controls and was 
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significantly increased compared to both IOP elevation and IOP elevation with PBS injection 
groups.  
 
 
 
 
Figure 22. MBV reduced RGC loss induced by elevated IOP. A. Representative images showing RGC cell bodies 
co-labeled with RBPMS and Brn3A. B, C. IOP elevation and IOP elevation with PBS injections caused a 
significant decrease in RGC survival. IOP elevation with MBV injections caused significant increase in RGC 
viability compared to IOP elevation only and IOP elevation with PBS injections 
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Figure 23. After IOP elevation, MBV decreases RGC axon degeneration. Representative images showing RGC 
axons labeled with CtxB in the A. retina and B. optic nerve. C. IOP elevation and IOP elevation with PBS 
injections caused a significant decrease in RGC axon survival, IOP elevation with MBV injections caused 
significant increase in RGC axon viability 
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4.3.7 MBV decrease GFAP expression after IOP elevation  
To analyze the effect of MBV on astrocyte activation in vivo, GFAP expression along the length 
of the optic nerve was analyzed (Fig. 24A). Compared to uninjured control nerves, GFAP 
expression significantly increased in the IOP elevation and IOP elevation with PBS injection 
groups, which is consistent with typical astrocyte migration and activation after optic nerve injury. 
Quantitatively, IOP elevation and IOP elevation with PBS significantly increased GFAP 
expression to 393 ± 22.7% and 413.7 ± 26.3%, respectively, compared to uninjured control (Fig. 
24B). Qualitatively and quantitatively the optic nerves of animals treated with MBV after IOP 
elevation showed decreased GFAP expression, and there was no significant difference (107.7 ± 
6.4% increase) in GFAP expression between uninjured control optic nerves and MBV treated optic 
nerves.  
4.3.8 MBV increase GAP43 expression after IOP elevation  
To determine if MBV can increase RGC axon growth in vivo, the expression of the axon growth 
marker GAP-43 was analyzed (Fig. 25A). Compared to uninjured control nerves, GAP43 
expression was significantly decreased in IOP elevation and IOP elevation with PBS injection 
groups at 77.5 ± 7.2% and 77.8 ± 8.4% of uninjured controls, respectively (Fig. 25B). Optic nerves 
of animals treated with MBV showed increased GAP43 expression, and there was no difference 
(108.6 ± 6.1%) in GAP43 expression between uninjured control and MBV treated optic nerves.  
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Figure 24. MBV decreases IOP induced GFAP expression in the optic nerve. A. Representative images of optic 
nerves labeled with GFAP. B. GFAP expression was increased following IOP elevation and IOP elevation with 
PBS injections. MBV injections decreased GFAP expression compared to untreated groups, and there was no 
difference in GFAP expression between MBV treated and uninjured animals. 
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Figure 25. MBV increases GAP-43 expression in the optic nerve. A. Representative images of optic nerves labeled 
with GAP-43. B. GAP-43 expression was decreased following IOP elevation and IOP elevation with PBS injections. 
MBV injections increased GAP-43 expression compared to untreated groups, and there was no difference in GAP-
43 expression between MBV treated and uninjured animals. 
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4.3.9 MBV improve retinal electrical function after IOP elevation 
Photopic negative response (PhNR) amplitude and latency were recorded using 
electroretinography (ERG) (Fig. 26). Compared to uninjured control eyes, IOP elevation and IOP 
elevation with PBS injection significantly decreased PhNR amplitude by 32.8 ± 4.4% and 42.0 ± 
16.8%, while there was no difference in PhNR amplitude between uninjured control and MBV 
treated eyes (Fig. 26C). Latency analysis showed IOP elevation significantly increased latency by 
16.6 ± 4.0% compared to uninjured control group, while IOP elevation with PBS injection and 
MBV treatment had no significant effect on latency (Fig. 26D).  
4.3.10 MBV decrease Mn transport deficits in the visual system 
Mn transport along the visual pathway was assessed in the optic nerve, LGN, and SC projected 
from the left and right eyes by quantifying the normalized signal intensity before (pre-MEMRI) 
and 8 hours after (post-MEMRI) MnCl2 injections (Fig. 27). No differences in percentage signal 
intensity were observed in the optic nerves for any of the three groups. In both the LGN an SC, 
percentage signal intensity differences were observed for the IOP only and IOP with PBS animals, 
and there was no difference in the LGN or SC for the IOP with MBV animals. 
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Figure 26. MBV prevents IOP induced decreases in the retinal photopic negative response (PhNR) and increases 
in the PhNR latency. IOP elevation with and without PBS injection decreased the photopic negative response 
(PhNR) amplitude. MBV treatment increased the PhNR amplitude compared to untreated groups and there 
was no difference in PhNR amplitude between uninjured and MBV treated groups. IOP elevation decreased 
latency of the PhNR and was significantly increased compared to IOP elevation with MBV treatment. 
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Figure 27. After IOP elevation, MBV increase anterograde Mn transport. A. Representative images of the 
optic nerve, lateral geniculate nucleus, and superior colliculus (SC) after IOP elevation, IOP elevation with 
PBS injection, and IOP elevation with MBV injections. Signal intensities were normalized to saline nearby 
saline phantom to account for system instability. Percent difference in manganese enhancement was 
calculated between right and left B. ON, C. LGN, and D. SC. Post-hoc Tukey’s tests between pre- and post-
MEMRI (*p<0.05). Data represented as mean ± SEM. Scale bar = 4mm 
R L 
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4.4 DISCUSSION 
This study shows MBV derived from UBM-ECM can increase RGC neurite growth in vitro, 
decrease secretion of pro-inflammatory markers from microglia and astrocytes in vitro, and 
increase RGC survival after acute ocular injury. MBV are highly stable and protect biologically 
active signaling cargo, including miRNAs and proteins, from degradation. MBV survive even 
harsh ECM decellularization processes and thus likely play a fundamental role in tissue and organ 
organization across species and a regulatory role in the tissue response to injury.  Recognition of 
their presence and an understanding of their biologic activity provides for possible new therapeutic 
approaches that are otherwise untenable. Derived from healthy, pro-regenerative tissues, MBV 
have biologic potential that exceeds that of extracellular vesicles derived from cultured cell lines. 
MBV carry unique (i.e. tissue specific) and complex cargo, including miRNAs, lipids, proteins, 
cytokines, carbohydrates, and other small molecules, capable of activating a variety of extra- and 
intracellular signaling pathways. Initial studies indicate that the cellular response to MBV depends 
on both surface proteins and the intra-luminal miRNA cargo [121]. Interestingly, miRNA cargo in 
MBV, derived from different tissues, are enriched in highly conserved miRNAs involved in cell 
cycle regulation and differentiation [121, 122], suggesting MBV play a fundamental role in ECM 
mediated tissue and organ development, organization, and function, possibly by regulating cellular 
phenotypes in a site appropriate manner. Small RNA sequencing (RNA-seq) identified known and 
novel candidate miRNA packaged within MBV [118] and results showed a differential miRNA 
signature dependent on the anatomical origin of the source tissue. Moreover, a cohort of miRNA 
known to regulate neuronal signaling pathways involved in neuronal differentiation and neurite 
growth, including miRNAs -30b, -125b, and -133b [123-125], were identified to be highly 
enriched in MBV. 
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MBV are non-neurotoxic in vitro at all concentrations tested, and significantly increased 
total neurite growth at 5, 10, and 20 µg/ml. While higher concentrations, i.e. 50 and 80 µg/ml, had 
no effect on RGC survival, these two concentrations did significantly stunt neurite growth 
compared to media controls, suggesting different components, including miRNA, regulating 
neuronal growth and survival are contained within MBV. The pathways MBV regulate to effect 
cell behavior are unknown. Extracellular vesicles are widely used as vehicles to shuttle proteins, 
lipids, carbohydrates, and nucleic acids between cells and organs that regulate cellular migration, 
proliferation, and organization [262, 263]. The discrepancy between regulation of neuronal 
survival and growth indicate different factors or cellular pathways, both extra- and intra-cellular, 
could be regulated by MBV.  
MBV suppressed pro-inflammatory cytokine secretion from microglia and astrocytes. 
Depending on factors released into the microenvironment after injury, microglia and macrophages 
polarize to either the pro-inflammatory M1-like or anti-inflammatory M2-like phenotypes, which 
in turn dictates astrocyte phenotype [256]. The macrophage and microglia M2/M1 ratio is a key 
determinant whether tissue forms a scar or promotes functional tissue remodeling events following 
injury. Generally, M1-like cells are pro-inflammatory and produce high levels of oxidative 
metabolites that damage healthy cells and tissues [59], contributing to scar tissue formation. In 
contrast, M2-like cells are generally anti-inflammatory and regulate functional tissue remodeling 
[256]. In CNS tissues, M1-like macrophages and microglia are neurotoxic and possess only 
moderate axon growth-promoting effects [256], whereas M2-like macrophages and microglia are 
non-neurotoxic and can promote long-distance axon growth, even in the presence of growth 
inhibitory molecules like chondroitin sulfate proteoglycans (CSPG) or myelin [256].  
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MBV recapitulate effects of the parent ECM from which they are derived. Pro-
inflammatory microglia and astrocytes are characterized by increased expression of IL-1β, IL-6, 
and TNF-α [264, 265], and MBV and UBM-ECM treatment following pro-inflammatory 
polarization of microglia decreased the release of IL-1β, IL-6, and TNF-α, suggesting MBV elicit 
a similar anti-inflammatory as UBM-ECM. Previous studies with bone marrow derived 
macrophages (BMDM) showed polarization with LPS/IFNγ to a pro-inflammatory phenotype is 
ameliorated by subsequent treatment with UBM-ECM or sub-intestinal submucosa (SIS-ECM) 
and leads to a gene expression profile distinct from transformed human mononuclear cell line 
(THP-1 cells) [266]. MBV were isolated from UBM-ECM and SIS-ECM, cultured with BMDM, 
and gene and protein expression evaluated [243]. While MBV derived from UBM-ECM and SIS-
ECM elicited distinct changes in gene and protein expression, the MBV did recapitulate some 
effects from the parent ECM, thereby indicating MBV may be responsible, in part, for changes in 
cellular behavior elicited by ECM. The transition from pro-inflammatory, M2-like to anti-
inflammatory, M1-like phenotype is an important regulator of the tissue healing response and 
returns the microenvironment to homeostasis after injury [194, 267] and failure to regulate the 
M2/M1 ratio results in chronic inflammation and impaired wound healing [268]. The 
downregulation of pro-inflammatory M1-like microglia polarization in the CNS also prevents the 
pro-inflammatory polarization of astrocytes to the A1-like pro-inflammatory phenotype that is 
associated with RGC cell death.  
MBV decreased pro-inflammatory cytokine secretion from microglia and astrocytes. TNF-
α is a pro-inflammatory protein known to stimulate A1-like astrocyte polarization [38], and since 
the secretion of TNF-α by LPS/IFNγ primed microglia was down regulated after MBV treatment, 
the pro-inflammatory cytokine secretion from astrocytes was subsequently prevented. IL-1β and 
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IL-6 expression, markers of pro-inflammatory astrocytes [264, 265], were also downregulated 
following MBV treatment, suggesting astrocytes were redirected from a pro-inflammatory 
phenotype and can therefore potentially avoid inducing RGC cell death. In the CNS, astrocytes 
participate in numerous functions essential to neuronal health [65, 66], metabolism [67, 68] 
survival, and signaling [69]. During development, astrocytes begin to form connections with 
neurons and other non-neuronal cells [70, 71].  In response to CNS injury or degeneration, 
astrocytes show a marked change in gene expression, hypertrophy and proliferation [72, 73], a 
process called reactive astrogliosis. Reactive astrogliosis can lead to several beneficial functions, 
including sequestration of damaged tissue and the buffering of excess cations and 
neurotransmitters [74-76]. However, these changes in astrocyte activity and gene expression also 
have negative consequences including exacerbation of tissue damage and glial scarring which 
inhibits axon regeneration [32]. These negative effects may be due to the over-production of 
reactive oxygen species and inflammatory cytokines as well as the release of extrinsic inhibitory 
factors [72, 77]. As shown in a previous study, factors released by pro-inflammatory astrocytes 
induce RGC cell death and immobilizing secreted factors TNF- α, IL-1 α, and C1q significantly 
increases RGC survival after [38]. The initial studies suggest the effect of MBV on microglia 
ameliorates the initial response in the CNS inflammatory chain which can rescue RGCs 
downstream. 
After acute ocular injury, three intravitreal injections of MBV increased RGC survival and 
modulated the typical healing response in the CNS. RGCs typically degenerate after injury [269]. 
However, the MBV treatment caused significant survival of RGC compared to untreated control. 
Following elevated IOP, RGCs typically undergo cell death to a higher extent in the periphery than 
around the ONH [259, 270], and similar results were seen in this study where the RGCs in the 
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peripheral retina of untreated animals had the lowest survival rate. A similar trend was observed 
in the MBV treated animals where the RGCs in the peripheral retina had a lower survival rate than 
RGCs around the ONH. There are around 30 RGC subtypes that exist throughout the retina and 
are susceptible to stresses to different degrees [271]. While the mechanism through which MBV 
effect RGC survival is unclear at the moment, the data suggests that MBV have an effect on all 
RGC subtypes since RGC survival throughout the retina was increased. In addition to RGC cell 
bodies, RGC axon survival was increased in the retina and down the length of the optic nerve as 
shown by positive CtxB staining. RGCs typically take 3-5 weeks to regenerate from the retina to 
the optic chiasm [272, 273], therefore since axons were observed the length of the optic nerve, the 
results are indicative of RGC axon preservation rather than regeneration of newly formed axons, 
although future studies will examine earlier time points to verify this conclusion. After injury in 
the CNS, immune cells, including astrocytes, migrate to and proliferate in the injury site, thereby 
increasing GFAP expression [32] and ultimately leading to gliotic scarring. The MBV treatment 
significantly decreased GFAP positive staining in the optic nerve, suggesting decreased astrocyte 
activation which will ultimately lead to decreased scarring in acute injuries and a decrease in 
secreted neurotoxic factors associated with glial scarring [72, 77] and neuronal death [38]. MBV 
after injury increased GAP-43 expression along the optic nerve, indicating an increased potential 
to regenerate. However, as previously mentioned, since the entire length of the optic nerve showed 
positive CtxB staining at 14 days after injury, the results suggest MBV increase RGC axon survival 
and preservation and not necessarily regeneration. Future studies will include earlier time points 
to confirm these conclusions.  
ERG and MEMRI results indicated MBV increased electrical function in the retina after 
injury and decreased Mn transport deficits in the visual system after injury. ERG used in this study 
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measured electrical function of neuronal and non-neuronal cells, therefore the results are not 
specific to RGC only. However, the RGC electrical activity is included in the measured response. 
MEMRI examines anterograde Mn transport between the retina and the visual pathway [163-165, 
274, 275]. As previously shown in the results from chapter 2, acute IOP elevation has no effect on 
Mn transport in the optic nerve, but causes detectable changes in Mn transport in the LGN and SC, 
and similar results were observed in these animals. One caveat to note is that Long Evans rats were 
used in chapter 2, while Sprague-Dawley rats were used in this study. While the same trends held 
between the two studies, slight differences in the percentage Mn transport deficits could be 
attributed to differences in strains of rats used for the two studies. MBV treatment after IOP 
elevation resulted in decreased Mn transport deficits, indicating MBV treatment preserves 
anterograde axonal transport after injury. ERG and MEMRI results suggest MBV treatment may 
increase visual function after injury, and future studies will include visual behavior analysis.  
This study shows MBV derived from UBM-ECM significantly increase RGC survival 
following injury and offer a minimally invasive therapeutic to treat ocular trauma. However, the 
mechanism through which MBV effect cellular behavior is unelucidated and outside the scope of 
the present study. Future studies will determine through which mechanism MBV enter cells, e.g. 
through internalization, fusion, or endocytosis, and which molecular pathways are being regulated 
in each cell type. Future studies will also determine at which time points and by which cell types 
MBV are internalized, both by uninjured and injured animals. In vitro results show MBV have a 
direct effect on RGC. However, the same conclusion cannot be drawn from in vivo studies at this 
time since MBV may be internalized by activated microglia, macrophages, or other circulating 
cells in the vitreous prior to being taken up by RGC following injury. Additionally, the optimal 
treatment window during which MBV need to be delivered will be determined. After injury, 
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immune cells infiltrate the site at various time points, therefore there exists a window during which 
MBV need to be delivered to avoid irreversible RGC and ocular morbidity. The current treatment 
regimen starts immediately after injury. However, this treatment regimen is not realistic in a 
clinical setting, therefore future studies will determine the time point after injury at which MBV 
need to be administered to serve as an effective treatment. The current study analyzed the cellular 
response 14 days after injury, and future studies will include analysis of the cellular survival and 
immune response at additional time points, e.g. 1, 3, and 7 days, and 1, 3, and 6 months, to gather 
a comprehensive understanding of the temporal effects of MBV after injury.  
MBV can easily be engineered to contain specific cargoes or combined with existing 
technologies to offer combinatorial devices. In addition to naturally containing bioactive factors 
that can positively regulate ocular tissue remodeling, MBV can be engineered to contain specific 
proteins, small molecules, and nucleic acids to further optimize constructive remodeling of injured 
ocular, and other, tissues [263]. MBV withstand harsh decellularization processes using 
mechanical agitation, detergents, and lyophilization, thereby making them rigid and robust 
delivery vehicles. The robust nature and small size of these vesicles make them good candidates 
to be incorporated into existing devices used for CNS and ocular repair after injury [219] to work 
in concert with and enhance the efficacy of existing devices.  
CNS injuries typically lead to a destructive pro-inflammatory response which prevents 
functional recovery of damaged CNS tissue. This study shows that MBV derived from UBM-ECM 
suppress secretion of pro-inflammatory cytokines and increase RGC survival after injury. MBV 
are derived from FDA approved, commercially available products, therefore hold minimal risk of 
adverse response in pre-clinical and clinical trials.  MBV are a versatile therapeutic that can be 
delivered in a minimally invasive manner, can be engineered to incorporate additional biologic 
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factors, and can be incorporated into and combined with existing devices to act in concert with 
other commercially available and experimental therapeutics. MBV thus offer a significant vertical 
advance for ocular and CNS functional remodeling.  
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5.0   DISSERTATION SYNOPSIS 
5.1 MAJOR FINDINGS  
The present work described the effects of elevated IOP on the visual system and the development 
of ECM bioscaffolds and MBV for ocular therapeutics. In the first section of work, the structural 
and functional changes in visual pathway integrity and function were described as a function of 
IOP elevation severity. The LGN was implicated in structural and functional changes, suggesting 
this region in the visual pathway is highly susceptible to damage following injury. Fetal brain 
tissue was decellularized using a vacuum assisted decellularization chamber to effectively remove 
cellular content from delicate fetal tissue. In vitro, fB-ECM was non-neurotoxic and increased 
neurite outgrowth, suggesting the fB-ECM would be suitable for in vivo applications. However, 
following optic nerve crush experiments, the fB-ECM hydrogels decreased astrocyte pro-
inflammatory activation and increased axonal growth marker expression in some animals, but this 
was not seen in all animals. The variability seen in animals is hypothesized to be due to the 
necessity to fenestrate the optic nerve sheath after optic nerve crush and prior to treatment, 
therefore indicating that while fB-ECM is a promising treatment for CNS injuries, it may not be 
an optimal delivery platform in the visual system. MBV were isolated from UBM-ECM and in 
vitro experiments indicated MBV have strong anti-inflammatory properties and induce neurite 
outgrowth. In vivo studies show intravitreal delivery of MBV decrease as pro-inflammatory 
astrocyte polarization and increase RGC survival and function after IOP elevation. MBV offer a 
vertical advance in the field of regenerative medicine and offers the ability to treat ocular and other 
CNS injuries in a minimally invasive manner. 
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5.2 FUTURE WORK 
This dissertation reports on multi-parametric neuroimaging of axon degeneration and the 
development of extracellular matrix (ECM) and matrix bound nanovesicles (MBV) therapeutics 
and their effects on the visual system after ocular injury. White matter integrity, active axonal 
transport, and functional connectivity were decreased following acute and chronic intraocular 
pressure (IOP) elevation, and these effects were ameliorated in the animals that received oral 
citicoline treatment prior to and after injury. ECM bioscaffolds have been used in many tissues 
and organs to increase functional remodeling after injury, and this dissertation reports on the 
derivation of fetal brain ECM (fB-ECM) and its application in vitro and in vivo. In vitro results 
using fB-ECM were promising, but in vivo studies showed variable results, indicating fB-ECM 
has the ability to promote functional remodeling but may not be the optimal solution to treat ocular 
injuries. The final section of work analyzed MBV derived from urinary bladder matrix (UBM) and 
their application in vitro and in vivo after ocular injury. MBV increase retinal ganglion cell (RGC) 
neurite growth and decreased pro-inflammatory cytokine secretion in vitro. Following ocular 
injury, MBV increased RGC survival, decreased astrocyte activation, increased electrical activity 
in the retina, and decreased axonal transport deficits. Although, these results indicate axonal 
degeneration and neuroprotection can be detected using MRI, and MBV may offer an easily 
administered therapeutic to preserve vision after injury, future work can expand on the findings 
included in this dissertation to further understand mechanisms of injury and refine MBV to be used 
as a clinical therapy.  
MRI results included in the second chapter of this dissertation indicate oral citicoline can 
decrease neurodegeneration after chronic IOP elevation. Animals were treated daily 7 days prior 
to injury and every 48 hours for 14 days after injury which proved to be effective in decreasing 
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neurodegeneration. However, only one treatment paradigm was used and therefore may not be the 
optimal dosage or frequency. Future work will investigate different doses of citicoline with 
treatment starting at earlier time points as well as concurrently with IOP elevation to determine 
the treatment window during which citicoline treatment needs to be administered to be effective. 
While such results are promising, there is still much more to be learned about both citicoline, such 
as in treatment later in the disease course, and other possible neuroprotective agents. Since brain 
regions other than the eyes are affected, treatment mechanisms should focus on treating neural 
structures throughout the visual and nervous system. Chemical exchange saturation transfer 
(CEST) MRI has been used to track citicoline in vivo, and this technique can be used in future 
studies to investigate citicoline action and delivery in the visual system in experimental glaucoma. 
The study showed MRI can be used to detect neurodegeneration and neuroprotection, therefore 
the modalities can be used to assess efficacy of experimental glaucoma therapies.  
MBV are bioactive, can regulate cellular processes, and can be administered in a minimally 
invasive manner. Extracellular microvesicles (EVs) are increasingly appreciated as important 
factors regulating intercellular communication in the visual system and are now being explored as 
biomarkers, therapeutics, and drug delivery vehicles. EVs are released by all cell types and 
comprise a several populations of sub-micron sized vesicles, including exosomes, ectosomes, 
oncosomes, shed vesicles or microvesicles, apoptotic bodies, and recently described matrix bound 
nanovesicles. Though the EV nomenclature is developing, EVs are generally classified by their 
origin and molecular profile into four main groups: exosomes, microvesicles, apoptotic bodies 
[276], and the recently described matrix bound nanovesicles [118]. The work included in this 
dissertation indicates ECM and MBV have the potential to modulate the immune response and 
promote functional remodeling in the visual system after injury. Aim 3 showed promising results 
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that indicate MBV derived from UBM-ECM have the potential to prevent RGC death after injury. 
However, UBM-ECM may not be the ideal source of MBV for ocular applications. Previous 
studies have shown there are negligible differences between ECM derived from different source 
tissues when analyzing effects on neurite outgrowth [221]. However, similar comparative studies 
have not been done using MBV derived from different tissue sources, and previous studies showed 
MBV derived from different source tissues contain different miRNA cargoes [118]. Therefore, 
future work should investigate the differences between MBV derived from different source tissue, 
e.g. dermal ECM, sub-intestinal submucosa, or CNS specific, as it pertains to neuronal cells to 
determine which tissue source will induce the greatest extent of RGC cell and axon survival after 
injury.  
Chapter 4 indicated MBV increase RGC survival after ocular injury. However, no 
mechanisms have been identified to explain how MBV enter cells of elicit the responses observed 
in these studies. Future studies will determine through which mechanism MBV enter cells, e.g. 
through internalization, fusion, or endocytosis, and which molecular pathways are being regulated 
in each cell type affected by MBV. Two potential mechanisms that have been hypothesized to 
explain how MBV regulate cellular behavior include miRNA cargoes and IL-33. UBM MBV have 
previously been shown to contain miRNAs involved in cellular development, growth, and 
viability. Five specific miRNA were identified, including miRNA-29b, -30b, -34a, -125b, and -
133b [118]. MiRNA-29b has been implicated in inhibiting apoptosis [277]. miRNA-30b and 
miRNA-125b have been shown to inhibit apoptosis and promote neuronal growth. miRNA-133b 
has been shown to promote neurite growth [124, 125, 278] and increase branch number [123, 279]. 
Conversely, miRNA-34a has been implicated in promoting apoptosis and decreasing neuronal 
growth [280]. Since miRNA are highly conserved, these miRNA contained in MBV from porcine 
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derived ECM can promote beneficial effects on cells from other species and can potentially explain 
the effects of MBV on RGC observed in Aim 3. Recently, MBV have been shown to be 
upregulated in IL-33. IL-33 has been shown to be downregulated after CNS injury, and the 
imbalance is associated with an imbalance in Th1/Th2 ratio which exarcerbates secondary injury 
[281]. Administration of recombinant IL-33 after CNS injury in mice has been shown to ameliorate 
the severity of CNS injury and improve functional recovery [282]. Future work will be focused on 
determining whether IL-33 is a key player in the immunomodulatory effect elicited by MBV.  
In aim 3, MBV were adminstered immediately after injury, and at days 2 and 7. This initial 
paradigm was chosen to first identify whether MBV are effective when adinsitered at an optimal 
time after injury. However, this is not a realistic or translatable method of adminstration. Patients 
often report to emergency rooms hours to days after injury and based on the nature of other 
potentially life-threatening injuries, ocular injuries are often not immediately addressed. Future 
work needs to determine the treatment window after injury during which the first MBV dose needs 
to be administered, and whether repeated injections are necessary.  
Although MBV increased RGC survival, the optimal combination of factors necessary to 
ameliorate damage after CNS injury and promote neuronal survival are yet to be determined. MBV 
are tunable and in addition to naturally containing bioactive factors that can positively regulate 
ocular tissue remodeling, MBV can be engineered to contain specific proteins, small molecules, 
and nucleic acids to further optimize constructive remodeling of injured ocular, and other, tissues 
[263], thereby making them ideal delivery vehicles to administer their own and loaded cargoes. 
Vesicles, or combinations of vesicles, can target and deliver diverse biomolecular cargoes to 
modulate distinct cellular populations, like immune cells, glia, and neurons, making them 
attractive developing combinatorial therapeutics to treat CNS and ocular injuries and diseases 
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clinically. Though clinical studies are in early development phases, this idea is supported by pre-
clinical rodent studies reporting positive tissue remodeling and increased functional recovery in a 
stroke model [283]. In addition to being tunable, MBV are good candidates to be loaded into 
existing devices used for ocular and CNS repair to enhance efficacy of the devices [219]. MBV 
withstand harsh decellularization processes using mechanical agitation, detergents, and 
lyophilization, thereby making them rigid and robust entities that can be incorporated into existing 
devices through multiple manufacturing methods. For example, Appendix A describes a study 
fabricating a synthetic polymer loaded with an anti-inflammatory agent, tacrolimus, that decreases 
the pro-inflammatory response in the optic nerve after injury. Although outside of the scope of this 
dissertation, future studies can investigate incorporating MBV and tacrolimus into a one device 
aimed at promoting functional tissue remodeling after injury. Since MBV are tunable and robust, 
the vesicles can either be loaded with tacrolimus or incorporate into the synthetic polymer.  
MBV are a natural component of the ECM in healthy tissues, have been shown to be 
non-cytotoxic, can promote CNS neurite growth, promote an anti-inflammatory macrophage 
and microglia phenotype, and can easily be administered in vivo, therefore making MBV an 
attractive option to promote neuroprotection and constructive remodeling in the CNS after 
injury. 
5.3 OVERALL CONCLUSIONS 
The work in this dissertation describes longitudinal MRI on the visual system after injury, 
and the development and effects of fetal derived ECM and MBV in vitro and in vivo after injury 
in rodent models. The decellularization process effectively decellularized delicate fetal tissue 
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which formed an injectable hydrogel capable of mitigating inflammatory responses and increasing 
neuronal growth. MBV were isolated from ECM bioscaffolds and successfully decreased the 
inflammatory response and increased RGC survival and retinal function after injury. MBV can be 
combined with other neurotrophic factors and bioactive components to deliver combinatorial 
approaches therapies. The work presented here offers an exciting opportunity to treat ocular and 
CNS injuries through a minimally invasive therapeutic.  
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APPENDIX A 
A POLYMERIC TACROLIMUS-ELUTING NERVE WRAP MODULATES 
LOCAL TISSUE REMODELING AFTER EXPERIMENTAL ACUTE OPTIC NERVE 
ISCHEMIA 
INTRODUCTION 
In adult mammals, central nervous system (CNS) injury remains a persistent experimental and 
clinical challenge. Trauma to CNS tissues triggers a pro-inflammatory innate immune response 
that leads to secondary tissue damage, injury site expansion, and cellular and extracellular matrix 
(ECM) remodeling [31]. This default healing response contributes to failed axon regeneration [30, 
284] and promotes scar tissue formation [32], often leading to irreversible CNS neuron death [285]
and permanently lost neurological function. Thus, combinatorial approaches are needed that can 
positively modulate the innate immune response to promote functional tissue remodeling over 
scarring while also providing key neuroprotective and neuroregenerative support to CNS neurons. 
Tacrolimus, also called FK506, is a macrolide immunosuppressive drug initially derived 
from Streptomyces tsukubaensis (Prograf ® Astellas, NJ) [286] used clinically to prevent organ 
transplant rejection [287] as well as to treat various dermatologic [288] and autoimmune diseases 
[289]. Tacrolimus binds to FK506-binding protein (FKBP) receptors of the immunophilin family, 
which comprises at least 15 members in humans. In humans, tacrolimus is thought to prevent organ 
transplant rejection by suppressing T-cell activation via binding to FKBP12 [290]. In the CNS, 
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FKBPs are widely expressed by numerous cell types, including both neurons and glia, with 
different cellular populations exhibiting distinct FKBP subtype expression patterns and 
pharmacokinetics. In the CNS, tacrolimus is hypothesized to modulate the innate immune response 
by reducing neutrophil and macrophage infiltration and microglial [291] and astrocyte activation 
[292-294], subsequently reducing oxidative stress, secondary damage, and injury site expansion 
[295].  
Experimentally, tacrolimus can also provide both neuroprotective and neuroregenerative 
benefits to CNS neurons. Although FKBPs are widely expressed by CNS neurons, tacrolimus 
appears to modulate neuronal activities by multiple mechanisms, including by FKBP-dependent 
and -independent routes [296]. After optic nerve (ON) ischemia in rats, tacrolimus increases retinal 
ganglion cell (RGC) survival by suppressing apoptotic signaling [297]. After spinal cord injury in 
rats, tacrolimus increases axon growth and the expression of growth associated protein-43 
(GAP43), an axon growth marker [298, 299] and can improve functional recovery [300]. In recent 
studies, tacrolimus has been shown to reduce ischemia reperfusion injury in white matter after 
cerebral artery occlusion surgery [295] and decrease apoptosis in hippocampal neurons [301]. 
However, most experimental studies have relied on systemic administration to deliver tacrolimus 
to CNS tissues [295, 301]. Tacrolimus is highly lipophilic and thus accumulates in fatty tissues 
throughout the body, including the myelin-based white matter in the CNS. However, systemic 
delivery to CNS tissues is complicated by preferential uptake by other organs, which requires 
higher systemic doses to effectively increase tacrolimus in CNS tissues. These increases in 
systemic tacrolimus often lead to often life-threatening toxicity in other tissues and organs. 
Clinically, tacrolimus is administered systemically either orally or by injection [302, 303]. 
The chemical properties of tacrolimus require careful consideration with regard to systemic 
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administration. The method of administration, frequency, and dosage, must be carefully to 
maintain effective therapeutic tissue levels without inducing toxicity is off-target tissues. 
Improperly regulated systemic levels can lead to several life-threatening side effects, including but 
not limited to diabetogenicity, nephrotoxicity, neurotoxicity and oncogenicity [287, 304]. 
Moreover, tacrolimus administration is further complicated by tacrolimus the number of 
distribution of FKBP binding proteins. Tacrolimus acts on at least 15 FKBP binding receptors in 
humans differentially expressed by cellular populations in different tissues and organs. Therefore, 
tacrolimus administration must be carefully optimized to maintain effective concentrations within 
the tissues of interest to maximize efficacy while minimizing toxic side-effects both to targeted 
and to non-targeted cellular populations and tissues. Thus, strategies being developed to deliver 
tacrolimus locally. Local delivery approaches include hydrogels [305], inhalants [306], and 
micelle [307] or polymer encapsulation technologies [308]. However, these technologies are 
limited for many CNS applications due to ineffective and/or inconsistent tacrolimus delivery to 
specific CNS tissues, incompatible mechanical properties, and the inability to remain intact and/or 
localized to the injury site.  
To deliver tacrolimus locally and controllably to CNS tissues, this study developed a 
biodegradable and elastic matrix using poly(ester urethane) urea (PEUU) [309]. PEUU polymers 
have desirable mechanical characteristics, including high elasticity and strength, good cell-
adhesive properties, and controllable biodegradation, all of which can be tuned to match the tissue 
of interest. By modifying a previously developed PEUU electrospinning platform [310], 
tacrolimus and PEUU were successfully blended into PEUU polymer matrices. This method 
allowed precise control over both the PEUU and tacrolimus concentrations as well as control over 
the size and the thickness of the PEUU-Tac matrices. PEUU-Tac material properties and release 
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kinetics were analyzed in vitro. The dose-dependent effects of tacrolimus on primary RGC 
viability, toxicity, and differentiation were analyzed in vitro. Finally, PEUU-Tac matrices were 
used as ON wraps to analyze local, trans-dural tacrolimus delivery to CNS tissues and to the blood 
in an acute ON ischemia model in rat.  
MATERIALS AND METHODS 
Animals 
Sprague-Dawley rats were purchased from Charles River Laboratories (Wilmington, MA). 
Animals were housed and maintained according to the guidelines set forth by the University of 
Pittsburgh Institutional Animal Care and Use Committee (IACUC) and the DOD Animal Care and 
Use Review Office (ACURO). All procedures complied with the American Association for the 
Accreditation of Laboratory Animal Care (AALAC).  
Retinal ganglion cells 
Primary RGCs were isolated from female and male postnatal day three (P3) Sprague-Dawley rat 
pups, purified by immunopanning, and cultured in NB-SATO media as described [215]. RGCs 
were seeded (5 × 103/cm2) on cell culture plates coated with poly-D-lysine (70 kDa, 10 μg/mL; 
Sigma-Aldrich Corp., St. Louis, MO, USA) and laminin (2 μg/mL, Sigma-Aldrich Corp.). 
Tacrolimus (Invitrogen) was diluted in 100% EtOH to make a 20 mM stock. The tacrolimus stock 
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was then diluted in NB-SATO as specified and the RGC cultures maintained at 37°C in 10% CO2 
for 3 days in vitro (DIV). 
RGC viability 
Viability was analyzed after 3 DIV using a calcein and propidium iodide based live/dead kit per 
manufacturer’s instructions (Life Technologies, R37601). For analysis, the first five non-
overlapping fields of view per well, moving from the left well edge, were imaged at 20X using 
standard epi-fluorescence fluorescein and rhodamine filter sets (Zeiss, Axio Observer). 
Experimentally blinded individuals analyzed live and dead cells using ImageJ (National Institutes 
of Health, Bethesda, MD, USA). Data represent triplicates from four experimental repeats, totaling 
at least 27 fields of view and at least 300 neurons per group as previously described [121]. 
Significance between groups was determined by one-way analysis of variance (ANOVA) as noted 
in section 2.13. 
RGC neurite growth  
After 3 DIV, RGCs were fixed with 4% paraformaldehyde (Alfa Aesar; 30525-89-4) in PBS, 
washed with PBS (2X), and permeabilized with 0.2% triton X-100 in PBS for 15 min. After 
blocking for 1 hr (1% BSA in PBS, Fisher Scientific), the RGCs were incubated with anti-β III 
tubulin (1:300, TUJ-1, Millipore, RRID: AB 570918) at 4°C overnight, washed in PBS (3X), 
incubated with a FITC-rabbit anti-chicken IgY H+L secondary (1:150, #31501, Thermo Scientific) 
for 3 hrs, washed with PBS (3X), counterstained with the nuclear marker DAPI (1:3000, 
Invitrogen, D1306) for 20 min at room temperature, and washed in PBS (2X, 5 min each). The 
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RGCs were imaged randomly as described above and neurite growth measured by blinded 
individuals as described [311] using the ImageJ plugin, NeuronJ (National Institutes of Health, 
Bethesda, MD, USA). The first ten non-contacting RGCs encountered, moving right from the left 
edge of the well, were analyzed from triplicate wells in each of three independent experimental 
repeats, totaling at least 90 neurons per condition. Significance between groups was determined 
by ANOVA as noted in section 2.13. 
PEUU-Tac  
Poly(ester urethane) urea (PEUU) was synthesized from polycaprolactone diol (Mn = 2000), 1,4-
diisocyanatobutane and putrescine, as described [309] and PEUU-Tac matrices fabricated by 
electrospinning as described [312]. Briefly, 10 mg or 20 mg of tacrolimus was dissolved in 500 
μL of 1,1,1,3,3,3-hexafluoroisopropanol (HFIP). Each tacrolimus solution was mixed with 0.45 g 
PEUU (12% w/v in HFIP) and electrospun onto a rotating stainless-steel mandrel (19 mm 
diameter) by feeding through a charged capillary at a rate of 3 mL/hr. The mandrel was located 17 
cm from the tip of the capillary and the voltage between the capillary and the mandrel was 19 kV. 
PEUU-Tac matrices were sterilized under UV light overnight and then with ethylene oxide (ETO) 
before use. 
PEUU-Tac release kinetics  
To determine tacrolimus release rate, PEUU-Tac matrices were cut into three equal weight sections 
(15 mg) and each section was placed in 25 mL of 0.5% Cremephor EL (C5135, Sigma, St. Louis, 
MO) in PBS (CrEL-PBS) [313] in Sigmacote (SL2, Sigma, St. Louis, MO) treated 50 mL glass 
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beakers with gentle agitation (60 RPM, Thermo Labline 2314 Orbital Shaker). At the indicated 
time points ranging from 1 hr to 14 days, 300 μl was removed for analysis and then replaced with 
300 μl of fresh CrEL-PBS. For each sample, 50 μl was mixed with 450 μl of blood and analyzed 
by UPLC-tandem mass spectrometry as described below. Three additional 50 mL glass beakers 
were coated with Sigmacote. One PEUU-Tac section was placed in each beaker with 25mL CrEL-
PBS with gentle agitation (60 RPM, Thermo Labline 2314 Orbital Shaker) for 24 hrs. The three 
PEUU-Tac sections were removed from the CrEL-PBS solution and each placed in 5 mL of HFIP 
with gentle agitation for 5 minutes to dissolve the PEUU scaffold. Three fresh PEUU-Tac sections 
of equal weight to the pre-release scaffold weight were also placed in 5mL HFIP. The tacrolimus 
concentration was then measured for each sample by HPLC. Significance between groups was 
determined by ANOVA as noted in section 2.13. 
PEUU and PEUU-Tac degradation 
The degradation rate of PEUU-Tac was analyzed at 37°C in PBS as described [314]. Briefly, equal 
size samples (10 × 5 × 0.1 mm) were cut from an unloaded PEUU matrix, 10 mg tacrolimus loaded, 
or 20 mg tacrolimus loaded PEUU-Tac and placed in 15 mL of PBS in a 20 mL vial. At each time 
point, the samples were removed from the buffer, washed with deionized water, and dried under 
vacuum at room temperature for 3 to 4 days before weighing to determine the mass lost, using the 
equation: 
Mass Remaining (%) =   
where md is the sample after drying and morig is the original mass. After weighing, each 
sample was placed in fresh PBS. The time in PBS indicates the total time in PBS, independent of 
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the drying time.  For visualization, the PEUU matrices were sputter-coated with gold/palladium 
and imaged using standard scanning electron microscopy methods (SEM; JSM-6330F, JEOL 
USA). Data represent triplicates from three experimental repeats. The average mass is reported 
with the error bars indicating one standard deviation. Significance between groups was determined 
by ANOVA as noted in section 2.13 
PEUU-Tac mechanical properties  
To test the mechanical properties of PEUU or PEUU-Tac, each matrix was cut into a dumbbell 
geometry (ASTM D1708) using a custom-made dog-bone cutting die with a 2.5 mm width, a 10 
mm gauge length, and a total length of 20 mm. PEUU tensile properties were analyzed by uniaxial 
tensile testing using an MTS Insight (MTS Systems Corporation, MN, USA) with a 10 N (0.01 N 
resolution) load cell at room temperature. The samples were extensionally deformed at 10 
mm/min, according to ASTM D638M. Young’s modulus was calculated by finding the initial slope 
of the stress versus strain curve (0<ε<10%) using linear regression. The ultimate stress was 
determined as the maximum stress and the strain-at-break recorded as the strain at the point where 
the force became zero. The averages and error bars, indicating one standard deviation, are reported. 
Data represent triplicates from three experimental repeats. Significance between groups was 
determined by ANOVA as noted in section 2.13.  
ON ischemia and PEUU-Tac  
Animals were anesthetized by injecting a 45:10 mg/kg ketamine/xylazine cocktail 
intraperitoneally. The ON was exposed by making a small incision in the conjunctiva and then 
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blunt dissecting a nearly bloodless plane back to the ON using #5 jeweler forceps. The muscle and 
connective tissues around the ON were gently separated to expose the ON sheath. Using a Yasargil 
aneurysm clip (Aesculap FT252T), the right ON was clamped approx. 2 mm behind the globe for 
10 seconds [315]. After clamping, the ophthalmic artery was visualized to confirm integrity. A 
subset of animals (n=5) had the ON sheath fenestrated at the clamp site by making a 1-2 mm 
incision using an ultra-sharp scalpel (#681.01, Oasis Medical). For animals receiving PEUU-Tac, 
a 2 x 5 mm section of 10 mg PEUU-Tac was wrapped around the injury site and sutured to itself 
and to the sheath. The conjunctiva was then sutured closed and antibiotic ointment (NDC 24208-
780-55, Gentamicin, Bausch & Lomb, Tampa, Florida) applied to the eye. In total, forty-six 
animals were used. The experimental groups included: 1. Injured. Nine animals received only 
ischemia to the right ON. 2. Injured, PEUU-Tac. After ischemia to the right ON of 14 animals, a 
2 mm x 5 mm section of 10 mg PEUU-Tac was sutured around the injury site (no fenestration). 3. 
Injured, PEUU-Tac (fenestrated). After ischemia to the right ON of five animals, the ON sheath 
was fenestrated as described above before a 2 mm x 5 mm section of 10 mg PEUU-Tac was sutured 
around the injury site. 4. Systemic. After ischemia to the right ON, nine animals were injected 
intraperitoneally with tacrolimus (2.2 mg/kg/day) for 14 days with the first injection administered 
immediately after surgery. 5. Nine animals served as sham surgery controls. Five animals per 
group were used for tacrolimus tissue levels analysis and four were used for 
immunohistochemistry. The injured, PEUU-Tac group had five additional animals that were used 
for Tac tissue level analysis at 24 hrs. Power analysis was used to determine sample size. The 
number of experimental animals was determined using G*power software (G*power software 
3.1.9.2, Germany).  We calculated the effect size to be 0.6 according to our previous experiments. 
Power analysis for ANOVA dictates n=4 animals for histological analysis and n=5 animals for 
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tacrolimus tissue levels per group for in vivo studies to achieve 80% power for α = 0.05. Animals 
were randomly assigned to groups by an experimentally blinded animal technician. 
Tacrolimus blood tissue analysis  
Twenty-four hours after surgery, 500 µl of blood was drawn via the tail vein. Additionally, at 24 
hours, four PEUU-Tac treated animals were sacrificed and the ONs and retinas collected. At 14 
days, the remaining thirty-six animals were sacrificed, and blood, retinas, and ONs collected. 
Tacrolimus tissue levels were analyzed from five animals per group and the remaining four 
animals per group were used for immunohistochemistry. The blood was collected in BD 
Microtainer blood collection tubes (Becton Dickinson, 363706) pre-coated with EDTA to avoid 
coagulation, and stored at 4ºC until analysis. Retinas and ONs were weighed, homogenized in 
100% methanol (MeOH) using a Mini-BeadBeater-1 sonicator (Mini-BeadBeater-16, Thomas 
Scientific), and left overnight to ensure complete tacrolimus extraction. The homogenate was 
centrifuged at 2100 ± 100 rpm for 10 min, the methanol transferred to a microcentrifuge tube, and 
evaporated completely using a vacufuge (Eppendorf Vacufuge Plus 5305 Concentrator Vacuum). 
The residue was then reconstituted in 1 mL of naïve rat blood prior to quantification as described 
below.  
Tacrolimus quantification by UPLC-tandem mass spectrometry  
Tacrolimus was analyzed by UPLC (Nova-pack® C18 column, 2.1 x 10 mm cartridge (Waters # 
186003523)) as described [316, 317]. Briefly, standard curves and quality control blood samples 
were prepared using dry tacrolimus (tlrl-fk5, Invivogen). For each sample, 50 µL blood was added 
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to a conical centrifugation tube, followed by 200 µL zinc sulfate heptahydrate (ZnSO4 ∙ 7H2O) to 
precipitate the blood proteins, and 500 µL ascomycin (20 ng/l in acetonitrile) as an internal 
standard. The samples were vortexed for 2 mins at 3,000 RPM, centrifuged for 3 mins at 13,000 
RPM, and the supernatants collected in LCMS vials (60180-508, Thermo Scientific). Analysis was 
done using a fully validated, reverse phase ultra high-performance liquid chromatographic method 
for detecting tacrolimus in blood with an injection volume of 10 µL. Analytes were separated using 
a gradient elution consisting of an aqueous mobile phase (95% H2O / 5% MeOH) and an organic 
mobile phase (100% MeOH), at a flow rate of 0.6 mL per min. To optimize ionization and enhance 
the chromatographic output quality, both mobile phases contained 0.1% formic acid (CH2O2) and 
2 mM ammonium acetate. Both intra- and inter-day precision were shown to be acceptable (C.V. 
<10%, n=3) at concentrations of 4.3, 15.7, and 24.6 ng/mL. Results are expressed as tacrolimus in 
ng/g of tissue or ng/mL of blood. For animal blood and tissue tacrolimus levels, data represent 
triplicates from at least five animals per condition analyzed by ANOVA as noted in section 2.13. 
Immunohistochemistry  
For immunohistochemistry, tissues were fixed in 4% paraformaldehyde for 4 hrs, cryoprotected in 
30% sucrose for 4 hrs, embedded in optical cutting temperature (OCT) medium (Tissue-Tek; Miles 
Inc, Elkhart, IN) and stored at 4°C overnight before freezing in liquid nitrogen. Embedded tissues 
were stored at -80°C prior to cryostat sectioning (15 µm thickness). ON sections were 
permeabilized with 0.2% triton X-100 in PBS for 15 mins, washed in PBS (2X), blocked for 1 hr 
(1% BSA in PBS, BP9706100, Fisher Scientific), and washed in PBS (2X). ON sections were 
labeled with anti-glial fibrillary acidic protein antibody (Anti-GFAP, 1:500, Abcam, AB7260, 
RRID:AB_296804) or anti-growth associated protein 43 (Anti-GAP-43, 1:500, Abcam, AB16053, 
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RRID:AB_598153), and DAPI (1:2000, Thermo Scientific, 62247). The sections were imaged and 
pixel intensities measured by experimentally blinded individuals using ImageJ as described [218]. 
Briefly, fifteen ROIs of 100 x 100 pixels were drawn around the crush site (GFAP) and distal to 
the crush site (GAP-43). Four ROIs were drawn on the image background. The area, mean 
fluorescence, and integrated density for each image were analyzed using the following formula: 
CTCF = integrated density – (area x mean background fluorescence). Data represent triplicates 
from three experimental repeats analyzed by ANOVA as noted in section 5.2.13. 
Statistical analysis.  
All analyses were done by experimentally blinded individuals. To determine significance between 
groups (p < 0.05), ANOVA was used in conjunction with a Tukey's post-hoc test using SPSS 
Statistical Analysis Software (IBM, Chicago, IL, USA). All error bars represent standard error of 
the mean (SEM) unless noted otherwise. 
RESULTS 
Tacrolimus regulates RGC viability bi-modally 
Previous studies indicate tacrolimus has both neuroprotective and neuroregenerative effects on 
CNS neurons, including RGCs in vitro [318] and in vivo [297]. However, the effective 
concentration ranges on RGC viability and growth have not been reported for primary RGCs in 
culture. To determine the dose-dependent effects of tacrolimus on RGC toxicity, RGCs were 
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cultured in tacrolimus concentrations, ranging from 0.1 to 100 µM (Figure 28b). Below 0.1 µM, 
RGC viability was unchanged. At 0.1 μM, RGC viability was 66%, or 94% of the vehicle control, 
which is in the typical range for primary RGCs cultured in vitro. Over 0.1 μM, RGC viability 
initially increased to a maximum of 91% viable, 21% greater than control, at 0.5 μM, before 
decreasing dose-dependently to 0% at 75 μM. Lethal dose (LD) response analysis was conducted 
by plotting the data points on a semi-logarithmic graph and then using non-linear regression to 
generate a dose response curve, which indicated an LD50=24.2 μM (Figure 28c).  
Effect of tacrolimus on RGC axon growth   
To determine tacrolimus effects on RGC neurite growth, RGCs were initially cultured at high 
density and total neurite growth, which included both axons and dendrites, was analyzed (Figure 
29b). The average total neurite growth per neuronal cell body was greatest at 5 nM but neurite 
growth did not follow a typical dose-response relationship. From 10 nM to 5 μM total neurite 
growth remained largely unchanged before decreasing coordinately with viability to 0 at 75 μM.  
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Figure 28. Tacrolimus regulates RGC viability bi-modally in a concentration dependent manner 
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Thus, although 5 nM stimulated growth to the greatest extent, tacrolimus appears to support RGC 
neurite growth over a broad concentration range up to 5 μM in vitro.   
In high-density cultures, the specific effects of tacrolimus on neurite growth, i.e. dendrite 
vs. axon growth or branching, is masked by neurite to neurite contact and fasciculation [319]. 
Therefore, we analyzed the effects of 5 μM tacrolimus on total neurite growth, axon growth, and 
branching in non-contacting neurons, cultured in low-density cultures (Figure 29c-e). In contrast 
to high-density cultures, tacrolimus increased total neurite growth by 60% and axon growth by 
70% (Figure 29b), whereas branching frequency was unchanged (Figure 29c). Thus, the majority, 
85%, of the total increase in neurite growth by tacrolimus is due to increased axon growth. These 
data provide a basis for identifying the receptors and the signaling pathways by which tacrolimus 
acts to modulate CNS neurons, like RGCs, directly.  
Electrospun PEUU and PEUU-Tac constructs        
To construct a tacrolimus releasing matrix, a previously reported electrospinning protocol for 
PEUU [310] was extended by electrospinning either 10 or 20 mg of tacrolimus blended with 
PEUU. Macroscopically, PEUU and 10 or 20 mg loaded PEUU-Tac matrices were off-white, 
pliable, and indistinguishable from one another (Figure 30a, inset). Microscopically, PEUU 
polymer fiber size and gross organization were also similar initially. In both PEUU and PEUU-
Tac matrices, scanning electron microscopy (SEM) revealed randomly organized polymer fibers 
with varied diameters (Figure 30a). The average polymer fiber diameter was similar in all three 
matrices; unloaded PEUU fibers were 510 ±130 nm and 10 or 20 mg loaded PEUU-Tac fibers 
averaged 560 ± 210 nm and 560 ± 160 nm, respectively. Thus, tacrolimus loading does not alter 
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the gross macroscopic appearance of PEUU matrices nor the microscopic organization and 
diameter of electrospun PEUU polymer fibers.  
 
 
 
 
Figure 29. Total RGC neurite growth was greatest at 5 nM but did not follow a typical dose response curve 
in high density cultures. However, at concentrations over 5 μM, total neurite growth decreased similar to 
viability, reaching zero at 75 μM. 
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Figure 30. Macro- and microscopic PEUU and PEUU-Tac morphologies, tacrolimus release kinetics, and 
degradation rates. 
 132 
PEUU-Tac release kinetics  
Both the 10 and the 20 mg PEUU-Tac matrices released tacrolimus at similar rates, yielding final 
concentrations proportional to their loading concentration (Figure 30c). The 10 mg PEUU-Tac 
matrix yielded a maximum concentration of 11.56 µg/mL (14.5 µM) within the first 24 hours and 
a final concentration that was not significantly different from the 24-hour time point of 9.53 µg/mL 
(11.3 µM) at 14 days. The 20 mg matrix released tacrolimus similarly, yielding a concentration of 
20.4 µg/mL (24.3 µM) within the first 24 hours and a final concentration of 23.7 µg/mL (28.2 µM) 
at 14 days that was also not significantly different from the 24-hour time point. Analysis of residual 
tacrolimus in PEUU-Tac matrices after 14 days showed that 85.7 ± 2.4 % was released within 24 
hours and the remainder was retained in the matrix over the 14 day time point analyzed. Thus, both 
10mg and 20 mg PEUU-Tac matrices release tacrolimus at similar rates in vitro with near 
maximum concentrations reached in approximately 24 hours without significant increases detected 
over the next 13 days analyzed.  
PEUU-Tac matrix degradation in vitro 
To determine if tacrolimus loading alters PEUU matrix degradation, we analyzed the percent 
change in mass of unloaded PEUU and 10 or 20 mg loaded PEUU-Tac matrices over eight weeks 
[314]. Changes in mass were similar for all three matrices (Figure 30d). At 1, 2, and 5 weeks, mass 
was largely unchanged. However, between weeks five and eight the mass decreased similarly and 
significantly in all three matrices. Unloaded PEUU matrix was reduced to 31 ± 1% and PEUU-
Tac, 10 and 20 mg tacrolimus loaded matrices, were reduced to 21 ± 9%, and 22 ± 18%, 
respectively. However, these similar changes in mass, were accompanied by distinct microscopic 
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changes in PEUU fiber morphology that correlated with tacrolimus loading. At eight weeks, SEM 
showed that polymeric fibers were less defined but still distinguishable in PEUU. However, 
PEUU-Tac lacked identifiable polymer fibrils (Figure 30b). Thus, although changes in mass were 
similar, tacrolimus loading leads to a more rapid loss in polymeric fiber architecture. Despite these 
changes in polymer organization and losses in mass, the PEUU and PEUU-Tac matrices remained 
sufficiently intact to be handled manually after 8 weeks.  
Mechanical properties of PEUU-Tac  
The stress-strain relationship, Young’s modulus, ultimate stress, and strain at break were 
calculated for the PEUU, 10 and 20mg PEUU-Tac matrices (Figure 31). The stress-strain 
relationship is shown for each PEUU device (Figure 31a). Tacrolimus loading did not significantly 
change Young’s modulus. Unloaded PEUU was 25 ± 9 MPa, 10mg PEUU-Tac was 19 ± 12 MPa, 
and 20 mg PEUU-Tac was 15 ± 11 MPa (Figure 31b). Similarly, no significant difference in strain 
at break was observed between the PEUU (262 ± 21 %), 10mg (217 ± 67 %), and 20mg (222 ± 34 
%) matrices (Figure 31c). However, ultimate stress was reduced significantly in tacrolimus loaded 
PEUU matrices compared to the unloaded matrix. PEUU ultimate stress was measured at 13 ± 4 
MPa, 10 mg PEUU-Tac at 6 ± 0.5 MPa, and 20 mg PEUU-Tac at 6 ± 3 MPa (Figure 31d).  
PEUU-Tac in an acute ON ischemia in rat  
To determine if PEUU-Tac can deliver tacrolimus locally to CNS tissues trans-durally without 
significantly increasing blood levels, 10 mg PEUU-Tac matrices were used as nerve wraps after  
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Figure 31. Mechanical properties of PEUU and PEUU-Tac matrices 
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acute ON ischemia in rat (Figure 32a). The ON was clamped using a Yasargil aneurism clip for 10 
seconds and then either left untreated or wrapped with PEUU or PEUU-Tac around the injury site 
and sutured to itself and to the dura mater to prevent movement (Figure 32b). In a subset of 
animals, the sheath was fenestrated at the injury site to expose the ON before applying the PEUU-
Tac matrix. In these in vivo studies, both the PEUU and PEUU-Tac sheets remained intact after 14 
days, similar to our in vitro degradation studies, as well as previous studies using PEUU matrices 
in other rodent models [320, 321]. The PEUU-Tac matrices were easily removed after 14 days 
(Figure 32c) with obvious growth of new muscular and connective tissues. In these studies, we did 
not observe obvious cellular toxicity, necrosis, abnormal growth, nor inflammation in the ONs, 
which exhibited typical gross anatomical organization (Figure 32d). 
PEUU-Tac delivered tacrolimus trans-durally to the optic nerve 
Tacrolimus concentrations were analyzed in the blood, the retinas, and the ONs at 24 hours and at 
14 days post injury. At 24 hours, PEUU-Tac increased tacrolimus in both fenestrated and 
unfenestrated ONs, but to significantly different extents (Figure 33 a-b). In fenestrated ONs, 
PEUU-Tac increased tacrolimus to approximately 56000 ± 4319 ng/g. In these animals, tacrolimus 
was also detected in the ipsilateral retina but at a much lower concentration, 1500 ± 898 ng/g, as 
well as in the contralateral retina, at 438 ± 31 ng/g, and ON, at 569 ± 64 ng/g (Figure 33a). In 
unfenestrated nerves, PEUU-Tac increased tacrolimus to approximately 5000 ± 1246 ng/g, 
approximately 11-fold lower than in fenestrated ONs. Similarly, tacrolimus also increased 
tacrolimus in the ipsilateral retina to 1900 ± 1484 µg/g, which was not significantly different than 
the ON. Moreover, tacrolimus was also detected in the contralateral retina at 341 ± 44 ng/g and 
ON at 1700 ± 225 ng/g.  
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Figure 32. Surgical approach to use PEUU-Tac to treat acute optic nerve (ON) ischemia 
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In PEUU-Tac treated ONs, tacrolimus persisted over the 14-day time point analyzed. 
Despite the rapid release kinetics measured in vitro, tacrolimus remained detectable in PEUU-Tac 
treated ONs at levels similar to animals treated with tacrolimus systemically. At 14 days, 
tacrolimus was measured at 3300 ± 1151 ng/g in the PEUU-Tac treated ONs and at 609 ± 144 ng/g 
in the ipsilateral retina. In the contralateral ON, tacrolimus was measured at 2200 ± 477 ng/g and 
at 559 ± 100 ng/g in the contralateral retina. Thus, in the unfenestrated ONs, tacrolimus levels 
were increased in the right ON compared to both retinas but not the contralateral ON. Interestingly, 
systemic injections of tacrolimus at 2.2 mg/kg/day increased tacrolimus similarly in both ONs and 
in both retinas but at significantly lower levels than their accompanying ON. Tacrolimus was 
measured at 2200 ± 304 ng/g in the right ON and at 1700± 175 ng/g in the left ON, and at 530 ± 
44 ng/g in the right retina and at 618 ± 60 ng/g in the left retina. Interestingly, tacrolimus levels in 
both the ONs and in the retinas were similar to the ONs and the retinas in the PEUU-Tac treated 
animals at 14 days post implantation (Figure 33c-d). Though further study is required, these data 
suggest PEUU-Tac applied to one ON delivers tacrolimus trans-durally to the treated ON and 
contiguous ocular tissues as effectively as daily systemic injections.  
PEUU-Tac fails to increase tacrolimus blood levels significantly 
Compared to systemic administration, tacrolimus blood levels in PEUU-Tac treated animals were 
significantly lower (Figure 33e-g). At 24 hours, tacrolimus blood concentrations were below 
detection. At 14 days, tacrolimus was detected at 0.15 ± 0.05 ng/mL, which is well below typical 
therapeutic trough levels, which range from 10-20 ng/mL. In contrast, systemic blood levels were 
measured at 7 ± 1 ng/mL at 24 hours and 28 ± 4 ng/mL at 14 days, above typical therapeutic trough 
levels. Thus, despite similar tacrolimus concentrations in the ONs and in the retinas, tacrolimus  
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Figure 33. Tacrolimus tissue concentrations in the optic nerves (ONs) and in the retinas. At 24 hrs, tacrolimus was 
undetectable in the blood in PEUU-Tac treated animals, whereas tacrolimus in systemically treated animals was 
significantly higher 
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blood levels were significantly reduced in PEUU-Tac treated animals, suggesting tacrolimus 
selectively accumulates in both the retinas and to a greater degree in the ONs irrespective of the 
administration route based on the 10 mg PEUU-Tac and systemic concentrations (2.2 mg/kg/day) 
used in this study. 
After acute ON ischemia, PEUU-Tac downregulates GFAP expression  
To determine if PEUU-Tac delivers bioactive tacrolimus trans-durally to glial cells, we analyzed 
GFAP expression, a marker for astrocyte activation, at the injury site (Figure 34). Compared to 
sham, uninjured nerves, GFAP expression increased significantly at the injury site in ONs after 
acute ischemia, consistent with typical astrocyte GFAP expression, migration, and proliferation 
responses to acute ON injury (Figure 34a-b). Qualitatively, increased magnification images 
showed obvious increases in GFAP expression at the injury site compared to uninjured nerves. 
GFAP was also increased in injured nerves treated with PEUU-Tac wraps or systemic tacrolimus 
but to a lesser extent (Figure 34c-f). Quantitatively, GFAP expression increased significantly in 
injured ONs, but not ONs wrapped in PEUU-Tac or treated systemically with tacrolimus (Figure 
34g), consistent with previous systemic tacrolimus studies [322].  
After acute ON ischemia, PEUU-Tac increases GAP-43 expression 
To determine if PEUU-Tac delivers bioactive tacrolimus that can promote RGC axon survival or 
growth, we asked if PEUU-Tac increased the expression of the axon growth marker GAP-43 
(Figure 35). Compared to injured nerves, PEUU-Tac increased GAP-43 expression dramatically 
along the length of the ON (Figure 35a-b). High magnification images of the injury site showed 
 140 
qualitatively that both PEUU-Tac and systemic tacrolimus increased GAP-43 expression 
compared to injured, untreated nerves (Figure 35 c-f), consistent with previous studies analyzing 
the effects of systemic tacrolimus on CNS axons after acute ischemic CNS injury [299, 318]. 
However, quantitatively, PEUU-Tac, but not systemic tacrolimus, increased GAP-43 expression 
significantly in the ON (Figure 35g). Though more detailed cellular analyses are warranted, these 
results demonstrate feasibility by showing that PEUU-Tac can deliver bioactive tacrolimus trans-
durally to the ON to positively effect cellular markers indicative of a more positive tissue 
remodeling response to injury in the CNS.  
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Figure 34. PEUU-Tac decreases GFAP expression at the injury site. GFAP expression increased significantly in 
injured ONs but not in ONs treated by PEUU-Tac or systemic tacrolimus 
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Figure 35. PEUU-Tac increases GAP43 expression at the injury site. GAP43 expression increased significantly 
in ONs treated with PEUU-Tac or systemic tacrolimus. 
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DISCUSSION 
This study shows PEUU-Tac matrices, manufactured by electrospinning blended PEUU and 
tacrolimus, can be used to locally deliver bioactive tacrolimus trans-durally to CNS tissues without 
significantly raising blood levels. Tacrolimus is a macrolide calcineurin inhibitor often used as an 
immunosuppressant after allogeneic organ transplantation. In solid organ transplantation, life-long 
systemic tacrolimus immunosuppression is typically required to prevent rejection. Tacrolimus also 
has desirable neuroprotective and neuroregenerative properties for treating peripheral nerve or 
CNS injury and disease. However, treating nervous system tissues with systemic tacrolimus is 
complicated by the pharmacokinetic properties of tacrolimus. Tacrolimus is highly lipophilic and 
thus accumulates in fatty tissues throughout the body, including the myelin-based white matter in 
the CNS. However, for reasons not completely understood, higher systemic tacrolimus 
concentrations are necessary to effectively increase tacrolimus levels in CNS tissues. Due to the 
narrow therapeutic window for tacrolimus, systemic increases are not feasible since they would 
likely lead to toxic secondary exposures and potentially life-threatening side effects in non-
targeted tissues or organs. Fortunately, pre-clinical models of acute ischemic nervous system 
injury indicate shorter therapeutic time windows are more effective in promoting positive CNS 
tissue remodeling, like increased axon growth [299, 300, 323]. These shorter therapeutic windows 
are in agreement with early modulation of the pro-inflammatory innate immune response and 
preventing or suppressing injury-induced microglial and astrocyte activation [324], which can 
increase CNS neuron survival [38] and decrease cellular and ECM remodeling preceding scar 
tissue formation [244]. Modulating the early innate immune response has been shown to be a 
critical factor in vertebrates that can functionally regenerate CNS tissues [325]. Thus, the PEUU-
Tac matrix reported here may fill a clinical need by providing a platform combining two FDA 
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approved materials, into a tunable platform that can be secured in place to effectively deliver 
tacrolimus trans-durally to CNS tissues. Moreover, PEUU can be easily tuned with additional 
genetic and biochemical reagents tailored to the nature and the scope of the injury.  
PEUU-Tac has desirable mechanical and biocompatible properties for treating CNS 
tissues. Like PEUU [310], PEUU-Tac is a flexible, biodegradable polymeric matrix that can be 
easily cut, shaped, and sutured to the dura mater with mechanical and degradation properties that 
can be easily tuned to match the tissue of interest. In this study, PEUU-Tac’s mechanical properties 
closely matched the biomechanical properties of the dura mater surrounding the CNS in both 
rodents and in humans. Matching biomechanics is necessary to effectively sustain physiologically 
applied mechanical forces [326]. In fact, PEUU was chosen specifically for this reason since 
PEUU polymers can be easily tuned to match the biomechanical properties of different tissues of 
interest [310, 312]. In this study, PEUU-Tac matrices had breaking strains around 200% and tensile 
strengths around 6 MPa. In rat, the tensile strength for rat dura mater is generally reported to be 
under 3 MPA with breaking strains around 140% [327, 328] and, similarly, tensile strengths for 
human dura mater have been reported to be approximately 1-5 MPa with breaking strains 
considerably lower than PEUU  [329-331]. Thus, the PEUU-Tac matrices appear to be a good 
match biomechanically for trans-dural drug delivery to CNS tissues. 
In vitro, PEUU-Tac released tacrolimus rapidly, approximately 85% was released within 
24 hours, resulting in a local concentration of 9.53 µg/mL or 11.3 µM for the 10 mg PEUU-Tac 
used in in vivo studies. After acute ON ischemia in rat, an ophthalmic surgeon surgically inserted 
PEUU-Tac through a narrow, almost bloodless conjunctival plane, wrapped the PEUU-Tac around 
the ON at the injury site by looping a suture connected to the wrap around the ON. The PEUU 
matrix was then sutured both to itself and to the dura to prevent movement. Like PEUU, PEUU-
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Tac exhibited good tolerance in vivo and possessed good suture retention. Obvious cellular 
toxicity, necrosis, abnormal growth, or inflammation were unobserved. After 2 weeks in vivo, 
PEUU-Tac matrices appeared intact and were easily removed, suggesting that if necessary, the 
matrices could have been removed earlier since tacrolimus release from PEUU-Tac was essentially 
complete within 24 hours. Moreover, PEUU matrices could be replaced if needed with the same 
or different matrices to treat different phases of the default healing response in the CNS [332].  
Finally, the ability of a trained surgeon to perform this procedure in a rodent model is encouraging 
for treating ONs in humans, which provide easier access and greater exposure, but also for treating 
spinal cord, brain, and peripheral nerve injuries where biomechanical tissue compliance during 
flexion and/or suturing are desired.  
PEUU-Tac delivered tacrolimus to ONs trans-durally without significantly increasing 
blood levels. In fenestrated ONs, tacrolimus increased to 56,000 ng/g, or approximately 70 µM, 
well above the toxicity limit (LD50=24 μM) measured for primary RGCs in vitro and above levels 
considered safe clinically which are typically in the low ng/g range. In unfenestrated nerves, 
PEUU-Tac also successfully increased tacrolimus but to levels 10-fold lower at 5000 ng/g or 
approximately 6 µM within 24 hours. In PEUU-Tac treated ONs, tacrolimus remained detectable 
at 14 days, at around 3200 ng/g or 3.8 µM, which is still well above clinically accepted levels. 
Moreover, these concentrations are several hundred fold higher than blood trough concentrations 
( > 10-30 ng/mL or 10-30 nM) shown to be neurotoxic in the CNS [333, 334] and in the PNS 
[335]. Tacrolimus was also detected in the contralateral ON (2200 ng/g, 2.6 µM) and at lower 
levels in both the ipsilateral (591 ng/g, 0.7 µM) and contralateral (541 ng/g, 0.66 µM) retinas, 
indicating contiguous ocular tissues also absorbed tacrolimus. However, despite high ON levels 
and detection in other ocular tissues, tacrolimus was undetectable in the blood at 24 hours and 
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minimally detected at 0.15 ± 0.05 ng/mL after 14 days compared to systemic tacrolimus blood 
levels measured at 27.66 ± 3.53 ng/mL after 14 days. These results indicate PEUU-Tac can deliver 
tacrolimus trans-durally to CNS tissues. However, the initial tacrolimus concentration measured 
in this study are too high, requiring either lower initial tacrolimus concentrations in the PEUU-Tac 
matrix and/or slower release kinetics, both properties that are easily modified and expected to 
further reduce absorption by adjacent ocular tissues and by the blood. Using data from this study 
and physiologically based pharmacokinetics, studies are ongoing to determine the appropriate 
tacrolimus loading concentrations and release kinetics from PEUU-Tac to maximize the cellular 
responses to acute ischemic injury and to minimize neurotoxicity.  
After acute ON ischemia, PEUU-Tac positively modulated typical markers of the default 
healing response in CNS tissues. After ON injury, injured RGC axons typically degenerate [336] 
and astrocytes, among other immune and glial cells, proliferate and migrate to the injury site, 
locally increasing GFAP expression and contribute to scar tissue formation [32]. In PEUU-Tac 
wrapped nerves, GFAP expression increased but to significantly lower levels at the injury site than 
in untreated, injured ONs. Moreover, in PEUU-Tac treated nerves GAP-43 expression increased 
along the length of the ON, similar to observations after systemic tacrolimus delivery [299, 318]. 
Though additional cellular and functional studies are required, these initial data show that, despite 
the high tacrolimus ON concentrations measured, PEUU-Tac delivers bioactive tacrolimus trans-
durally that is sufficient to decrease GFAP expression and presumably astrogliosis, while 
increasing GAP-43 expression and presumably RGC axon growth. Once tacrolimus loading and/or 
release kinetics are optimized for the PEUU-Tac matrices, future studies will include functional 
studies to correlate axon growth and decreased astrocyte activation with neuronal signaling and 
visual function.  
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Though these initial studies demonstrate feasibility, several caveats need to be addressed 
for optimizing PEUU-Tac for functional studies. FKBPs are enriched in CNS tissues [337] and 
tacrolimus is highly lipophilic, suggesting tacrolimus may selectively accumulate in CNS tissues 
with high myelin content, like the ON. Though oligodendrocytes may not express FKBP [338], 
tacrolimus influences myelination [339] and oligodendrocyte survival in vitro [340, 341].  Second, 
different FKBP receptors are differentially expressed by CNS neurons like RGCs [297] and many 
glial cells, resulting in varying regulation of different signaling pathways involved in cell cycle 
control [342], neuronal motility [343], and apoptosis [344], highlighting the importance of 
analyzing the inter- and intracellular effects of tacrolimus within CNS cellular populations. Third, 
tacrolimus has also been shown to effect blood brain barrier integrity and function [344] and thus 
may differentially regulate absorption, particularly at local delivery sites where tacrolimus 
concentrations are high. Regulating tacrolimus tissue and blood levels is critical due to the narrow 
therapeutic index, tissue absorption variability, and pharmokinetic variability, [345] and thus is 
further complicated by the number of cellular targets and compartmentalization. Hence, 
bioavailability of tacrolimus differs across cellular populations. Whether the measured tacrolimus 
concentration in the ON in this study accurately reflects tacrolimus bioavailability is unknown, but 
this information is required to properly tune PEUU-Tac matrices for dosing. Clinically, tacrolimus 
doses are based on whole blood trough levels, which poorly predict tissue levels; even within the 
therapeutic range, toxicity may occur [346]. Furthermore, physiology, age, and concurrent 
medications can alter tacrolimus levels and biological activity [347]. Thus, tacrolimus tissue 
concentrations at target sites may better predict outcomes [348], highlighting the need to optimize 
tacrolimus delivery time and concentration indices for CNS tissues specifically prior to conducting 
functional studies.   
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CONCLUSION 
Injury to CNS tissues like the ON often leads to a pro-inflammatory innate immune response, 
negative tissue remodeling to form scar tissue, and axon degeneration that leads to permanently 
lost neurological function. The PEUU-Tac matrix proposed here utilizes cost effective materials 
already used in FDA approved products. These materials are readily available, do not produce 
adverse immune responses when used correctly, and are highly translatable clinically. The 
combination of the two materials provides a device capable of being tailored to a patient’s specific 
injury, increasing the probability of a positive outcome. Clinically, tacrolimus has a narrow 
therapeutic index and high inter- and intra-individual pharmacokinetic variability, necessitating 
therapeutic drug monitoring to individualize dosage. The sustained detection of tacrolimus in the 
ON and positive effects on tissue remodeling indicate that a single PEUU-Tac application may be 
sufficient to treat ON injury where systemic administration requires frequent injections to maintain 
the same tacrolimus levels. Thus, PEUU-Tac could greatly reduce issues with patient 
compliance/adherence to the treatment and decrease the chances of unwanted, potentially life-
threatening side-effects [304, 349, 350]. 
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